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A B S T R A C T
Background
Transitional care provides for the continuity of care as patients move between different stages and settings of care. Medication discrep-
ancies arising at care transitions have been reported as prevalent and are linked with adverse drug events (ADEs) (e.g. rehospitalisation).
Medication reconciliation is a process to prevent medication errors at transitions. Reconciliation involves building a complete list of a
person’s medications, checking them for accuracy, reconciling and documenting any changes. Despite reconciliation being recognised
as a key aspect of patient safety, there remains a lack of consensus and evidence about the most effective methods of implementing
reconciliation and calls have been made to strengthen the evidence base prior to widespread adoption.
Objectives
To assess the effect of medication reconciliation on medication discrepancies, patient-related outcomes and healthcare utilisation in
people receiving this intervention during care transitions compared to people not receiving medication reconciliation.
Search methods
We searchedCENTRAL,MEDLINE, Embase, seven other databases and two trials registers on 18 January 2018 together with reference
checking, citation searching, grey literature searches and contact with study authors to identify additional studies.
Selection criteria
We included only randomised trials. Eligible studies described interventions fulfilling the Institute for Healthcare Improvement defini-
tion of medication reconciliation aimed at all patients experiencing a transition of care as compared to standard care in that institution.
Included studies had to report on medication discrepancies as an outcome.
Data collection and analysis
Two review authors independently screened titles and abstracts, assessed studies for eligibility, assessed risk of bias and extracted data.
Study-specific estimates were pooled, using a random-effects model to yield summary estimates of effect and 95% confidence intervals
(CI). We used the GRADE approach to assess the overall certainty of evidence for each pooled outcome.
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Main results
We identified 25 randomised trials involving 6995 participants. All studies were conducted in hospital or immediately related set-
tings in eight countries. Twenty-three studies were provider orientated (pharmacist mediated) and two were structural (an electronic
reconciliation tool and medical record changes). A pooled result of 20 studies comparing medication reconciliation interventions to
standard care of participants with at least one medication discrepancy showed a risk ratio (RR) of 0.53 (95% CI 0.42 to 0.67; 4629
participants). The certainty of the evidence on this outcome was very low and therefore the effect of medication reconciliation to reduce
discrepancies was uncertain. Similarly, reconciliation’s effect on the number of reported discrepancies per participant was also uncertain
(mean difference (MD) -1.18, 95% CI -2.58 to 0.23; 4 studies; 1963 participants), as well as its effect on the number of medication
discrepancies per participant medication (RR 0.13, 95% CI 0.01 to 1.29; 2 studies; 3595 participants) as the certainty of the evidence
for both outcomes was very low.
Reconciliation may also have had little or no effect on preventable adverse drug events (PADEs) due to the very low certainty of the
available evidence (RR 0.37. 95% CI 0.09 to 1.57; 3 studies; 1253 participants), with again uncertainty on its effect on ADE (RR 1.09,
95% CI 0.91 to 1.30; 4 studies; 1363 participants; low-certainty evidence). Evidence of the effect of the interventions on healthcare
utilisation was conflicting; it probably made little or no difference on unplanned rehospitalisation when reported alone (RR 0.72, 95%
CI 0.44 to 1.18; 5 studies; 1206 participants; moderate-certainty evidence), and had an uncertain effect on a composite measure of
hospital utilisation (emergency department, rehospitalisation RR 0.78, 95% CI 0.50 to 1.22; 4 studies; 597 participants; very low-
certainty evidence).
Authors’ conclusions
The impact of medication reconciliation interventions, in particular pharmacist-mediated interventions, on medication discrepancies
is uncertain due to the certainty of the evidence being very low. There was also no certainty of the effect of the interventions on the
secondary clinical outcomes of ADEs, PADEs and healthcare utilisation.
P L A I N L A N G U A G E S U M M A R Y
What interventions improve the accuracy and continuity of medication lists as patients move between healthcare providers and
settings?
What is the aim of this review?
We aimed to find out ifmedication (medicine) reconciliation improvesmedication discrepancies, outcomes affecting patients specifically
and healthcare utilisation as patients move or transition between healthcare providers (e.g. pharmacists, nurses, doctors) and settings
(e.g. emergency department, primary care). Medication reconciliation involves building a complete list of a person’s medications,
checking them for accuracy, reconciling and documenting any changes. Medication reconciliation is recommended as an intervention
to improve the accuracy of medication information at transitions. All care transitions (e.g. home to hospital, ED to hospital ward) and
patient types (e.g. children, older people) were open for inclusion in the review.
Key messages
Review authors collected and analysed all relevant studies to answer this question and found 25 studies. This review found unreliable
evidence that interventions reduced the number of discrepancies in patients’ medications as they transition between different healthcare
settings. Similarly, the benefit in terms of clinically orientated outcomes (e.g. admission to hospital) was uncertain.
What was studied in the review?
We included studies that used a randomised designwhere people were randomly put into one of two ormore treatment groups. Themain
outcome of interest was whether the possibility of any discrepancies in a patient’s medication list was reduced following the intervention.
Other outcomes that were assessed in the review were the intervention’s impact on the number of medication discrepancies, medication
side effects, preventable medication side effects, hospital usage (e.g. emergency department visits and readmission to hospital), negative/
adverse impacts of the intervention and resource usage.
What are the main results of the review?
The review authors found 25 studies conducted in eight different countries in hospital or immediately related settings. Twenty-three
studies were primarily pharmacist delivered, one was an electronic reconciliation tool and one medical record changes. Studies mainly
included older people prescribed multiple medications.
2Impact of medication reconciliation for improving transitions of care (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
While many studies reduced the presence of at least one medication discrepancy in people receiving the intervention, we were uncertain
whether reconciliation reduced discrepancies as the reliability of the evidence was very low. The evidence for the intervention’s effect
on the number of discrepancies and on clinical outcomes such as actual and preventable medication side effects, combined measures
of healthcare utilisation and unplanned readmissions to hospital itself was varying with evidence ranging from moderate to low or very
low reliability.
How up-to-date is this review?
The review authors searched for studies that had been published up to January 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Medication reconciliation interventions compared to standard care for all patients at a transition of care
Patient or population: all pat ients (aged > 18 years) at a transit ion of care
Setting: hospitals, primary care pract ices, long-term care facilit ies in USA (6 studies); Australia (6 studies); Canada (4 studies); and Colombia, Egypt, Netherlands, Singapore
and Ireland (1 study each))
Intervention: medicat ion reconciliat ion (construct of best possible medicat ion list by clinical pharmacists; medicat ion review and communicat ion)
Comparison: standard care (no intervent ion or ’usual care’ as provided by the relevant healthcare provider)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard care Risk with medication
reconciliation
≥ 1 medication dis-
crepancy per partici-
pant (dichotomous)
559 per 1000 296 per 1000
(235 to 375)
RR 0.53
(0.42 to 0.67)
4629
(20 RCTs)
⊕©©©
Very lowa,b,c,d,e
Number of part icipants
with medicat ion dis-
crepancies (≥ 1) was
equivalent to those who
did not achieve ‘‘med-
icat ion prof ile appro-
priateness’’ in Beckett
2012 study.
Mult iple t ime points
and locat ions reported.
1 t ime point per study
reported here to coin-
cide with end of inter-
vent ion
Number of medication
discrepancies per par-
ticipant (cont inuous)
The mean number of
medicat ion discrepan-
cies per part icipant
(cont inuous) was 0
MD 1.18 lower
(2.58 lower to 0.23
higher)
- 1963
(4 RCTs)
⊕©©©
Very lowa,c,f
3 studies could not be
included in the meta-
analysis of this out-
come; Bolas 2004 re-
ported improved accu-
racy of medicat ion in
the intervent ion group
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(P < 0.005) but did
not provide compara-
ble discrepancy f ig-
ures for meta-analysis.
Sim ilarly, Khalil 2016
reported reduced er-
ror rates (which in-
cluded omissions) in
intervent ion group (P
< 0.0001) but could
not provide discrep-
ancy f igures specif i-
cally. Cadman 2017
showed 0.02 discrep-
ancies in the interven-
t ion vs 2.71 in the con-
trol group
Discrepancies per par-
ticipant medication
256 per 1000 33 per 1000
(3 to 331)
RR 0.13
(0.01 to 1.29)
3595
(2 RCTs)
⊕©©©
Very lowa,b,e,f
-
PADEs 241 per 1000 89 per 1000
(22 to 379)
RR 0.37
(0.09 to 1.57)
1253
(3 RCTs)
⊕©©©
Very lowa,b,c,d,e,f
Assessed with Bates
and colleagues method
and Naranjo causality
using part icipant inter-
view ± chart review post
discharge (Bates 1995;
Naranjo 1992)
follow-up: range 25-35
days
ADEs 244 per 1000 266 per 1000
(222 to 317)
RR 1.09
(0.91 to 1.30)
1363
(4 RCTs)
⊕⊕©©
Lowb,c
Assessed with a mix-
ture of methods. Bates
and colleagues method
and Naranjo causality
using part icipant inter-
view ± chart review post
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discharge (Bates 1995;
Naranjo 1992)
follow-up: range 25-60
days
Unplanned rehospitali-
sation
146 per 1000 105 per 1000
(64 to 172)
RR 0.72
(0.44 to 1.18)
1206
(5 RCTs)
⊕⊕⊕©
Moderateb,d,e,f
5 studies dist inct ly re-
ported numbers of un-
planned rehospitalisa-
t ion
Assessed with re-
view of medical record
or part icipant interview
(or both)
follow-up: range 5-30
days
Hospital usage (com-
posite measure of ED,
rehospitalisation)
300 per 1000 234 per 1000
(150 to 366)
RR 0.78
(0.50 to 1.22)
597
(4 RCTs)
⊕©©©
Very lowa,b,c,d,f
A composite measure
of hospital ut ilisat ion
reported by 4 studies
making no dist inct ion
between ED attendance
or rehospitalisat ion (or
both)
Assessed with mix-
ture of methods. Using
part icipant interview ±
chart review post dis-
charge
follow-up: range 25-60
days
Bolas 2004 reported a
dif ference in hospitali-
sat ion in favour of the
intervent ion group (P >
0.05) but did not re-
port the actual number
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of part icipants in each
group or the CI
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ADE: adverse drug events; CI: conf idence interval; ED: emergency department; MD: mean dif ference; PADE: preventable adverse drug event; RCT: randomised controlled trial;
RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aEvidence downgraded due to inconsistency of evidence.
bEvidence downgraded due to high risk of bias.
cEvidence downgraded due to indirectness of evidence.
dEvidence upgraded due to no publicat ion bias.
eEvidence upgraded due to large ef fect size.
f Evidence downgraded due to imprecision of evidence.
Full GRADE evidence prof ile provided in Appendix 3.
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B A C K G R O U N D
Errors in the prescribing and administration of medication are
frequent, costly and harmful (Bates 2007). More than 40% of
medication errors result from inadequate medication reconcilia-
tion at care transitions (Hughes 2008). Transitional care provides
for the continuity of care as patients move between different stages
and settings of care (Coleman 2004). The prevalence of medica-
tion discrepancies arising at care transitions have been reported in
many different settings (hospital, community and long-term care
facilities) and stages of care (admission, transfer and discharge);
in particular, transitioning between an inpatient and outpatient
setting is associated with an increase in medication errors relative
to other stages of care (Boockvar 2006; Coleman 2004; Moore
2003; Tam 2005). Prevalence of adverse events post hospitalisa-
tion as high as 19% have been reported with the majority of these
related to adverse drug events (ADEs), which may be the result of
medication error (Forster 2003).
“Medication reconciliation is a conscientious, patient centred, in-
ter-professional process that supports optimal medicines manage-
ment” (Greenwald 2010). The process aims to create the most ac-
curate list of medications at all transition points, with the goal of
providing the correctmedications to the patient (Karapinar 2011).
Different patient groups and locations have been studied. A vari-
ety of intervention types have been investigated, including infor-
mation technology (Kramer 2007; Schnipper 2009), pharmacist-
led (Gillespie 2009), and more complex multifaceted interven-
tions (Koehler 2009). The benefits of medication reconciliation
interventions are often assessed by comparing medication regi-
mens across transitions and reporting discrepancy reduction as the
primary outcome. A previous systematic review reported that al-
though unintendedmedicationdiscrepancieswere common, clini-
cally significant discrepancies may affect only a few patients (Kwan
2013). Challenges arise in identifying those discrepancies that are
considered clinically significant and which may give rise to patient
harm.
Therefore, despite reconciliation being recognised as a key aspect
of patient safety, there remains a lack of consensus and evidence
as to the most effective methods of implementing reconciliation
and calls have been made to strengthen the evidence base prior to
widespread adoption (Greenwald 2010).
Description of the condition
Transitional care describes the care provided to patients to ensure
the co-ordination and continuity of healthcare as they transfer be-
tween different settings or different stages of care (or both) within
the same settings (Coleman 2003a). Improved continuity of pre-
scribed medication via medication reconciliation for patients at
care transitions is recommended by national standard setting bod-
ies and internationally led initiatives (e.g. World Health Organi-
zation’s (WHO) High 5s project (IHI 2011; NICE 2007; WHO
2006). However, the effectiveness, and most effective method of
conducting reconciliation, remains unclear.
Description of the intervention
Medication reconciliation consists of the following three steps (IHI
2011).
• Verification: a current medication list is developed using
one or more sources of information (e.g. general practitioner
medical records, patient’s own supply, pharmacy records).
• Clarification: medication and dosages are checked for
appropriateness. Here appropriateness means ensuring that there
are no unintentional changes, rather than a medication review
leading to optimal medication appropriateness).
• Reconciliation: newly prescribed medications are
compared to old and any changes made are documented.
How the intervention might work
Failure to reconcile medications can result in medication error and
subsequent ADEs (IHI 2011). Interventions to improve medica-
tion reconciliation may work by improving the communication
between all those involved in the medication-use process (dispens-
ing, administration, monitoring across settings and stages of care),
including the patient. Additionally, these interventions may well
help in reducing transcribing errors, improved monitoring of pre-
scriptions, information technology systems and reorganisation of
care delivery.
Why it is important to do this review
Medication reconciliation is incorporated into the National Pa-
tient Safety Goals of the Joint Commission under the umbrella of
improving the safety of using medications (The Joint Commission
2013). The National Institute for Health and Care Excellence
(NICE) in collaboration with the National Patient Safety Agency
in the UK encouraged the standardisation of reconciliation pro-
cesses within healthcare organisations (NICE 2007). The Cana-
dian Patient Safety Institute and the Institute for Safe Medication
Practices (Canada) have advocated for medication reconciliation
and the WHO launched the High 5s project, focusing on care
transitions, as well as the 3rd Global Patient Safety Challenge:
Medication without Harm in 2017 (Donaldson 2017).
The findings of this proposed review are relevant at both a na-
tional and international level. Regulatory bodies, healthcare insti-
tutions, patient safety advocates, healthcare practitioners and the
wider public would be receptive audiences for the findings from a
systematic review of the most effective method of medicines rec-
onciliation.
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O B J E C T I V E S
To assess the effect of medication reconciliation on medication
discrepancies, patient-related outcomes and healthcare utilisation
in people receiving this intervention during care transitions com-
pared to people not receiving medication reconciliation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials only. Studies were eligible for in-
clusion irrespective of language or publication status.We excluded
non-randomised trials, controlled before-and-after studies, inter-
rupted time series studies and repeated measures studies.
Types of participants
We included studies involving patients experiencing a transition
of care. Care transitions referred to changes in the level, location
or providers of care as patients moved within the healthcare sys-
tem (Coleman 2003b; Kim 2013). This included, but was not
limited to, hospital admission/discharge, acute and subacute facil-
ities/units/wards, primary and speciality care, long-term care insti-
tutions and patients’ homes. Transition could have been in either
direction (e.g. admission or discharge (or both) to an intensive
care unit from a general ward).
There was no restriction on age, gender, ethnicity, location or
patient population.
Types of interventions
We included studies where the interventionwas broadly compliant
with the process of medication reconciliation as outlined by the
Institute for Healthcare Improvement (IHI 2011): “the process of
creating the most accurate list possible of all medications a patient
is taking - including drug name, dosage, frequency, and route - and
comparing that list against the physician’s admission, transfer, and/
or discharge orders, with the goal of providing correct medications
to the patient at all transition points...” Medication reconciliation
involves three steps (IHI 2011):
• create an accurate and complete list of current medications
(verify);
• check appropriateness of medication regimens (clarify);
• document the reason for medication changes (reconcile).
The intervention must have been applied as patients transitioned
from different levels or locations of care (or both).
Medication reconciliation interventions must have been aligned
to a number of broad interventional categories, as defined by the
Cochrane Effective Practice and Organisation of Care (EPOC)
review group, including professional interventions, financial, or-
ganisational and regulatory (EPOC 2013a).
We excluded trials investigating interventions to improve the qual-
ity of prescribing during care transitions, with no medication rec-
onciliation focus.
The comparator group was those patients who did not receive
reconciliation (i.e. received ’usual care’ as provided by the relevant
healthcare provider (HCP)).
Types of outcome measures
The outcomes chosen reflected the EPOC guidance as those being
important to the population of interest as well as decision mak-
ers in healthcare (EPOC 2013b). We excluded studies reporting
secondary outcomes only. We included process measures, patient-
related outcomes and healthcare utilisation.
Primary outcomes
• Medication discrepancies; this has previously been defined
as unexplained differences in documented medication regimens
across different sites of care (Mueller 2012). Discrepancies,
dependent on available study data, were presented as:
◦ at least one medication discrepancy per participant
(dichotomous);
◦ number of medication discrepancies per participant
(continuous);
◦ discrepancies per participant medication (e.g. drug/
dose/name/mode of administration/frequency - both continuous
and dichotomous).
Secondary outcomes
• Participant-related and process outcomes:
◦ medication discrepancy with the potential for ADEs,
which have been previously described as “incidents with
potential for injury related to a drug” (PADEs) (Bates 1995);
◦ adverse drug events (ADEs);
◦ mortality;
◦ medication adherence (non-adherent with at least one
medication).
• Healthcare utilisation:
◦ primary care visits;
◦ emergency department (ED) visits;
◦ unplanned rehospitalisation;
◦ hospital usage (composite measure of ED,
rehospitalisation);
◦ length of stay.
• Additional outcomes:
◦ adverse effects of interventions (e.g. unanticipated
increased workload, health worker attrition);
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◦ resource use (dependent on studies of effectiveness
selected for inclusion in the review, a narrative summary of the
characteristics of economic analysis is reported.
Search methods for identification of studies
Cochrane EPOC searched the Cochrane Database of Systematic
Reviews (CDSR) and the Database of Abstracts of Reviews of
Effects (DARE) for related systematic reviews and the following
databases for primary studies.
Electronic searches
We searched the following databases without language, publica-
tion year or publication status restrictions up to 18 January 2018:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 12) in the Cochrane Library;
• MEDLINE and MEDLINE Epub Ahead of Print, In-
Process and other non-indexed citations, Ovid (1946 to 18
January 2018);
• Embase, Ovid (1974 to 18 January 2018);
• PsycINFO, Ovid (2002 to January Week 2 2018);
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature), EBSCO;
• Dissertations and Theses Database; COS conference papers
index, ProQuest;
• Science Citation Index, ISI Web of Knowledge (1945 to 18
January 2018);
• Conference Proceedings Citation Index - Science, ISI Web
of Knowledge (1990 to 18 January 2018);
• International Pharmaceutical Abstracts (IPA), ProQuest (22
January 2018).
We translated the MEDLINE search strategy for other databases
using appropriate syntax and vocabulary for those databases. The
strategy includedmedical subject headings and synonyms formed-
ication reconciliation and care transitions. We limited results us-
ing the “Cochrane Highly Sensitive Search Strategy for identifying
randomised trials in MEDLINE: sensitivity- and precision-max-
imising version (2008 revision); Ovid format,” to identify ran-
domised trials, as well as the Cochrane EPOCmethodology filter.
Search strategies for major databases are provided in Appendix 1.
Searching other resources
We conducted a grey literature search to identify studies not in-
dexed in the databases listed above. Sources included the sites listed
below.
• Open Grey (www.opengrey.eu/; date of last search: 22
January 2018);
• Grey Literature Report ( New York Academy of Medicine) (
greylit.org/; date of last search: 22 January 2018);
• Agency for Healthcare Research and Quality ( AHRQ) (
www.ahrq.gov/; date of last search: 22 January 2018);
• National Research Register ( NRR) Archive (
www.nihr.ac.uk/Pages/NRRArchive.aspx; date of last search: 28
August 2013);
• Joanna Briggs Institute ( joannabriggs.org/; date of last
search: 22 January 2018);
• NICE ( www.nice.org.uk/; date of last search: 22 January
2018);
• NHS Evidence Search ( www.evidence.nhs.uk/; date of last
search: 22 January 2018).
We searched the following registries:
• International Clinical Trials Registry Platform ( ICTRP)
search portal, WHO ( apps.who.int/trialsearch/; date of last
search: 22 January 2018);
• ClinicalTrials.gov, US National Institutes of Health ( NIH)
( clinicaltrials.gov/; date of last search: 22 January 2018).
We also:
• screened individual journals and conference proceedings;
• reviewed reference lists of all included studies, relevant
systematic reviews/primary studies/other publications;
• contacted authors of relevant studies or reviews to clarify
reported published information/seek unpublished results/data;
• contacted researchers with expertise relevant to the review
topic/Cochrane EPOC interventions.
Data collection and analysis
Selection of studies
A combination of two review authors (PR, TG, RMcD, FB) in-
dependently screened titles and abstracts to decide which studies
satisfied the inclusion criteria and identified multiple reports from
single studies. Any papers not meeting the inclusion criteria were
excluded at this stage. If there was uncertainty, we reached con-
sensus by discussion with another review author. Following this, a
combination of two review authors (PR, TG, FB) independently
assessed the full-text articles to ensure the studies still fulfilled the
inclusion criteria. We collated multiple reports for the same study,
so that each study rather than each report is the unit of interest
Data extraction and management
A combination of two review authors (PR, TG, RMcD, FB) inde-
pendently undertook data extraction using a modified version of
theCochrane EPOCdata collection checklist to include: study de-
sign, study population, intervention, usual care, outcomemeasures
used and length of follow-up data (EPOC 2013c). We resolved
any disagreements by discussion between review authors. Where
necessary, we contacted study authors for missing information or
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clarification. Information from data extraction forms guided the
extraction of numerical data for meta-analysis in Cochrane’s sta-
tistical software, Review Manager 5 (Review Manager 2013).
Assessment of risk of bias in included studies
A combination of two review authors ( PR, TG, RMcD, FB, CH,
TF) independently performed the risk of bias assessment. We re-
solved disagreements by discussion and, if needed, arbitration by
a third review author. The criteria against which the risk of bias in
a study was judged was based on the following domains ( EPOC
2011; Higgins 2011):
• Random sequence generation (selection bias);
• Allocation concealment (selection bias);
• Were baseline outcome measurements similar?
• Were baseline characteristics similar?
• Incomplete outcome data (attrition bias);
• Was knowledge of the allocated interventions adequately
prevented during the study?
• Was the study adequately protected against contamination?
• Selective outcome reporting (reporting bias);
• Other biases.
We tabulated the description of the domains for each included
study, along with a judgement on the risk of bias (low, high or
unclear), using one key domain of a study-level entry (allocation
concealment) and one key domain of an outcome-level entry (in-
complete outcome data) based on the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We undertook a
summary assessment of the risk of bias for the primary outcome
across the studies (Higgins 2011).
Measures of treatment effect
We reported outcomes for each study in natural units. We cal-
culated, where possible, absolute change from baseline with 95%
confidence intervals (CI). We reported estimates for dichotomous
outcomes (e.g. ADEs) as risk ratios (RR). We reported estimates
for continuous outcomes as mean differences (MD) if they were
measured on the same scale; if continuous outcomes were mea-
sured on multiple scales, we reported the standardised mean dif-
ference (SMD).
We tabulated all relevant information of studies included in the
review. This included all pre- and postintervention results (sample
sizes, means, proportions, 95% CIs, etc.) for each group for each
outcome of interest.
Unit of analysis issues
We dealt with unit of analysis issues (including clustering) accord-
ing to guidance of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Dealing with missing data
We contacted lead study investigators or corresponding authors
for any missing trial data or data missing from published reports
or for additional clarification. If there were any missing data from
a study, we explicitly stated this.
Assessment of heterogeneity
We identified and measured statistical and clinical heterogeneity
as recommended by the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Assessment of reporting biases
We examined asymmetry in funnel plots of the primary outcome
to assess the potential for study effects such as publication bias.
Where there was a possibility of publication bias and small-study
effects, we undertook a sensitivity analysis as described below.
Data synthesis
Weperformed statistical analysis using ReviewManager 5 (Review
Manager 2013). Pooled estimates (RRs with 95% CIs) of the eval-
uated outcome measures were calculated by the generic inverse
variance method.
Where it was not possible to synthesise the data from the included
studies, we provided a narrative synthesis of the results, grouping
together studies that used similar interventions and provided a
comparison of different approaches.
’Summary of findings’ table
We prepared a ’Summary of findings’ table to draw conclusions
about the certainty of the evidence within the text of the review.
Two review authors (PR, TG) independently assessed the certainty
of the evidence (high, moderate, low and very low) using the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness andpublicationbias) (GRADEpro GDT
2015; Schünemann 2013).
The ’Summary of findings’ table reported the following important
outcomes:
• at least one medication discrepancy per participant
(dichotomous)
• number of medication discrepancies per participant
(continuous)
• discrepancies per participant medication
• PADEs
• ADEs
• unplanned rehospitalisation;
• hospital usage (composite measure of ED,
rehospitalisation).
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Subgroup analysis and investigation of heterogeneity
Subgroup analyses and investigation of heterogeneity (via meta-
regression) was carried out a priori on the following characteristics:
• participants with polypharmacy;
• participants’ age;
• different approaches to medication reconciliation (e.g.
information technology, pharmacist delivered, integrated
medicines management);
• different transitions/settings of care.
Sensitivity analysis
We conducted a sensitivity analysis to calculate the effect of risk of
bias (including missing data) within studies on effect size, by cal-
culating the effect of excluding or including studies with a higher
risk of bias.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
ongoing studies tables.
Results of the search
Following searches and deduplication, we reviewed the titles and
abstracts of 13,585 records. We retrieved 549 full-text records (in-
cluding publications, conference presentations, reports, etc.) for
more detailed assessment. Of these, 25 studies met all inclusion
criteria and we included these in the review. We excluded 508
records (Figure 1). We identified 16 ongoing studies from confer-
ence abstracts, published protocols and trial registry listings (see
Characteristics of ongoing studies table).
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Figure 1. PRISMA flow diagram of search strategy.
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Included studies
Twenty-five studies meet the inclusion criteria. We contacted the
authors of seven studies to attain data relevant for this review
(Farley 2014; George 2011; Hale 2013; Kripalani 2012; Lalonde
2008; Marotti 2011; Tompson 2012). Two studies, despite con-
tacting the authors, did not have data available to allow pooling of
results (Bolas 2004; Khalil 2016). All study details are provided in
the Characteristics of included studies table and are briefly sum-
marised below.
Study design
There were 24 randomised trials and one cluster randomised trial
(Schnipper 2011). Three studies had two intervention arms and
one control arm (Farley 2014; Marotti 2011; Pevnick 2018).
Settings
All of the studies were conducted in hospital or immediately re-
lated settings. The included studies were carried out in eight coun-
tries: USA (seven studies); Australia (six studies); Canada (four
studies); Singapore (two studies); and the UK, Colombia, Egypt,
Netherlands, Spain and Ireland (one study each).
Participants
There were 6995 participants (3654 in the intervention group,
3341 in the control group) included in the review. The mean age
of participants was 66.1 years. Two studies did not report the age
of study participants (Heng 2013; Schnipper 2011). Most studies
recruited participants prescribed multiple medications (e.g. more
than onemedication: Cadman 2017;George 2011; Lalonde 2008;
Marotti 2011; Vega 2016; Yau 2008;more than threemedications:
Becerra-Camargo 2013; Bolas 2004; Tompson 2012; five or more
medications: Char 2017; Eggink 2010; Schnipper 2011; more
than eight medications: Hawes 2014; more than 10 medications
Pevnick 2018).
Interventions
All studied interventions were classified as ’organisational’ accord-
ing to EPOC taxonomy.
Organisational
• Provider orientated
◦ Twenty-three studies were complex, multifaceted
interventions within the EPOC ’organisational’ subclassification
of ’provider-orientated interventions’. Studies were a mix of
’continuity of care’, ’skills mix changes’, ’revision of professional
roles’, ’clinical multidisciplinary teams’, ’formal integration of
services’ and ’communication of case discussions between distant
health professionals’.
• Structural
◦ One study, subclassified as ’changes in physical
structure, facilities and equipment’, examined the availability of
an electronic reconciliation tool built into the electronic medical
record of a network of primary care practices (Schnipper 2011).
◦ One study, subclassified as ’changes in medical records
system’, examined the inclusion of a ’medication discharge plan’
at the time of discharge (Lalonde 2008).
Provider(s) of intervention
In 22 studies, clinical pharmacists primarily delivered the inter-
vention. One study’s intervention arm was provided by “phar-
macist supervised pharmacy technicians” (Pevnick 2018). One
study’s intervention was primarily the provision of a ’medication
discharge plan’ also provided by the hospital clinical pharmacy
service (Lalonde 2008). The final study was provided through an
information and communication technology (ICT) reconciliation
tool linking secondary and primary care (Schnipper 2011).
Medication reconciliation was commonly provided by pharma-
cists working closely with other healthcare professionals in a va-
riety of settings (at preadmission: three; admission: six; during
hospitalisation; five; discharge: five; postdischarge: four; hospital
outpatient clinic setting: two).
Format of reconciliation intervention
Information gathering
All study interventions included an attempt to construct a ’best
possible medication list’, with various levels of intensity and al-
most all including patient interview. Twenty-two study interven-
tions were conducted face-to-face with participants; in two it was
unclear (Heng 2013; Lalonde 2008), and one was ICT mediated
(Schnipper 2011).
Post-transition communication
Ten studies included a provision within the intervention to com-
municate the output of reconciliation to receiving HCPs (Bolas
2004; Cadman 2017; Crotty 2004; Eggink 2010; Farley 2014;
Lalonde 2008;Nickerson 2005; Schnipper 2006; Schnipper 2011;
Yau 2008). Four studies included a follow-up telephone call to
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participants post transition to clarify medication regimens, as-
sess adherence, etc. (Farley 2014; Ibrahim 2012; Kripalani 2012;
Schnipper 2006).
Resources
Six studies provided personalised medication information sheets
to participants (Bolas 2004; Farley 2014; George 2011; Hawes
2014; Kripalani 2012; Lalonde 2008), with one study developing
low literacy aids specific to its population (Kripalani 2012). One
study required the development and integration of an electronic
reconciliation tool into an existing functioning linked electronic
medical record (Schnipper 2011), while two studies used an elec-
tronic link with community pharmacists or access to a “central
clinical data repository” to gather preadmission medication infor-
mation (Char 2017; Tompson 2012). In addition to the four in-
terventions which performed follow-up telephone calls, one study
established a medication helpline for participants post-transition
(Bolas 2004).
Additional interventions beyond medication reconciliation in-
cluded ’medication review’ (Bolas 2004; Crotty 2004; Eggink
2010; Ibrahim 2012; Khalil 2016; Nickerson 2005; Schnipper
2006), participant counselling/education (Bolas 2004; Eggink
2010; Farley 2014; Hawes 2014; Ibrahim 2012; Kripalani 2012;
Lalonde 2008; Nickerson 2005; Schnipper 2006), prescriber ed-
ucation (Crotty 2004), and enhanced roles as non-medical pre-
scribers (Hale 2013; Khalil 2016; Marotti 2011).
Comparisons
Twenty-three studies reported the control group’s intervention to
consist of usual care in the context in which the study took place.
This meant there was a large interstudy variation in the usual care
provided to control groups.
Three studies had two intervention groups in addition to a usual
care group (Farley 2014; Marotti 2011; Pevnick 2018).
Outcomes
Primary outcome
The primary outcome for this reviewwasmedication discrepancies
per patient or medication (or both).
None of the studies used a validated measure of the primary out-
come. Ten studies clearly reported an outcome of unintentional
discrepancy, where the discrepancy betweenmedication lists could
not be accounted for through reviewing medical records, order
forms or discussion with treating physicians (Cadman 2017; Char
2017; Farley 2014; Hawes 2014; Ibrahim 2012; Kwan 2007;
Schnipper 2006; Schnipper 2011; Tompson 2012; Yau 2008).
Three studies reported an outcome of discrepancy but did not
clearly define or investigate whether that discrepancy was in-
tentional or not (Becerra-Camargo 2013; Beckett 2012; Eggink
2010). Three studies reported discrepancies as a mismatch in a di-
rect comparison of two lists (e.g. discharge prescription and home
medication) (Bolas 2004), medication summary sent to a long-
term care facility and actual medication sent (Crotty 2004), and a
medication discharge planner and community pharmacy records
(Lalonde 2008). One study recorded the outcome as whether
reconciliation took place or not (George 2011). Seven studies
recorded the outcome in various ways (“Omissions, prescribing
and communication errors” Hale 2013; “medication discrepan-
cies with potential ADEs” Kripalani 2012; “missed and incorrect
dose and frequency of medications” Marotti 2011; “drug therapy
inconsistency and omission” Nickerson 2005 and medication er-
rors (including omissions) Khalil 2016, “Reconciliation Error that
Reached the Patient” (Vega 2016), “admission medication order
error” (Pevnick 2018), and one study did not report how the out-
come was defined (Heng 2013).
Seven study authors provided additional study data or a reanal-
ysis of published data (Farley 2014; George 2011; Hale 2013;
Kripalani 2012; Lalonde 2008; Marotti 2011; Tompson 2012).
Outcome assessment was done variously by the study pharmacist
(Beckett 2012; Eggink 2010; Farley 2014; Hawes 2014; Kwan
2007; Nickerson 2005; Pevnick 2018; Tompson 2012), or other
members of the research team (Becerra-Camargo 2013; Bolas
2004; Char 2017; George 2011; Hale 2013; Ibrahim 2012; Khalil
2016; Kripalani 2012; Marotti 2011; Schnipper 2006; Schnipper
2011); and it was unclear in five studies who had performed the
outcome assessment (Cadman 2017; Crotty 2004; Heng 2013;
Lalonde 2008; Vega 2016). Only six studies specifically men-
tioned blinding of outcome assessors (Becerra-Camargo 2013;
Farley 2014;Hale 2013; Ibrahim2012;Kripalani 2012; Schnipper
2006).
Twenty studies reported a dichotomous outcome of at least one
discrepancy per patient (Becerra-Camargo 2013; Beckett 2012;
Char 2017; Crotty 2004; Eggink 2010; George 2011; Hale 2013;
Hawes 2014; Heng 2013; Ibrahim 2012; Kripalani 2012; Kwan
2007; Lalonde 2008; Marotti 2011; Nickerson 2005; Schnipper
2006; Schnipper 2011; Tompson 2012; Vega 2016; Yau 2008).
Two studies reported a dichotomous outcome of any discrep-
ancy per medication (Eggink 2010; Hale 2013). Five stud-
ies reported discrepancies per patient as a continuous outcome
(Becerra-Camargo 2013; Cadman 2017; Farley 2014; Kripalani
2012; Pevnick 2018). One study reported discrepancies per med-
ication as a continuous outcome (Lalonde 2008). In those studies
reporting discrepancies as a continuous outcome, not all studies
reported a mean and standard deviation of discrepancies per unit
of analysis. Only two studies reported median figures per group
(Becerra-Camargo 2013; Kripalani 2012).
Secondary outcomes
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Participant-related and process outcomes
Three studies reported PADEs (Ibrahim 2012; Kripalani 2012;
Schnipper 2006). Ibrahim 2012 and Schnipper 2006 report this
as “preventable” ADEs but used the same methodology (Bates
1995). Four studies reported ADEs (Crotty 2004; Ibrahim 2012;
Kripalani 2012; Schnipper 2006). One study reported mortality
(Cadman 2017).
Healthcare utilisation
Eight studies reported anoutcomefitting the descriptionof health-
care utilisation. These were often listed as secondary or composite
outcomes and the trialswere not powered todetect a significant dif-
ference between groups. Schnipper 2006 stated primary care visits
(“scheduled/unscheduled office visits”) as an outcome but did not
actually report them. Five studies reported ED visits (Crotty 2004;
Hawes 2014; Ibrahim 2012; Kripalani 2012; Schnipper 2006), 10
reported unplanned rehospitalisation (Bolas 2004; Cadman 2017;
Char 2017; Crotty 2004; Hawes 2014; Ibrahim 2012; Kripalani
2012; Pevnick 2018; Schnipper 2006; Tompson 2012), and five
reported length of stay (Bolas 2004; Cadman 2017; George 2011;
Pevnick 2018; Tompson 2012).
Additional outcomes
None of the studies reported adverse effects of interventions. Two
studies reported resource use by reporting the median time spent
with participants to deliver the intervention, with one extrapolat-
ing possible full-time equivalent (FTE) pharmacists required for
intervention implementation (Beckett 2012; Khalil 2016).
Excluded studies
Most studies that we excluded were not randomised trials (Figure
1). We reported on a selection studies in the Characteristics of
excluded studies table.
Studies awaiting classification
We found no studies awaiting classification.
Ongoing studies
There were 16 ongoing studies (see Characteristics of ongoing
studies table). These included trial registered protocols, abstracts,
conference proceedings or a combination of these. All studies
stated a randomised design. Seven studies are listed as occurring
in the USA; three in France; two in Australia; and one each in
Norway, Taiwan, the UK and Germany. Only one study is re-
cruiting participants under 18 years of age. Five studies specifically
recruited participants aged 65 years and older. Three studies are
based in primary care and the remainder are hospital based. Six
studies describe their intervention as ICT-based and the remain-
der are pharmacist delivered.
Risk of bias in included studies
Details of the risk of bias are presented in Figure 2 and Figure 3
and in the Characteristics of included studies tables. There were
no major differences in the risk of bias of studies included in the
review.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Twenty-two trials reported adequate sequence generation;13 re-
ported concealment of allocation (Figure 2).Two studies were at
high risk of bias with no concealment of allocation (Tompson
2012) or allocation sequence generation (Beckett 2012), and the
remainder were at unclear risk.
Blinding
Nine studies had low risk of performance and detection bias as ei-
ther blinded measurement of outcomes had taken place to ensure
that primary outcome assessors had no knowledge of the inter-
vention received by participants or the outcomes were objective
(Figure 2).
Incomplete outcome data
Fifteen studies adequately addressed incomplete outcome data
(Figure 2). In one study, 35 participants consented but the analysis
included only 29 participants and were removed with no expla-
nation ( Yau 2008). Another study randomised 92 participants to
the intervention group and 84 participants to the control group
( Schnipper 2006). Due to loss to follow-up, their primary anal-
ysis included only 79 in the intervention group and 73 in the
control group. There was no imputation of missing data when
reporting the results. Loss to follow up, with either an imbalance
between groups or insufficient descriptive detail, affected other
studies (Ibrahim 2012;Lalonde 2008;Tompson 2012).
Selective reporting
Farley 2014 was a substudy of a larger trial and did not report
identified outcomes of the larger trial.
Other potential sources of bias
Two studies had no information beyond a conference abstract
so there was little methodological detail to assess (Heng 2013;
Schnipper 2011), with one study author providing an unpublished
manuscript for additional detail (Yau 2008). Two studies had pos-
sible selection bias issues by not including certain wards ( Kwan
2007) or prespecifying a large number of conditions/requirements
for exclusion ( Lalonde 2008). Two studies only recruited partic-
ipants when the intervention pharmacist was scheduled to work
in the clinic or between certain hours ( George 2011; Nickerson
2005). One study changed the inclusion criteria significantly in
the second year of recruitment (Hawes 2014). Contamination bias
(when members of the control group were inadvertently exposed
to the intervention) was an important limitation in many of the
included studies in this review. Sixteen studies were at high risk of
contamination, with a further two where it was unclear whether
protection against contamination had been provided.
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Publication bias
Funnel plots of postintervention estimates of the primary outcome
for 20 studies showed a visually mildly asymmetrical plot suggest-
ing the possible presence of bias potentially because some smaller
studies of lower methodological quality producing an exaggerated
intervention effect estimates (Figure 4). However, considering the
dichotomous nature of the outcome, this was further tested using
theHarbord’s modified test for small-study effects (P = 0.601) and
the Peter’s test (P = 0.739); neither of which showed evidence of
a publication bias.
Figure 4. Funnel plot: at least 1 medication discrepancy per participant (dichotomous, per participant):
reconciliation at any time point.
Unit of analysis error
One study, a cluster randomised trial, did not appear to take ac-
count of clustering at the practice level (Schnipper 2011). Adjust-
ment of the reported incident rate and subsequent effect size was
undertaken to allow for this (an intracluster correlation coefficient
(ICC) of 0.06 was chosen from a similar study’s methodology
(Westbrook 2016)). None of these influenced the pooled point
estimate and CIs in considering the primary comparison where
the study was included. See Analysis 1.1.1.
Effects of interventions
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See: Summary of findings for the main comparisonMedication
reconciliation interventions compared to standard care for all
patients at a transition of care
Primary outcomes
See Summary of findings for the main comparison for the main
comparisons. Meta-analysis of the primary outcomes showed a
high degree of statistical heterogeneity and low certainty of evi-
dence, making it difficult to have any certainty of the effect of the
interventions.
Medication discrepancies
At least one medication discrepancy per participant
Twenty studies (participants = 4629; intervention group = 2274;
control group = 2355) had sufficient data to pool results for the
dichotomous outcome of at least one medication discrepancy per
patient. There was no certainty of the effect due to very low cer-
tainty evidence (RR 0.53, 95% CI 0.42 to 0.67; Analysis 1.1.1;
very low-certainty evidence). There was marked heterogeneity be-
tween studies (I2 = 91%, P < 0.00001) (note that this RR was for
reconciliation at any time point).
• Reconciliation at admission:
◦ RR 0.43, 95% CI 0.27 to 0.68; participants = 1167;
studies = 4; very low-certainty evidence (Analysis 1.1.2).
• Reconciliation at discharge:
◦ RR 0.71, 95% CI 0.50 to 1.02; participants = 649;
studies = 5; very low-certainty evidence. (Analysis 1.1.3).
• Reconciliation throughout hospital stay:
◦ RR 0.92, 95% CI 0.80 to 1.07; participants = 933;
studies = 2; very low-certainty evidence. Farley 2014 described
the intervention as being discharge focused, but provided
reconciliation at admission and discharge and reported a
continuous outcome (Analysis 1.1.4).
• Reconciliation at preadmission clinic (PAC):
◦ RR 0.38, 95% CI 0.13 to 1.11; participants = 1082;
studies = 3; very low-certainty evidence (Analysis 1.1.5).
Number of medication discrepancies per participant
There was no certainty on the effect of reconciliation (MD -1.18,
95% CI -2.58 to 0.23; studies = 4; participants = 1963; very low-
certainty evidence; Analysis 1.2) and a high degree of statistical
heterogeneity (I2 = 96%). Cadman 2017 reported 0.02 discrep-
ancies in the intervention and 2.71 in the control group, but did
not provide a standard deviation for pooling.
Discrepancies per participant medication
It was uncertain if discrepancies per medication (reported dichoto-
mously) were reduced, as the certainty of the evidence was very
low (RR 0.13, 95% CI 0.01 to 1.29; studies = 2; participants =
3595; very low-certainty evidence; Analysis 1.3). There was a high
degree of statistical heterogeneity in the pooled odds ratio of these
studies (I2 = 98%). Only one study reported discrepancies per
medication as a continuous measure (MD -2.10, 95% CI -9.64
to 5.44; participants = 82; Analysis 1.4).
Interventions often concentrated on a specific transitionpoint (e.g.
hospital admission), therefore studies reporting the primary out-
come were further subgrouped into the transition point primarily
focused on in their intervention. Again, due to the certainty of
evidence being very low no conclusions could be drawn on the
impact of the intervention.
Two studies did not report the outcome of discrepancies in a di-
rectly comparable way. The study authors when contacted were
unable to provide the original data (Bolas 2004; Khalil 2016).
Bolas 2004 reported the mismatch between discharge prescrip-
tions and home medication upon discharge in 171 participants
based on three criteria: drug name (P < 0.005), dose (P < 0.07) and
frequency (P < 0.004). There were no further details, including
number of participants per groups etc., available. Khalil 2016 re-
ported a reduction in all medication errors (which included omis-
sions) in the intervention group (P < 0.0001).
Secondary outcomes
Participant-related and process outcomes
Medication discrepancy with potential for adverse drug
events
One study reported potential ADEs; defined as being due to dis-
crepancies or non-adherence (Kripalani 2012). It reported an ad-
justed incidence rate ratio between groups of 0.79 (95% CI 0.61
to 1.01).
Three studies described an outcome of PADEs or ameliorable
ADEs calculated using the Bates methodology to retrospectively
identify medication-related ADEs with no certainty of whether
reconciliation reduced PADEs (RR 0.37, 95% CI 0.09 to 1.57;
participants = 1253; very low-certainty evidence).Note Kripalani’s
methodology lists secondary outcomes of PADEs and potential
ADEs but reported ADEs and potential ADEs (Analysis 1.5).
Adverse drug events
Four studies reported reconciliation may make little or no dif-
ference to ADEs (RR 1.09, 95% CI 0.91 to 1.30; participants =
1363; studies = 4; low-certainty evidence; Analysis 1.6). There was
little statistical heterogeneity between the studies (I2 = 0%).
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Mortality
One study reported no difference in mortality (RR 0.75, 95% CI
0.27 to 2.08; participants = 190; low-certainty evidence; Analysis
1.7).
Medication adherence (non-adherent with at least one
medication)
Two studies directly asked participants about adherence to medi-
cation, reporting a dichotomous outcome of those who were not
adherent to at least one medication (RR 0.76, 95% CI 0.41 to
1.42; participants = 379; very low certainty) (Analysis 1.8). One
study reported adherence via the Morisky Medication Adherence
Scale (MMAS-8), but only for all participants as one group (Char
2017).
Healthcare utilisation
Primary care visits
None of the studies reported primary care visits.
Emergency department visits
One study reported reduced rates in favour of the intervention
(RR 0.07, 95% CI 0.00 to 1.07; participants = 61; Analysis 1.9).
Unplanned rehospitalisation
There was probably little or no difference in unplanned rehospi-
talisations (RR 0.72, 95% CI 0.44 to 1.18; participants = 1206;
studies = 5; I2 = 45%;moderate-certainty evidence; Analysis 1.10).
Hospital usage (composite measure of emergency
department, rehospitalisation)
Four studies reported a combined measure (hospitalisation, ED
attendance) of healthcare utilisation with no certainty of the effect
of the intervention (RR 0.78, 95% CI 0.50 to 1.22; participants =
597; studies = 4; very low-certainty evidence). There was some ev-
idence of heterogeneity between these studies (I2 = 48%) (Analysis
1.11).
Length of stay
Five studies reported on length of stay, with only two studies pro-
viding both means and standard deviations (MD 0.48, 95% CI -
1.04 to 1.99; participants = 475; studies = 2; I2 = 52%; very low-
certainty evidence; Analysis 1.12).
Additional outcomes
Adverse effects of interventions
None of the studies reported adverse effects of interventions.
Resource use
Two studies reported on the median time spent with patients to
deliver the intervention, with one extrapolating possible Full Time
Equivalent ( FTE) pharmacists required for intervention imple-
mentation ( Beckett 2012; Khalil 2016).
Sensitivity analysis
The primary comparison of at least one medication discrepancy
per participant: reconciliation at any time point reported a high
degree of statistical heterogeneity (RR 0.53, 95% CI 0.42 to 0.67;
participants = 4629; studies = 20; I2 = 91%; Analysis 1.1.1).
We undertook a sensitivity analysis to investigate the effect of
those studies with a high risk of bias on the primary comparison.
Five studies reported a high summary risk of bias (Beckett 2012;
Ibrahim 2012; Lalonde 2008; Tompson 2012; Yau 2008). Once
we excluded these studies, there was no appreciable difference in
the pooled estimate or CI of the primary outcome (RR 0.50, 95%
CI 0.38 to 0.67; participants = 3700; studies = 15). There was
also no improvement in the reported statistical heterogeneity (I2
= 91%).
Furthermore, we undertook an analysis of the 20 studies included
in the primary outcome to investigate the influence of a single
study on the overall meta-analysis estimate. This was done via
the ’metainf ’ command in Stata (where the meta-analysis was re-
estimated omitting each study in turn). Inspection of the graphical
output showed no undue influence of any one study (figure not
shown).
Metaregression
To examine the potential effect of certain study characteristics on
the effect size, we identified a small number of characteristics a pri-
ori and we undertook a metaregression of the effect estimate and
potential effect modifiers. We tested age, number of medications,
summary risk of bias and transition point at which an intervention
was applied. It was agreed that the proportions of chronic illnesses
in studies was less clearly reported and, therefore, not appropriate
to examine further. Pharmacists primarily delivered the interven-
tion in 18 of the 21 studies, therefore, there was little value in
subgrouping between different intervention types.
We tested mean number of medications in 18 studies as a contin-
uous and categorical (five or more medications - polypharmacy,
10 or more medications - excessive polypharmacy) variable. Nei-
ther continuous (β = 0.14, 95% CI -0.14 to 0.41, P = 0.312) nor
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categorical (polypharmacy: β = 1.17, 95% CI -0.17 to 2.51, P =
0.082), excessive polypharmacy: β = 1.28, 95% CI -0.89 to 3.46,
P = 0.229) variables proved to be influential. We repeated this
analysis with polypharmacy defined as four or more medications
with the results unchanged.
We tested mean age of study participants in 20 studies with no
effect found (β = 0.01, 95% CI -0.04 to 0.02, P = 0.472) and a
summary risk of bias measure for 20 studies with no effect found
(e.g. low risk of bias compared to unclear risk of bias) (β = 0.33,
95% CI -1.07 to 1.73, P = 0.624).
We included 20 studies comparing the transition point at which
the study intervention was applied (PAC, admission, throughout
hospital stay, discharge and others) with none reporting differ-
ences.
D I S C U S S I O N
Summary of main results
The outcomes are presented in Summary of findings for the main
comparison with the presence of at least one medication discrep-
ancy per participant, at any transition following reconciliation,
being the main outcome used in the included studies to measure
the effectiveness of reconciliation. We pooled 20 of the 25 studies
in a meta-analysis of the dichotomous outcome of the presence
of discrepancies or not. The pooled effect showed a reduced rel-
ative risk in the intervention group at any time point (RR 0.53,
95% CI 0.42 to 0.67; Analysis 1.1). However, there was a high
degree of heterogeneity in the effect of the interventions on the
presence of discrepancies (I2 = 91%).We investigated this via both
meta-regression and sensitivity analysis with no obvious influence
of a single study, or study characteristic (number of medications,
age, transition point, risk of bias). Consequently, the limited ev-
idence that reconciliation reduced medication discrepancy has to
be treated with caution.
We also reported the primary outcome of discrepancies as both a
continuous measure per patient and per medication. Neither of
these showed a consistent trend in the effect of the intervention.
The certainty of the evidence for these outcomes was very low.
We undertook subgroup analysis to investigate the effect of recon-
ciliation on specific transitions. Studies were grouped via hospital
admission, discharge, throughout the hospital stay and PACs. Of
the four studies pooled where interventions were applied primar-
ily at hospital admission, there was uncertainty of the effect on
discrepancies (RR 0.43, 95% CI 0.27 to 0.68), again with a high
degree of heterogeneity (I2 = 91%). None of the other transitions
showed an effect of the intervention on discrepancies. The cer-
tainty of the evidence was very low.
Secondary outcomes of PADEs, ADEs, a composite measure of
healthcare utilisation (ED visits, and rehospitalisation) and med-
ication adherence showed no consistent effect of the intervention
with the certainty of the evidence being low or very low. The inter-
vention also probably had little or no impact on unplanned rehos-
pitalisation with moderate-certainty evidence (RR 0.72, 95% CI
0.44 to 1.18; participants = 1206; studies = 5; I2 = 45%; Analysis
1.10)). Of note, none of the studies reported the potential adverse
effects of interventions and only two studies briefly mentioned
resource usage.
Overall completeness and applicability of
evidence
The types of interventions included in the review were primarily
pharmacist delivered. Only one trial involved using an electronic
reconciliation tool. The interventions were complex and mostly
multifaceted with notable variability between studies in how they
were applied locally. This considerable local variability limits the
generalisability of effects to settings beyond the original study en-
vironments.
Although there was a promising result suggesting that the inter-
ventions described in this review were successful in improving the
presence of discrepancies per participant, the certainty of the ev-
idence was very low. In addition, the clinical impact of this in-
tervention on the secondary clinical outcomes was also unknown.
The various endpoints of medication discrepancies and PADEs
considered in this review were surrogate markers. Only five of the
included studies reported healthcare utilisation, with the outcome
variously reported. Of note, other non-included studies have fo-
cused on this outcome but this review included studies based on
the primary outcome of discrepancies. Future research should fo-
cus on designing studies adequately powered to investigate clinical
outcomes such ADEs, ED visits and hospital (re)admissions.
Finally, many of the studies were affected by incomplete outcome
data with 10 studies classed as high or unclear risk of attrition bias.
This impacts on the certainty of the evidence as reported in the
GRADE process of the ’Summary of findings’ table.
Certainty of the evidence
Different definitions, data collection procedures and follow-up
duration make comparison to other studies difficult. The hetero-
geneity between studies included in this review should be treated
cautiously as the interventions did not seem to work consistently
across all studies. Factors contributing to this heterogeneity in-
cluded variation in types, intensity and duration of interventions,
or differences in timing of follow-up measurements. This is per-
haps because of differences in how the interventions were pro-
vided, background practice, and culture and variable processes in
delivery of care.
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Potential biases in the review process
There was evidence of potential bias in some studies, for example
only 13 studies reported adequate concealment of allocation and
only three reported appropriate protection from contamination,
both of which may have influenced the effect estimate in these
studies and therefore the overall pooled estimate.
A limited number of the possible studies testing reconciliation as
an interventionwere included in this review asmany did not report
the primary outcome of this review (medication discrepancies).
This limits the relevance of this review in commenting on the
effects of reconciliation on long-term patient-focused outcomes
(e.g. ADEs, rehospitalisation). However, in considering the causal
pathway of ADEs arising from care transitions, it was deemed that
discrepancies were the most likely starting point and, therefore,
most worthwhile studying.
As shown in the ’Summary of findings’ table for the main com-
parisons, the certainty of evidence presented in this review, as de-
scribed by the GRADE approach, was almost universally very low
(Summary of findings for the main comparison).
We placed no language restrictions on the search strategy, but
all of the included trials were published in English. Funnel plots
and formal tests of publication bias showed no apparent cause for
concern regarding this bias.
Agreements and disagreements with other
studies or reviews
We identified 45 relevant previously published reviews and reports
(Appendix 2). The conclusions were similar, that is, there were
mixed results from several intervention types tested in heteroge-
neous studies of limited methodological quality.
Many reviews included non-randomised study designs, a reflec-
tion of the more common method by which reconciliation ef-
forts are studied (e.g. controlled before-and-after study, inter-
rupted time series). Most studies included in reviews were con-
ducted in high-income countries. Hospital-based care was the
most commonly studied transition, with primary care (Bayoumi
2009; Nazar 2015), and long term-care (Chhabra 2012), less so.
Medication discrepancies were extremely common (3.4% to
98.2% of participants) (Lehnbom 2014). However, there is lim-
ited evidence of the potential for harm from these discrepancies
(Kwan 2013).
Most studies found an improvement in process measures (
Spinewine 2013), but disagreed on the impact of interventions
on ADEs, hospital readmissions andmedication adherence (Kwan
2013; Mueller 2012; Mekonnen 2016; Mekonnen 2016a). There
was significant study population, intervention and outcome het-
erogeneity. In addition, most studies were underpowered to ex-
amine clinical outcomes. No review carried out formal cost-ben-
efit analysis of interventions, this is an underexplored area with
limited publications generally (Karnon 2009). Meta-analysis was
often not undertaken due to the dissimilarity of studies.
Pharmacist-conducted reconciliation (e.g. transition pharmacist
co-ordinator) was the most commonly studied intervention, with
ICT interventions less commonly tested (Bassi 2010). Measures
that worked included pharmacist involvement, patient education,
counselling, improved HCP communication and targeting high-
risk populations.
Reviews call for further research on high-risk populations, multi-
centre designs and adequate sample size to evaluate clinical out-
comes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The interventions implemented in the studies in this review re-
duced the number of medication discrepancies at care transitions;
however, the certainty in this result is unclear as the evidence was
of very low certainty. Included studies had no clear effect on any
other patient-focused outcome (e.g. emergency department visits,
adverse drug events) again with the evidence being of very low
certainty. The majority of studies implemented reconciliation via
pharmacist-mediated efforts.
Implications for research
Overall, the quality of the studies in this review was poor and
further research should attend to the rigour in study design. The
term ’medication discrepancies’ has no uniform definition, mak-
ing objective comparison between studies difficult. Further work
is required to develop a consensus on identifying, defining, mea-
suring and reporting discrepancies. Future studies should utilise
clear definitions of discrepancies as well as objective measurement
techniques and appropriate choice of time points attendant to the
transition point at which the intervention is applied. Similarly the
method by which ’gold standard’ medication lists are compiled
is not uniform and therefore the subsequent identification of dis-
crepancies is entirely dependent on this process.
To ensure the accurate replication of successful study interven-
tions there should be careful documentation of the development
of interventions and the training and background of the providers.
Documentation of intervention processes utilised would enable
identification of the critical elements for successful interventions.
Many of the studies included in this review lacked sufficient detail
in how these processes were conducted.
The lack of economic analysis of the interventions included in
this review is also important. Policy makers require cost-benefit
analysis information in deciding to fund interventions.
The prioritisation of patient-level outcomes (e.g. hospitalisations,
adverse drug events) is also an important consideration. The link
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between discrepancies and subsequent increased healthcare utili-
sation, while plausible, is not clear. Therefore, planning studies of
sufficient power to test these hypotheses is important.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Becerra-Camargo 2013
Methods Study design: multicentre, double-blind, randomised and controlled parallel-group trial
Unit of allocation: participants and doctors randomly assigned to intervention or stan-
dard care groups
Unit of analysis: individual participant
Follow-up: outcome recorded at admission
Duration: admission interface, first 24 hours
Providers: pharmacist-acquired medication history, made available for use to support the
doctor. Little detail provided regarding credentials of intervention pharmacist
Participants Setting/participants: 270 participants (intervention: 134; control: 136). 3 large teaching
hospitals in Bogota, Colombia
Lost to follow-up: intervention: 17; control: 11
Study period: 26 October to 30 November 2012
Inclusion criteria: consecutive participants (aged ≥ 18 years) admitted an ED, taking
≥ 1 medication or had been prescribed ≥ 1 prescription medication before admission,
assessed as triage I and II on admission and hospitalised for ≥ 24 hours
Transition of care: admission through ED
Age (mean): intervention: 59 (SD 18) years; control: 58 (SD 20) years
Female: intervention: 59.8%; control: 56%
Ethnicity: no information
Interventions Intervention: pharmacist-acquired medication history in ED focusing on participant’s
current homemedication regimen documented on the AMO form (F1). Doctors verified
data with participants and indicated which home medications were to be reordered,
suspended or discontinued
Control: standard care; included doctors documenting medication histories in admis-
sion notes and nurses reviewing medication orders for appropriateness. Doctors wrote
inpatient orders during consultation without having access to F1 (form completed for
intervention group). Medication information entered on each medical chart forming
part of hospital’s eHRs. Pharmacists not routinely involved in documenting participants’
admission medication histories, which was primarily the admitting resident doctor or
medical student’s responsibility
Outcomes ≥ 1 admission medication discrepancy (defined as any medication clarification related
to current home medication made whilst being in ED. Could have been associated with
any of the following: drug, dosage, frequency, administration route, appropriateness of
restarting medication, therapeutic duplicity, medications lacking indication, or a com-
bination. Discrepancies identified using a systematic approach
Characteristics of discrepancy: not recorded.
Clinical severity of discrepancy: degree of effect for each medication discrepancy defined
as (Cornish 2005): Class 1: unlikely to cause participant discomfort or clinical deterio-
ration; Class 2: potential to cause moderate discomfort or clinical deterioration; Class 3:
potential to result in severe discomfort or clinical deterioration
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Becerra-Camargo 2013 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by each randomisation manager
daily and depended on number of partici-
pants, doctors and residents per shift. Com-
bined coded numbers concealed in sequen-
tially numbered, sealed, opaque envelopes
and kept by clinical trials group at Univer-
sidad Nacional de Colombia, Bogota. As-
signments concealed in sequentially num-
bered containers. All envelopes numbered
in advance and equal in weight and ap-
pearance. Guaranteed that envelopes were
opened sequentially and only after a par-
ticipant’s name and other details had been
written on the assignation list (page 5)
Allocation concealment (selection bias) Unclear risk Allocation by each randomisation manager
daily and depended on number of partici-
pants, doctors and residents per shift. Com-
bined coded numbers concealed in sequen-
tially numbered, sealed, opaque envelopes
and kept by clinical trials group at Univer-
sidad Nacional de Colombia, Bogota. As-
signments concealed in sequentially num-
bered containers
Were baseline outcome measurements sim-
ilar?
Low risk Table 1 gave participants’ baseline demo-
graphic and clinical characteristics. Little or
no differences between treatment groups
Were baseline characteristics similar? Low risk Number lost to follow-up: intervention:
17; control: 11; mainly due to non-adher-
ence to protocol (i.e. discharged before 24
hours’ follow-up) (Figure 2, page 7)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcome was objective.
Secondary outcomes: authors stated, “The
clinical severity ofmedicationdiscrepancies
was independently assessed by two clinical
pharmacists blinded to the patient data col-
lection forms” (page 3)
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Becerra-Camargo 2013 (Continued)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk Participants and doctors randomised. Doc-
tors assigned to receive only participants
in intervention or control group during
their shifts to ensure blinding. Forms were
identical (e.g. logo, colours and fonts) so
doctor though s/he was filling out another
new form. All statistical analysis involved
maintaining the masking. Analysis com-
pleted before randomisation code broken
at end of completed trial. Each researcher
sent data online via an information system
link provided by statistics office. All records
checked
Was the study adequately protected against
contamination?
Low risk No issues
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in results section (page 3, outcomes;
page 5, results)
Other bias Low risk No evidence of any other bias.
Summary risk of bias Unclear risk Unclear
Beckett 2012
Methods Study design: randomised non-blinded trial with randomisation based on last digit of
medical card number (i.e. quasi-randomised); intervention: even numbers; control: odd
numbers
Unit of allocation: participant
Unit of analysis: participant
Follow-up: 48 hours post admission
Duration: admission to 48-hour post pharmacist medication review
Providers: pharmacists, no information provided regarding their credentials
Participants Setting/participants: 81 participants (: 41; control: 40 control). Aged > 70 years eligible
for inclusion if they were admitted to 1 of 2 general medicine floors or 1 general surgery
floor, Rush University Medical Center, Chicago, IL, USA (676-bed tertiary care medical
centre)
Study period: 1 December 2009 to 31 March 2010)
Exclusion criteria: expected duration of hospital stay < 48 hours as indicated by admission
to a designated short-stay service or if admitted to a primary service rounding with a
clinical pharmacist
Transition of care: comprehensive MR performed by a pharmacist within 24 hours of
admission
Age (mean): intervention: 80 (SD 6.7) years; control: 79 (SD 7.1) years
Female: intervention: 63.4%; control: 62.5%
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Beckett 2012 (Continued)
Ethnicity: intervention: white 46.3%; African American 43.9%; Hispanic 9.8%; Asian
American 0%. Control: white 55%; African American 32.5%; Hispanic 7.5%; Asian
American 5%
Interventions Intervention: pharmacist-led MR within 24 hours of inpatient admission. Pharmacists
were required to use ≥ 1 source of information apart from participant’s eMR and in-
terviewed every participant when feasible. There were situations when a full participant
interview by pharmacist was not conducted, but these were limited to participants un-
able to participate in an interview for medical, psychological or social reasons. Other
sources of information included, but were not limited to, family discussion, review of a
home medication list, assessment of prescription vials and communication with outpa-
tient or retail pharmacy. Pharmacists used standard MR form prefilled with participant
demographic and background information and home medications from the medical res-
ident history and physical note to guide participant discussion. Prior to, and throughout,
study, pharmacists received training regarding expectation for the project and how best
to interview participants, identify discrepancies and document interventions (primarily
to promote standardised approach between clinicians). Discrepancies broadly defined
as: any inappropriate medication use or ordering requiring intervention per the pharma-
cists’ clinical judgement. Interventions communicated to participant’s primary medical
resident using electronic paging, telephone conversation or personal interaction
Control group: standard hospital practice of admitting medical resident or intern per-
formed MR at time of admission or as soon as family could be contacted for any neces-
sary input. Additionally, as part of existing hospital practice, staff pharmacists reviewed
medication orders for appropriateness and agreement with electronic home medication
list completed by admitting medical resident; however, they did not have significant
opportunity for direct participant contact and relied on that list to be accurate. Con-
trol participants received standard practice followed by additional quality assurance per-
formed by a pharmacist at 48 hours after admission, to determine whether the original
medication list was reconciled correctly and allow for comparison to intervention group
Outcomes Primary endpoint: medication profile appropriateness at 48-hour pharmacist review (all
discrepancies from MR resolved and all medication use appropriate as documented by
reviewing pharmacist)
Secondary endpoint: type of discrepancies (Table 2 and Table 3)
Notes Included based on advice from EPOC contact editor (JS). Possible bias because of quasi-
randomisation
Limited to people aged ≥ 70 years (e.g. potential bias with regard to comorbidity,
polypharmacy, susceptibility to drug-related harm)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk All participants randomly assigned to con-
trol or pharmacist-ledMR based on the last
digit of their medical record number (i.e.
intervention: evens; controls: odds) (page
137). Discussed with EPOC contact editor
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Beckett 2012 (Continued)
(JW) and advised to keep in with note of
possible bias
Allocation concealment (selection bias) High risk All participants randomly assigned to either
control or pharmacist-ledMR based on the
last digit of their medical record number (i.
e. intervention: evens; controls: odds) (page
137)
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measure of outcome
Were baseline characteristics similar? High risk Baseline characteristics similar between
groups except that 37% of participants had
altered mental status per pharmacist assess-
ment in intervention group compared to
23% in control group (Table 1). Analysis
not adjusted for any differences (page 138)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not specified
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk Outcomes were objective.
Was the study adequately protected against
contamination?
High risk Participants randomised and intervention
conducted by pharmacist and control by
admitting medical resident or intern
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in results section (pages 137 and
138)
Other bias Low risk No evidence of any other bias
Summary risk of bias High risk High
Bolas 2004
Methods Study design: randomised trial (cluster)
Unit of allocation: participant
Unit of analysis: participant
Follow-up: following discharge, at participant’s home
Duration: full inpatient episode, from initial presentation through to discharge
Providers: liaison pharmacist, no information provided regarding credentials
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Bolas 2004 (Continued)
Participants Setting/participants: 243 participants (intervention: 119; control: 124). 162 participants
completed full protocol. Recruited after emergency or unplanned admission to medical
admissions unit at Antrim Area Hospital, Northern Ireland (426-bed district general
hospital). Participants in the area were registered with 1 GP and admitted to Antrim
Hospital on a geographical basis
Inclusion criteria: aged ≥ 55 years and receiving > 3 drugs, which were taken regularly
and not on an as required basis. Participants were excluded from the study if they were:
transferred to another hospital, admitted or transferred to a nursing home, participant
or carer unable to communicate with pharmacist, any mental illness or alcohol-related
admission or home visit or follow-up was declined on admission
Transition of care: admission and discharge
Age (mean): intervention: 73 years; control: 75 years
Female: intervention 41/81; control: 39/81
Ethnicity: not reported
Interventions Intervention: full medication history taken by comparing GP referral letter, initial in-
patient prescription, GP surgery record, community pharmacy PMR, participant’s own
drugs brought into hospital and participant or carer as sources of information. Uninten-
tional discrepancies were recorded. Recorded prescription and non-prescription medi-
cation and herbal product use. Final correct version of drug history verified by liaison
pharmacist was used as gold standard to compare the other sources for accuracy
• Daily contact with participant to explain changes made to their treatment as they
happened.
• Preparation of discharge letter which was then signed by junior doctor (currently
signed off by the clinical pharmacists).
• Preparation of a pharmaceutical discharge letter which was faxed with discharge
prescription to the GP and CP on day of discharge.
• Preparation of personalised medicines record sheet and discharge counselling.
• Provision of medicines helpline which was advertised by a card given to all
participants enrolled in study inviting them to request further information if required
after discharge.
• Assessment and management of participant’s own drugs brought into hospital and
rationalisation of these against discharge medication when participant was going home.
Control: standard clinical pharmacy service, which did not include discharge counselling.
Few further details provided
Outcomes Primary outcome unclear.
Outcomes included: Eadon scores (for intervention only); name of drug, dose and fre-
quency of complete drug history compared to other sources (intervention only); mis-
match between GP prescription and hospital discharge letter; participant recall of drugs;
emergency readmission rates; rate of reconciliation of participants own drugs with dis-
charge medications
Notes Contacted authors for original data to reanalyse the mismatch data (presented as %) for
our primary outcome; unable to provide additional data
Risk of bias
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Bolas 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number
(page 115)
Allocation concealment (selection bias) Unclear risk Not specified, computer-generated num-
ber but was the computer on site? (page
115)
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measurements (pages 116 and
117)
Were baseline characteristics similar? High risk Characteristics only for those who finished
the protocol, not all those randomised
(page 116)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Table 1 had similar numbers in each group
(page 117)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Unclear risk Not all outcomes were objective.
Was the study adequately protected against
contamination?
High risk Participants were randomised; however, 11
received counselling and were excluded
(pages 115 and 116)
Selective reporting (reporting bias) Low risk All outcomes mentioned in the methods
were reported in the results (page 116 and
117)
Other bias Low risk Primary outcome not clearly specified
Summary risk of bias Unclear risk Unclear
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Cadman 2017
Methods Study design: parallel-group randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: admission through to GP provided data at 3 months post discharge
Duration: admission through to discharge
Providers: hospital pharmacist
Randomisation: Norwich Clinical Trials Unit automated service with participants strat-
ified by ward. When wards were later closed for infection control reasons, participants
on the ’backup ward’ were randomised and stratified as if they had entered the closed
ward
Participants Setting/participants: 200participants randomised (intervention: 96; control: 102). Cam-
bridge University Hospitals NHS Foundation Trust on 5 adult medical wards from a
range of medical specialities where participants did not routinely receive MR from a
pharmacist within 24 hours of admission. 1 similar ward was identified as a ’backup’,
in the eventuality that one of the study wards was closed for any reason (e.g. norovirus
outbreak) during recruitment period
Transition of care: hospital admission through to discharge
Ethnicity: not reported
Baseline characteristics
Intervention
• Female: 45 (46.9%)
• Age (mean): 67.6 (SD 19.0) years
• Number of regular medicines (mean): 5.84 (SD 4.07)
• Number of as required medicines (mean): 0.85 (SD 2.08)
• EQ5D Quality of Life score (mean): 55.9 (SD 23.2)
Control
• Female: 60 (58.8%)
• Age (mean): 65.4 (SD 20.2)
• Number of regular medicines (mean): 6.67 (SD 4.64)
• Number of as required medicines (mean): 0.95 (SD 2.53)
• EQ5D Quality of Life score (mean): 54.7 (SD 23.5)
Overall
• Female: not reported
• Age: not reported
• Number of regular medicines: not reported
• Number of as required medicines: not reported
• EQ5D Quality of Life: not reported
Inclusion criteria: aged ≥18 years; admitted with ≥ 1 prescribed medicine to 1 of 5
medical wards; not already received MR from pharmacy team as part of routine phar-
maceutical input at time of recruitment; identified from hospital computer system as
having been admitted straight from ED to 1 of the 2 participating wards within previous
24 hours
Exclusion criteria: none reported
Pretreatment: “The groups were broadly comparable”. Statistical significance not re-
ported. Intervention participants appeared to have a slightly higher number of medica-
tions and slightly higher QoL score. Number of regular medicines (mean): control: 6.
67 (4.64); intervention: 5.84 (SD 4.07); EQ5D Quality of Life VAS (mean): control:
54.7 (SD 23.5); intervention 55.9 (SD 23.2)
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Cadman 2017 (Continued)
Interventions Intervention: SOP based on hospital guidelines used to deliver MR by 5 trained MRP
within 24 hours of admission (including weekends) and at point of transfer of care out
of hospital, or as soon as possible following participant discharge from hospital to the
next care provider. Recorded all UDs, defined as differences between participant records
with no identifiable rationale, identified between collated information and inpatient
medication chart on admission and between inpatient chart and discharge letter. MRPs
followed up on all identified UDs to ensure that they were addressed prior to discharge
Control: usual care which may or may not have consisted of MR and where it was
provided it may not have occurred within 24 hours and could either be delivered by a
pharmacist or pharmacy technician. The MRPs within the intervention group did not
deliver MR to control participants and the SOP used for study intervention purposes
was not automatically followed within the control group. All MR details regarding
interventions undertaken within the control group were recorded and costed
Outcomes Length of stay
• Outcome type: continuous
Unintentional discrepancies
• Outcome type: continuous
• Reporting: full
• Notes: number of discrepancies per patient
Hospital readmissions (any)
• Outcome type: dichotomous
• Reporting: fully
• Direction: lower was better
Hospital readmissions (emergency)
• Outcome type: dichotomous
• Reporting: fully
• Direction: lower was better
• Data value: endpoint
Mortality
• Outcome type: dichotomous
• Direction: lower was better
• Data value: endpoint
EQ5D-3L Quality of Life
• Outcome type: continuous
• Reporting: fully
• Data value: change from baseline
Notes Sponsorship source: independent research funded by the NIHR under its Research for
Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0110-20116)
Country: UK
Authors name: Prof David Wright
Institution: University of East Anglia
Email: d.j.wright@uea.ac.uk
Address: School of Pharmacy, University of East Anglia, Norwich, UK
Risk of bias
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Cadman 2017 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisationwas performed us-
ing the Norwich Clinical Trials Unit au-
tomated service with patients stratified by
ward”
Allocation concealment (selection bias) Unclear risk Judgement comment: nothing reported
about concealment prior to delivery of in-
tervention. The manuscript reported that
Norwich Clinical Trials unit was used to
randomise, but did not explicitly mention
allocation concealment
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measurement
Were baseline characteristics similar? High risk Reported groups were “broadly compara-
ble” but did not provide statistical evidence.
There were more women in the control
group and older participants in the inter-
vention. The QoL scoring between groups
was also different
Incomplete outcome data (attrition bias)
All outcomes
Low risk In terms of outcomes, there were complete
data available on length of stay and read-
mission data
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk 3 months post discharge the stored infor-
mation was used to develop an ’accurate
medication list’ for the control group par-
ticipants by the research team on admis-
sion and at discharge. Thesewere compared
with the inpatient chart on admission and
discharge letter to identify any discrepan-
cies. Medical notes were subsequently re-
viewed, unblinded to group allocation, to
enable differentiation between those that
wereUDs that could not be explained from
the information available and those that
were intentional
Was the study adequately protected against
contamination?
High risk High risk due to the nature of the interven-
tion delivery
Selective reporting (reporting bias) High risk Participants’ satisfaction and morbidity
mentioned in protocol, did not seem to be
reported
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Other bias Low risk No evidence of any other bias
Summary risk of bias Unclear risk Unclear risk
Char 2017
Methods Study design: parallel-group randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: primary care visit to 30 days following consultation
Duration: primary clinic review following hospital discharge
Providers: pharmacist
Randomisation: randomised to intervention or control group in balanced allocation.
Computer-generated random list generated using STATA (StataCorp. 2011. Stata Sta-
tistical Software: Release 12. College Station, TX: StataCorp LP). Assignment occurred
within randomly ordered blocks of 2, 4 or 6
Participants Setting/participants: 200 participants recruited and randomised, only 189 (intervention:
95; control: 94) analysed. 3 public sector primary care clinics in Singapore that provide
outpatient, maternal, and child health services in the community
Study period: March 2016 to February 2017
Inclusion criteria: aged ≥ 21 years, taking ≥ 5 chronic medications and on first follow-
up visit to NHGP for chronic disease management following recent discharge from local
public hospital or an ED short stay ward where the participant was admitted for ≥ 24
hours. Required to be able to self-administer medications or be accompanied by a carer
who assisted in administering medications on day of recruitment. Only participants or
primary carers who could give informed consent and speak English, Mandarin or Malay
were recruited
Exclusion criteria: nursing home residents, seeing a NHGPdoctor for an acute condition
or were unwilling to consent to a 30-day follow-up telephone call
Transition of care: primary care visit
Ethnicity (Chinese): intervention: 85.3%; control: 76.6%
Baseline characteristics
• Female: 45 (47.4%)
• Age (mean): 74.8 (SD 10.8) years
• Number of regular medicines (mean): 8.6 (SD 2.9)
• Number of as required medicines: not reported.
Control
• Female: 49 (52.1%)
• Age (mean): 73.7 (SD 11.2) years
• Number of regular medicines (mean): 8.8 (SD 2.7
Interventions Intervention: pharmacist MR. Underwent MR with pharmacist before physician’s con-
sultation and a BPMH was created and saved as an electronic draft in the CPSS2. Ini-
tial system MR performed by retrieving participant’s medication records (up to 1 year
from date of recruitment or latest medication record from a specific prescribing insti-
tution, whichever was more recent) from the different prescribing institutions using;
1. NEHR; 2. CCDR; 3. discharge memorandum brought by participants. Pharmacist
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then drafted an initial BPMH list in the form of an electronic prescription in CPSS2.
Pharmacist performed physical MR via an interview with the participant or carer (or
both) regarding the administration of each of the recorded medications and the intake
of any other chronic medications not initially recorded. Discrepancies detected during
system MR would then be clarified and documented in CPSS2 and on the Uninten-
tional Medication Discrepancy Form. Final BPMH list in the form of an electronic
prescription in CPSS2 was drafted for the physician’s review during consultation. The
drafted prescription would document all medication discrepancies, both intentional and
unintentional. Postconsultation MR process: MR performed by comparing electronic
prescription given on date of visit against medication records from different prescribing
institutions. Subsequently, pharmacist drafted an initial BPMH list under the Patient
Medication List function in NEHR. Physical MR was then conducted via an interview
with participant or carer (or both). Any further unintentional medication discrepancies
were recorded on the Unintentional Medication Discrepancy Form and were resolved
via a discussion with the prescribing physician. Final BPMH created in NEHR and a
copy printed and given to the participant or carer (or both). All study pharmacists were
registered with the Singapore Pharmacy Council and underwent a structured inhouse
training for conducting MR before study commencement
Control: usual care where the consulting physician reviewed the participant and ordered
an electronic prescription
Outcomes ≥1 medication discrepancy
• Outcome type: dichotomous
• Direction: lower was better
30-day rehospitalisation
• Outcome type: dichotomous
• Direction: lower was better
MMAS-8
• Outcome type: continuous
• Reporting: full
• Direction: higher was better
• Notes: not reported per group - reports for all participants at end of study
Medication discrepancy per participant
• Outcome type: continuous
• Reporting: full
• Direction: lower was better
• Data value: endpoint
• Notes: intervention: 95 people; 0.2 (SD 0.5); control: 94 people; 1.1 (SD 1.4)
Notes Sponsorship source: Clinician-Scientist Preparatory Programme Grant from National
Healthcare Group Research and Development Office
Authors name: Cheryl Wai Teng Char
Institution: National Healthcare Group Pharmacy, Hougang Polyclinic, 89 Avenue, Sin-
gapore
Email: cheryl wai teng char@pharmacy.nhg.com.sg
Address: National Healthcare Group Pharmacy, Hougang Polyclinic, 89 Avenue, Singa-
pore
Risk of bias
41Impact of medication reconciliation for improving transitions of care (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Char 2017 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised to intervention or control
group in balanced allocation. Computer-
generated random list generated using
STATA (StataCorp. 2011. Stata Statisti-
cal Software: Release 12. College Station,
TX: StataCorp LP). Assignment occurred
within randomly ordered blocks of 2, 4 or
6
Allocation concealment (selection bias) Low risk Sequentially numbered opaque and sealed
envelopes. To prevent subversion of alloca-
tion sequence, initials of participant were
written on the envelope before the envelope
was opened.Randomisation assignment re-
vealed to participants
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measure of outcome
Were baseline characteristics similar? Low risk Participants’ baseline demographics (age,
gender, race, income level, education level)
, number of chronic medications, ability to
administer medications independently and
medication adherence level summarised in
Table 1. No significant differences in base-
line characteristics
Incomplete outcome data (attrition bias)
All outcomes
Low risk Figure 2 shows similar numbers excluded
from both groups for main analysis and a
further 4 participants in intervention and
1 in control could not be contacted for 30
days follow-up. However, in some of the
tables it was unclear howmany participants
were used in calculations
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Unclear risk Postconsultation reconciliation (to deter-
mine outcome) was conducted by a sepa-
rate pharmacist but there was no comment
on whether s/he was blinded to allocation.
Participants were unblinded
Was the study adequately protected against
contamination?
High risk Participants were randomised. No clear
separation of groups, contamination was
possible
Selective reporting (reporting bias) Low risk All outcomes specified in methods section
appeared to be reported in results section
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Other bias High risk Excluded any personwhowas discharged to
a nursing home. Also in some of the tables
it was unclear how many participants were
used in calculations
Summary risk of bias Low risk Low risk
Crotty 2004
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: 3 months
Duration: 2 case conferences 6-12 weeks apart. Prior to transfer through to 28 days after
transfer
Providers: pharmacist transition co-ordinator, who also worked with the CP, and who
co-ordinated a case conference with the family physician, CP and nurse at the long-term
care facility
Participants Setting/participants: 110 participants (intervention: 56; control: 54) frommaking a first-
time transition from a hospital to a long-term residential care facility were recruited from
the 3 metropolitan public hospitals in southern region of Adelaide
Study period: October 2002 and July 2003
Inclusion criteria: they or their carer gave consent and they had a life-expectancy of ≥ 1
month as assessed by their medical team. Residents were prescribed > 5 medications
Transition of care: discharge from hospital and admission to the long-term care facility
Age (mean): intervention: 82 (95% CI 80.2 to 83.7) years; control: 83.4 (95% CI 81.7
to 85.1) years
Female (%): intervention: 58.9%; control: 63%
Ethnicity: “non English speaking background:” intervention: 8.9%; control: 5.6%
Interventions Intervention: focused on transferring information on medications to case providers in
long-term care facilities, including nursing staff; family physician and accredited CP. On
participant’s discharge from hospital to long-term care facility, both family physician and
CP were faxed a medication transfer summary compiled by transition pharmacist and
signed by hospital medical officer. This communication supplemented the usual hospital
discharge summary and included specific information on changes to medications that
had been made in file hospital and aspects of medication management that required
monitoring. After transfer of participant to long-term care facility, the transition phar-
macist co-ordinated evidence-based medication review that was to be performed by CP
contracted to facility within 10-14 days of transfer. Transition pharmacist also co-ordi-
nated a case conference involving himself or herself, family physician, CP and registered
nurse at the facility within 14-28 days of the transfer. At this case conference, transition
pharmacist provided information concerning medication use and appropriateness
A half-day training workshop examining use of a toolkit in the management of challeng-
ing behaviours was provided to all facilities in the study, including control facilities
Control: usual hospital discharge process including standard hospital discharge summary.
In Australia, CPs were paid to perform an annual medication review for residents of
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long-term care facilities. This review is usually independent of GP and is not necessarily
co-ordinated with first-time transfer
Outcomes Appropriateness of participants’ medication plans as assessed using the MAI. All regular
and as-neededmedications prescribed as of the date of hospital discharge (baseline) and 8
weeks after discharge (follow-up) were included in the MAI assessment. Change in MAI
was reported. All residents had their medication charts reviewed before and after the
intervention by an independent pharmacist. The NHBPS was used to assess the effect of
the intervention on residents’ behaviour. Monthly drug costs for all regular medications
on the government’s pharmaceutical benefits scheme were calculated for all residents in
the intervention and control groups
Other outcomes included unplanned visits to the ED or hospital readmissions (grouped
together as hospital usage), ADEs, falls, worsening mobility, worsening behaviours, in-
creased confusion and worsening pain
Discrepancies did not seem to be recorded. However, in Table 2 it listed: “discrepancy
between medication summary and medication sent” although this was not listed in
outcomes
Notes Discrepancies did not seem to be recorded. However, in Table 2 it listed: “discrepancy
between medication summary and medication sent” although this was not listed in
outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation sequence
using block randomisation stratified by
hospital (page 258)
Allocation concealment (selection bias) Low risk Randomisation co-ordinated by a cen-
tralised hospital pharmacy service
Were baseline outcome measurements sim-
ilar?
Low risk No significant differences in primary out-
come (Table 1, page 259)
Were baseline characteristics similar? Low risk No significant differences in characteris-
tics between treatment groups with the
exception of the number of medications
discontinued during hospitalisation. How-
ever, analysis controlled for this difference
(page 259, results paragraph 2 and statisti-
cal analysis paragraph 2)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12 participants in intervention and 10 in
control group died or did not complete the
study or follow-up.High-risk data available
on 44 participants for intervention and 44
for control (page 259, results paragraph 1)
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Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Unclear risk Did not indicate who assessed the out-
comes. Pharmacists blinded but did not
state if they did assessment (pages 258 and
259; study assessments)
Was the study adequately protected against
contamination?
High risk Participants were randomised (page 258,
study intervention paragraph 1)
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
reported in the results (page 263 Table IV)
Other bias Low risk No evidence of any other bias
Summary risk of bias Low risk Low
Eggink 2010
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: OPD visit ≤ 6 weeks’ postdischarge
Duration: discharge from the hospital + post discharge clinic visit - included anoutpatient
visit within 6 weeks after hospital discharge and an additional visit to the heart failure
nurse if necessary
Providers: clinical pharmacist + cardiologist + hospital physician. Provided by a single
pharmacist only - no credentials provided
Participants Setting/participants: 89 participants (intervention: 41; control: 48). The study was con-
ducted at the department of cardiology of a teaching hospital in Tilburg, theNetherlands
Study period: May 2007 and July 2008.
Inclusion criteria: aged > 18 years admitted with diagnosis of heart failure and prescribed
≥ 5 medicines (from any class) at discharge
Exclusion criteria: living in a nursing home or unable to give informed consent, due to
mental incapacity or terminal illness
Transition of care: discharge from hospital
Age (years): intervention: 74 (SD 12); control: 72 (SD 10)
Male (%): intervention: 59%; control: 75%
Ethnicity: not reported
Interventions Intervention: clinical pharmacist identified potential prescription errors in discharge
medication and discussing them with cardiologist. This resulted in final discharge med-
ication. Participants received both verbal and written information about (side) effects
of, and changes in, their inhospital drug therapy from a clinical pharmacist upon hos-
pital discharge. In addition to this, the clinical pharmacist made a discharge medication
list which contained additional information related to dosage changes and discontinued
items. After physician approval, list was faxed to CP and given as written information
to participant with instruction to hand it to their GP
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All participants (both regular care and intervention) collected medication at their com-
munity pharmacy and received usual routine management by their cardiologist after
discharge. This included an outpatient visit within 6 weeks after hospital discharge and
an additional visit to the heart failure nurse if necessary
Outcomes Primary endpoint: frequency of prescription errors in the discharge medication and
medication discrepancies after discharge combined
Discrepancies classified as: restart of discontinued medication, discontinuation of pre-
scribed discharge medication, use of higher or lower dose, more or less frequent use than
prescribed and incorrect time of taking medication
Prescription error defined as an error which occurred in the process of prescribing med-
ication, namely dosing errors, dosage form errors, contraindications, drug-drug inter-
actions and double-medication. All prescription errors identified by clinical pharmacist
and agreed upon by the cardiologist were collected
The clinical relevance of prescriptionor discrepancy errorwas assessed by theNCCMERP
Index
Brief Medication Questionnaire - Regimen Screen, a measure of adherence
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All participants who provided written in-
formed consent were randomised using a
random number table, to receive interven-
tion or regular care (page 761, setting and
study population, 3rd paragraph)
Allocation concealment (selection bias) Unclear risk Not specified in the paper
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measure of outcome
Were baseline characteristics similar? Low risk Participant characteristics represented in
Table 3. The characteristics of both groups
did not differ (page 763, Table 3)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 (2 lost to follow-up and 2 died in the
control group) and all were followed up in
the intervention group (page 736, Figure
1)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk Primary outcome measure was objective,
the primary endpoint was the frequency of
prescription errors in the discharge medi-
cation and medication discrepancies after
discharge combined (page 761, paragraphs
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3, 4, 5 and 6)
Was the study adequately protected against
contamination?
High risk All participants who provided written in-
formed consent were randomised using a
random number table, to receive interven-
tion or regular care. No clear separation of
groups, contamination was possible
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in results section (pages 763 and
764, results)
Other bias Low risk No evidence of any other bias
Summary risk of bias Unclear risk Unclear
Farley 2014
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: up to 90 days post discharge
Duration: admission to discharge from hospital
Providers: PCM
Participants Setting/participants: 592 participants (enhanced intervention: 195; minimal interven-
tion: 199; control: 198). The broader ICOC study enrolled participants that were ad-
mitted to the cardiology, internal medicine, family medicine or orthopaedic services at
the University of Iowa Hospitals and Clinics (UIHC), a large, tertiary care, academic
medical centre in the USA
Inclusion criteria: aged ≥ 18 years, spoke English or Spanish and had ≥ 1 of the fol-
lowing diagnoses: hypertension, hyperlipidaemia, heart failure, coronary artery disease,
myocardial infarction, transient Ischaemic attack, stroke, diabetes, asthma, chronic ob-
structive pulmonary disease or require anticoagulation
Exclusion criteria: hearing impairments, life expectancy < 6 months, cognitive impair-
ments, substance abuse problems or severe psychiatric conditions
Transition of care: admission and discharge from hospital
Age (mean): minimal intervention: 59.8 (SD 12.8) years; enhanced intervention: 61.1
(SD 12.8); control: 60 (SD 12.7) years
Female (%): minimal Intervention: 51.7%; enhanced intervention: 49.2%; control: 44.
9%
Ethnicity: not reported
Interventions Enhanced intervention: minimal intervention + having the discharge care plan prepared
and faxed to their community physician and community pharmacy. Plan focused on
medication issues and changes that happened during the hospitalisation and highlighted
which medications had been added, changed or stopped. They also received a follow-up
telephone call from the clinical PCM 3-5 days after discharge to address any medication-
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related issues that had developed since discharge
Minimal intervention: visit from a clinical PCM to counsel them on their medications
after admission to hospital. Clinical PCM took a detailed medical history, including
interview participant, called pharmacy and updated medical record. This was followed
by MR where the clinical PCM compared the inpatient medications to the participant’s
home list to identify any discrepancies and bring them to the attention of the prescriber.
The MR process was repeated at discharge and a teaching session covering the impor-
tant aspects of the participant’s current medications and making sure new medications
were fully understood by the participant. The discharge MR focused on comparing the
medications a participant was currently taking in the hospital with the participant’s prior
to admission (home) medication list and making sure all medications were addressed
and active medications were appropriate for the participant and consistent with practice
guidelines. The participant also received a discharge medication list listing all discharge
medication and their purpose
Control: usual hospital care without any involvement of clinical PCM
All participants in the study received exposure to usual hospital medication list collection
process, which was most often done by the participant’s floor nurse on admission. They
also received the typical discharge summaries from the University of Iowa Hospitals and
Clinics sent to primary care physicians for their records
Outcomes Medication discrepancies: discrepancy was deemed present if 1. medications that doc-
umentation indicated should be active were not on the list (unintended omission), 2.
medications were on list without documentation (unintended addition) or 3. medica-
tions were found with different dose or frequency
Clinical significance of discrepancies: CRP determined the clinical significance of each
discrepancy by giving a low, moderate or high designation based on the potential for
participant harm. The following definitions were used by CRP in the evaluation of
medication discrepancy significance
• Low unlikely to impact any therapeutic outcome, little/no risk of harm to
participant, most non-prescription medication discrepancies.
• Moderate may impact therapeutic outcome or possibility of harm to participant,
or both.
• High likely to adversely affect outcome, medications with narrow therapeutic
index, medications on Institute for safe medication practices high alert list or
impending risk to participant, or a combination of these.
Notes This was a substudy from the ICOC study, funded by the NIH. The study was a
randomised controlled trial to determine if introducing clinical PCMs into the inpatient
care teamcould reducemedicationunderutilisation, ADEs, and readmissions. Additional
outcomes were listed in the ICOC protocol paper but were not reported in this study
Retrieved additional data and recalculations from author. Data now available included
mean discrepancies per patient for each group recorded from physician notes and phar-
macists notes. Also reported at 30 and 90 days. Outcome chosen for comparison was
combined discrepancies from both records at 30 days. A pooled mean of the 2 interven-
tion groups was calculated for meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomisation developed using pseudo-
random number generation via SAS statis-
tical software to ensure the probabilities of
assignment to each treatment group were
equal. It stated in Carter 2008 that the ran-
domisation was developed using pseudo-
random number generation via SAS statis-
tical software to ensure the probabilities of
assignment to each treatment group were
equal. Definition of pseudo-random was a
process that appeared to be randombutwas
not. However, it was done using a statisti-
cal package and hence allocation was likely
concealed (page 4 of Carter 2008).
Allocation concealment (selection bias) Unclear risk Specified ’sealed envelopes’ but unclear if
they were opaque (page 4 of Carter 2008).
Were baseline outcome measurements sim-
ilar?
Unclear risk Not measured
Were baseline characteristics similar? Low risk No significant differences (Table 1 and de-
mographics in results section)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of loss to follow-up
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk For the primary outcomemeasure, blinded,
CRPevaluated and compared the discharge
medication lists from the hospital (updated
to reflect intended changes since discharge)
to 30- and 90-day postdischarge medica-
tion lists found in the community physi-
cian and community pharmacy records
evaluating the lists for medication discrep-
ancies (methods, data collection)
Was the study adequately protected against
contamination?
High risk Participants were randomised. No clear
separation of groups, contamination was
possible
Selective reporting (reporting bias) High risk Farley et al refer to another paper, Carter
2008, for the background andmethods. All
the outcomemeasuresmentioned inCarter
paper were not reported in Farley paper (
Carter 2008, pages 7-9)
Other bias Low risk No evidence of any other bias
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Summary risk of bias Unclear risk Unclear
George 2011
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: preadmission clinic to discharge
Duration: preadmission to admission
Providers: 2 pharmacists on rotation 3 days each week. 2 and 8 years of clinical pharmacy
experience, although no previous experience in PAC
Participants Setting/participants: 401 participants (intervention: 192 ; control: 209). Participants
were eligible if they attended the surgical PAC at a large metropolitan teaching hospital
in Melbourne prior to orthopaedic, colorectal and vascular surgery
Inclusion criteria: aged≥ 60 years, with or without comorbidities or current medication
use, or < 60 years of age, with≥ 1 pre-existing comorbidity and taking regular prescribed
medication
Exclusion criteria: people for non-elective, day and other surgical procedures and people
unable to give written informed consent
Transition of care: preadmission clinic to admission
Age (median): intervention: 68 (IQR 61-75) years; control: 67 (IQR 60-76) years
Female (%): intervention: 54%; control: 51%
Ethnicity: not reported but non-English speaking: intervention: 17%; control: 10%
Interventions Intervention: standard PAC care plus assessment by a PAC pharmacist including partic-
ipant interview in a dedicated consulting room in PAC, consisted of taking a history of
the participant’s regular and as neededmedications, including self- and doctor-prescribed
medications, on the hospital’s dedicated form. Details were corroborated with ≥ 1 other
source, e.g. participant’s own, GP, CP. Participant’s medication supply requirements on
discharge were noted on the form for attention following admission. Given amedication
management plan detailing medications to cease and medications to continue or start
up to and including the day of admission. The completed form was filed in the medical
record for reference by hospital staff when prescribing admission medications. The PAC
pharmacist contacted the intervention group participants during the preoperative period
to confirm they understood the drug plan, and to document and advise on any changes
since their PAC visit. Participants were also asked to contact the PAC pharmacist if there
were any changes to their medication regimen during the preoperative period
Control: standard care saw allied health staff when appropriate
Both groups received standard inpatient care on admission, including clinical pharmacy
services from the rostered clinical pharmacist. Important to note that standard care
involved a ward pharmacist involved in building the preadmission medication list
Outcomes Interventions:
Pharmacist interventions were any actions that resulted in a change in medication man-
agement or therapy
Intervention severity assessment:
Visual analogue scale (0 = no potential adverse effect to 10 = potential for causing death
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or lasting impairment)
MR:
Process of checking that the medicines the participant was taking prior to hospital
admission correlated with medicines prescribed during the admission and on discharge,
and any discrepancies were intentional. Further communication with the author clarified
exactly what this outcome reported: “It means the percentage [of participants] that
had accurate medications as an outcome assessment... inaccurate meaning at least one
unintended medication discrepancy”
Notes MR was reported at admission and discharge. Discharge outcome recording was chosen
for comparison data
Study had a selected population, reasoning given as: “Patients from these surgery types
were selected as they would benefit from a PAC pharmacist’s input, due to their age,
length of inpatient stay, potential for co morbidities and complex medication regimens.
”
Also the study hospital had a well-established PAC, where participants were assessed by
nurses, surgeons and anaesthetists, approximately 2 weeks prior to surgery. Important to
note that standard care involved award pharmacist involved in building the preadmission
medication list
Original published data reanalysed by author following communication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation num-
bers and group assignments were pre-
sealed in sequentially numbered, opaque
envelopes held by the pharmacy technician
(page 213)
Allocation concealment (selection bias) Low risk Computer-generated randomisation num-
bers and group assignments were pre-
sealed in sequentially numbered, opaque
envelopes held by the pharmacy technician
(page 213)
Were baseline outcome measurements sim-
ilar?
Unclear risk Outcomes measurements not clear and
some measurements appeared to have no
baseline information collected (e.g. medi-
cation documentation) (pages 214, 215)
Were baseline characteristics similar? Low risk It appeared from the data in Table 1 there
was little or no difference in baseline char-
acteristics of participants between the inter-
vention and control group. Note that Table
1 showed differences in medication docu-
mentation, but review authors think this
was an outcome (Table 1, page 215)
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Incomplete outcome data (attrition bias)
All outcomes
Low risk In Figure 1 it showed that 21 participants
were ineligible for analysis in the interven-
tion group and 25 in the control group.
However, review authors noted that in the
paragraph on MR on page 215 it was un-
clear if all the participants were followed
up. It gave denominator figures for admis-
sionbut not for follow-up. follow-up todis-
charge was not clear (Figure 1, page 214)
. Following contact with the study authors
loss to follow-up was confirmed: interven-
tion: 9 (5.3%); control: 12 (6.5%)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Unclear risk Did not specify if outcomes were assessed
blindly (page 213)
Was the study adequately protected against
contamination?
High risk The PAC, pharmacy and ward staff were
aware a study was underway, but were not
privy to the study protocol or participant al-
location. Randomised by participant (page
213)
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in the results section (page 214-
215)
Other bias High risk Participants were only recruited on cer-
tain days; “Eligible patients attending clinic
days when the PAC pharmacist was in at-
tendance were invited to participate” (page
213)
Summary risk of bias Low risk Low
Hale 2013
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: perioperatively
Duration: PAC attendance to admission
Providers: nurse, prescribing pharmacist, RMO and anaesthetist
Participants Setting/participants: 400 participants; intervention: 200; control: 200. Following can-
celled surgeries: intervention: 194; control: 190. Surgical PAC at Princess Alexandra
Hospital, a 750-bed tertiary teaching hospital in Queensland, Australia
Inclusion criteria: people who attended PAC and could provide written informed consent
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Exclusion criteria: aged < 18 years, unable to communicate due to language difficulties
or undergoing day surgery, urology and renal transplant participants were excluded
(intervention: 34; control: 43) from VTE prophylaxis prescribing as the director of
urologywas unavailable to confirm the scope of the project, and the director for transplant
requested exclusion on the grounds that VTEprophylaxis in these participants was driven
more by consultant discretion as opposed to being driven by guidelines
Transition of care: PAC attendance, admission to hospital
Age (mean): intervention: 55.8 (range 18-86) years; control: 57.6 (range 18-89) years
Male (%): intervention: 59%; control: 58%
Ethnicity: not reported
Interventions Intervention: participants were seen by a nurse, prescribing pharmacist, RMO and anaes-
thetist. Participants had to be seen by the pharmacist before they were seen by the RMO
to allow usual RMO duties and a countersignature of the pharmacist prescriptions, a site
requirement. The pharmacist undertook all pharmacist duties as per usual care, as well
as prescribing medications on the medication chart. The scope of prescribing was con-
tinuing or withholding regular medications and prescribing VTE prophylaxis according
to local and national guidelines, following a risk and contraindication assessment
Control: participants were seen by all 4 healthcare professionals in clinic, in no particular
order, as per usual care. Either pharmacist in the clinic saw control participants for
documentation of medication history. The prescribing of the medication chart was the
responsibility of the RMO
In both groups, review and monitoring were undertaken, both by RMOs in clinic at
countersignature and by RMOs and clinical pharmacists at the ward level, once the par-
ticipant was admitted. Changes made by RMOs to intervention participant medication
charts in clinic were recorded
Outcomes Primary endpoint: accuracy of medication charts, with regard to concordance of the
medication chart with medication history, plan for medications perioperatively, and
quality of the individual orders related to legality and safety for administration purposes
Prescribing errors: anomaly in drug name, strength, dose, frequency or route, with no
documentation in participant chart
Communication errors: unclear prescription in terms of name, route, dose, frequency,
slow release medication notification or intermittent order prescribing
VTE prophylaxis prescribing: VTE risk assessment, contraindication assessment and
VTE prescribing
Assessment of clinical significance of omissions: an expert panel, comprising a surgeon,
clinical pharmacologist, anaesthetist, RMO, pharmacist and nurse, was convened to
assess the clinical significance of omissions in a randomly selected 5% sample of the total
cohort of participants from both arms (intervention: 9; control: 10). Panel members
were blinded to randomisation
Notes Original data from author retrieved and reanalysed, combining both prescribing and
communication errors. Both regular and PRN medications summarised together
Only 1 pharmacist in the PAC, with 3 years’ experience as a hospital pharmacist and
having a postgraduate diploma in clinical pharmacy, was trained to be a prescriber.
The pharmacist attended a prescribing course which was accredited by the General
Pharmaceutical Council, UK as an Independent Pharmacist PrescribingCourse. Training
included a minimum of 12 days of ’period of learning in practice’ under a DMP),
who was the consultant anaesthetist for PAC. The training included case studies and
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sessions on VTE prophylaxis with a consultant vascular physician and the clinical nurse
consultant for VTE prophylaxis at Princess Alexandra Hospital. The DMP endorsed
the pharmacist’s competency to prescribe before the study could start. For the pilot, an
amendment was facilitated to the Queensland Health (Drugs and Poisons) Regulation
1996 to allow “Pharmacists registered in Queensland who are employed or contracted
to Queensland Health and working in the Pharmacist Prescribing Pilot” to prescribe
controlled drugs, restricted drugs and schedule 2 and 3 poisons
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk After consent, participants were ran-
domised using computer-generated ran-
domisation list, in blocks of 10 (Microsoft
Excel). Sealed envelopes (not prepared by
the recruiting researcher) contained a 0 or
1 as per the computer list; the next enve-
lope was opened after consent to determine
whether a participant entered the control
(0) or intervention (1) group (page 3)
Allocation concealment (selection bias) Low risk After consent, participants were ran-
domised using computer-generated ran-
domisation list, in blocks of 10 (Microsoft
Excel). Sealed envelopes (not prepared by
the recruiting researcher) contained a 0 or
1 as per the computer list; the next enve-
lope was opened after consent to determine
whether a participant entered the control
(0) or intervention (1) group (page 3)
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measurements (pages 4 and 5)
Were baseline characteristics similar? High risk The demographics of the participants ran-
domised into the trial were similar, except
for the higher number ofmedications taken
by participants in the control group (see ta-
ble 3, page 5)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Figure 1 showed people omitted because
their surgery was cancelled, 6 in inter-
vention group and 10 in control group.
However, no mention of loss to follow-up.
Participants may not have been follow-up
(page 3)
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Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk Assessment was conducted in tandem by 2
assessors, 1 a member of the research team
and 1 an external assessor, both trained in
the use of validated audit tools and blinded
to randomisation. Any ambiguities were
clarified by consensus (page 4)
Was the study adequately protected against
contamination?
High risk Participants were randomised (page 3). No
clear separation of groups, contamination
was possible
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods ap-
peared to be reported in results
Other bias Low risk None
Summary risk of bias Unclear risk Unclear
Hawes 2014
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: 30 days post discharge
Duration: 72 hours post discharge
Providers: transition pharmacist + clinical pharmacy service
Participants Setting/participants: 61 participants (intervention: 24; control: 37) conducted at an 804-
bed academic medical centre. Participants with risk factors for rehospitalisation admitted
to the FMIS who also received primary care at the health care system’s outpatient family
medicine centre were eligible for inclusion
Study period: October 2009 to April 2011
Inclusion criteria:
Year 1: participant must meet 1 of the 3 criteria below:
• Reason for admission:
◦ heart failure
◦ chronic obstructive pulmonary disease
◦ hyperglycaemic crisis
◦ stroke
◦ non-ST elevation myocardial infarction/unstable angina
• > 3 hospitalisations in past 5 years
• ≥ 8 scheduled medications anticipated at discharge
Year 2:
• Inclusion criteria: ≥ 8 scheduled medications anticipated at discharge.
Exclusion criteria: inability to speak English, incarceration, no telephone access, trans-
ferring to another medical service/SNF/rehabilitation facility/hospice, no transportation
to follow-up clinic, decisionally impaired people, aged < 18 years, not receiving care from
PCP involved with research institution. Year 2 removed most of these restrictions except
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number of medications
Transition of care: hospital discharge to primary care physician
Age (mean): 62.8 year; no breakdown given
Female (%): 61%; no breakdown given
Ethnicity: 59% African American, 41% Caucasian; no breakdown given
Interventions Intervention: participants were scheduled for a care transitions clinic visit with a clinical
pharmacist approximately 72 hours postdischarge, and prior to the post hospitalisation
PCP visit. The visit involved performing a complete medication history, identifying
and resolving medication discrepancies, creating a current medication list for both the
medical record and the participant, and counselling on appropriate medication use.
During these visits, the pharmacist identified discrepancies between the Best Possible
Medication Discharge List and the discharge summary and characterised medication
discrepancies using predefined categories
Control: participants were scheduled to see their PCP for a post hospitalisation visit with
no interim pharmacist intervention. Medication discrepancies of study participants not
attending care transitions visits were identified and characterised by study personnel in
the same manner as those in the intervention group
At the study institution, pharmacists provide clinical pharmacy services for the FMIS
and outpatient family medicine clinic. Inpatient clinical pharmacists round with the
medical team daily, review and monitor medications for effectiveness and safety, and
make recommendations to the physician staff to optimise medications. Participants in
both groups received this usual care from the inpatient pharmacist. The role of the
inpatient pharmacist in the study was to collaborate with the inpatient medical team to
create a Best Possible Medication Discharge List for all study participants just prior to
discharge
Outcomes Primary outcomes were a composite of the occurrence of a hospital admission or an
ED visit within 30 days after hospital discharge and the resolution of medication dis-
crepancies before the PCP visit. Secondary outcomes included the individual rates of
rehospitalisation and ED visits within 30 days after discharge
We counted no more than 1 rehospitalisation and ED visit for each study participant.
If participants were admitted to the hospital from the ED, they were not considered to
have both an ED visit and a hospital admission
Resolution of medication discrepancies before the PCP visit: BPMDL used to generate
list of medication discrepancies. Reported as “medication discrepancies resolved or not
resolved” having reviewed discrepancies present at discharge, prior to transition visit.
Only participants who were noted to have a discrepancy at discharge were included for
discrepancy analysis at 30 days
Individual rates of rehospitalisation within 30 days after discharge: we counted no more
than one rehospitalisation and ED visit for each study participant. If participants were
admitted to the hospital from the ED, they were not considered to have both an ED
visit and a hospital admission
Individual rates of ED visits within 30 days after discharge
Notes During first year of the study, 30 participants enrolled and a random number generator
used for randomisation. Because of unequal allocation of participants to the study groups,
block randomisation with a block size of 4 was used for the second year of the study,
during which 31 participants were enrolled. Also there was a significant change in the
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inclusion criteria in the second year of the study
Only participants who were noted to have a discrepancy at discharge were included for
discrepancy analysis at 30 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 30 participants enrolled and a random
number generator used for randomisation.
Because of unequal allocation of partici-
pants to the study groups, block randomi-
sation with a block size of 4 was used for
the second year of the study, during which
31 participants were enrolled. Change in
methodology as other risk of bias (page 2)
Allocation concealment (selection bias) Unclear risk Not specified in paper
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measure
Were baseline characteristics similar? Unclear risk There were few or no differences in base-
line characteristics between groups (page 3;
results paragraph 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were reported on.
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk Although a medication discrepancy iden-
tification tool was used and discrepancies
were categorised into prespecified groups
to reduce subjectivity, clinician judgement
was required, which could have introduced
bias. All other outcomes were objective
(page 4 discussion; page 3)
Was the study adequately protected against
contamination?
Low risk Participants randomised but unlikely that
control received intervention or vice versa
(page 3)
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in the results section (page 3 and
Table 2 on page 4)
Other bias High risk In year 2 of study, the inclusion crite-
ria changed (from those of year 1). Un-
equally sized groups (i.e. control/interven-
tion). Numerous participants in the inter-
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vention group did not attend the clinic visit
(page 2, study design, page 3, results (para-
graph 2), page 4, discussion (paragraph 2)
). Also discrepancies outcome was decided
based on discrepancies at discharge, after
randomisation and < 50% of enrolled par-
ticipants
Summary risk of bias Unclear risk Unclear
Heng 2013
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: unclear
Duration: immediately prior to clinic appointment
Providers: pharmacist + doctor
Participants Setting/participants: 40 participants (intervention: 20; control: 20). Endocrine outpa-
tient clinic in Tan Tock Seng Hospital, Singapore
Inclusion criteria: not specified.
Exclusion criteria: not specified.
Transition of care: endocrine hospital outpatient clinic visit
Age: not reported
Gender: not reported
Ethnicity: not reported
Interventions Intervention: pharmacist performed MR done before consultation, and the MR list was
passed to the doctor
Control: pharmacist performed MR done before consultation, but the MR list was not
passed to the doctor
Outcomes Discrepancies between doctor’s orders and pharmacist’s MR list
No further details given.
Notes Endocrine clinic only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number
Allocation concealment (selection bias) Unclear risk Not specified
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Were baseline outcome measurements sim-
ilar?
Unclear risk No outcome measurement
Were baseline characteristics similar? Unclear risk Not specified
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not specified in the paper
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Unclear risk Not specified
Was the study adequately protected against
contamination?
High risk Participants were randomised. No clear
separation of groups, contamination was
possible
Selective reporting (reporting bias) Unclear risk Outcomes not clearly specified
Other bias High risk There was not enough information given
and contact details for authors could not
be found
Summary risk of bias Unclear risk Unclear
Ibrahim 2012
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: admitted to 30 days post discharge
Duration: day of discharge to 3-4 days following
Providers: clinical pharmacist + medical team
Participants Setting/participants: 250 participants (intervention: 125 ; control: 125). Conducted at
a major teaching hospital in Cairo, Egypt
Study period: April 2009 to March 2010.
Inclusion criteria: participants admitted to the general medicine service then being dis-
charged home and who could be followed up by telephone 30 days after discharge
Exclusion criteria: not reported
Transition of care: hospital discharge
Age (mean): intervention: 62.7 (18.3) years; control: 59.8 (16.8) years
Female: intervention: 47.2%; control: 44.8%
Ethnicity: not reported
Interventions Intervention: pharmacist review on the day of discharge consisted of several parts. First,
DRP including therapeutic failure and regimens and all discrepancies were reconciled
with the medical team’s help. Participants were screened for previous DRPs, including
non-adherence, lack of efficacy and adverse effects. Pharmacist reviewed the indications,
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directions for use and potential adverse effects of each discharge medication with the
participant. Intervention group also received a telephone follow-up 3-4 days after dis-
charge during which the clinical pharmacist asked about medication adherence, possible
ADEs, and adherence with scheduled follow-up visits and laboratory appointments
Control: usual care with routine review of medication orders by a ward-based pharmacist
at the time of discharge. Discharge counselling typically focused on directions to use
medications and may have included a discussion of indications or potential adverse
effects, especially for new medications
Outcomes Presence of a preventable ADE in participants 30 days after hospital discharge: assessed
with a modified version of the method developed by Bates 1995.Participants were asked
a screening question for new or worsening symptoms since hospital admission. In the
case of an affirmative response, follow-up questions to uncover details about these symp-
toms and their relation to medications. Case summaries were prepared from these an-
swers and they also included medication lists at admission and discharge, the hospital
discharge summary, any available outpatient visit notes, discharge summaries from ED
visits or hospital readmissions, and any available laboratory test results in themonth since
discharge. From these summaries, a clinical pharmacist who was blinded to treatment
group determined whether an ADE had occurred, using the Naranjo algorithm which is
a validated scoring system to assess causality. The clinical pharmacist also evaluated ADE
severity and preventability. For all hospital admissions or ED visits, the blinded clinical
pharmacist assessed any relationship to medication use or preventability. Preventable
medication-related ED visits or readmissions were considered to be preventable ADEs.
If participants could not be contacted by telephone 30 days after discharge but had been
readmitted to the hospital or visited the ED, case summaries were prepared and ADEs
assessed but without the participants’ responses
Participant satisfaction: satisfaction with hospitalisation and discharge processes assessed
using a standard questionnaire
Medication adherence: assessed by asking participants whether they had taken each
medication exactly as prescribed during the previous day and on how many days during
the previous week
Medication discrepancies: determined by comparing the discharge medication regimen
with themedications reported by each participant at 30 days.Differences not attributable
to a physician’s order or completion of a prescribed course of treatment were considered
discrepancies
Healthcare utilisation: ED visit or readmission. Assessed as per primary outcome
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation performed through com-
puter-generated algorithm, and treatment
assignments kept in sealed opaque en-
velopes which were opened after partici-
pant consent was obtained (page 1, meth-
ods, second paragraph)
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Allocation concealment (selection bias) Low risk Randomisation performed through com-
puter-generated algorithm, and treatment
assignments kept in sealed opaque en-
velopes which were opened after partici-
pant consent was obtained (page 1, meth-
ods (second paragraph)
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measure of outcomes
Were baseline characteristics similar? Low risk At baseline, there were no significant differ-
ences between participants in the 2 study
groups (page 2, statistical analysis, para-
graph 2)
Incomplete outcome data (attrition bias)
All outcomes
High risk Lost to follow-up: Intervention: 15; con-
trol: 21. Effect size low so could be affected
by loss to follow-up (page 2, Figure 1)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk Although participants and clinical pharma-
cists were not blinded to the treatment as-
signment, outcomes were assessed by re-
search assistants who were blinded to treat-
ment assignment. A clinical pharmacist
who was blinded to treatment group deter-
mined whether an ADE had occurred, us-
ing the Naranjo algorithm which is a val-
idated scoring system to assess causality].
The clinical pharmacist also evaluatedADE
severity and preventability. For all hospi-
tal admissions or ED visits, the blinded
clinical pharmacist assessed any relation-
ship to medication use or preventability.
Preventable medication-related ED visits
or readmissions were considered to be pre-
ventable ADEs (page 1, methods, para-
graphs 2 and 6)
Was the study adequately protected against
contamination?
High risk Participants were randomised. No clear
separation of groups, contamination was
possible
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in the results section (page 1, meth-
ods, paragraph 5 and page 3, Table 3)
Other bias Low risk None obvious
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Summary risk of bias High risk High
Khalil 2016
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: 24 hours post hospital admission
Duration: hospital admission to 24 hours post admission
Providers: clinical pharmacist + medical team
Participants Setting/participants: 110 participants (intervention: 56; control: 54). 400 bed Australian
metropolitan hospital. Intervention specifically targeted general medical inpatients ad-
mitted to the AAA via the ED. Participants were managed by the AAA medical staff
Exclusion criteria: participants excluded if they were not admitted to AAA ward within
24 hours or if they did not have any medications prior to admission or were not a general
medical participant
Transition of care: hospital admission
Age (mean): intervention: 65.1 (95% CI 60 to 69); control: 74.8 (95% CI 70 to 79)
year
Male:female ratio: intervention: 1.24; control: 1.45
Number of medications per participant: intervention: 10.66; control: 10.26
Ethnicity: not reported
Interventions Intervention: pharmacist accepted referrals from senior medical staff and obtained a
BPMH from the participant or other sources (or both). The pharmacist would then
undertake admission MR (according to the hospital policy for medication history and
reconciliation process, a minimum of 2 sources were required to verify participants’
medications - the participant or carer (primary source) and participant’s community
pharmacies, primaryHCPs, ownmedications or previousmedical records (second source)
, or a combination of these, review currentmedications and the need for newmedications
in relation to the admission diagnosis. A medication management plan was developed
collaboratively with, and signed off by, the referring senior medical officer prior to the
pharmacist charting on the electronic MAR
Control: medications orders charted by the medical staff.
Outcomes Primary endpoints: number of medication errors per participant and per drug order at
24 hours after admission. The quality of allergy documentation and appropriateness of
VTE prophylaxis was also assessed. All data from the control period were compared with
the intervention period
Secondary endpoints included the types of errors based on an inhouse classification
system and their severity which were rated by a blinded independent physician and a
senior pharmacist using the risk assessment tool from the Society of Hospital Pharmacists
of Australia standards of practice of clinical pharmacy
Number of errors per participant (continuous): total and mean per group reported
Number of errors per drug order (continuous)
Error severity: “The severity of all errorswas then rated by a ’blinded’ consultant physician
and an independent senior pharmacist according to a standardized matrix and recorded
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for analysis”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly allocated to
groups using a random number generator
(page 663, methods)
Allocation concealment (selection bias) Unclear risk No details provided
Were baseline outcome measurements sim-
ilar?
Unclear risk No baseline measures
Were baseline characteristics similar? High risk Control participants were older (Table 1)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Findings were reported for all 110 partic-
ipants. However, there was no detail on
the numbers of participants randomised;
no study flow chart; and no mention of
withdrawals, exclusions, attrition or miss-
ing data
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Unclear risk No blinding but senior clinical pharmacist
who reconciled errors in both groups was
“independent.” Classification of severity of
error was undertaken by a “blinded consul-
tant physician and an independent senior
pharmacist.” There was no explicit men-
tion of concealment
Was the study adequately protected against
contamination?
High risk Randomisation of participants but inter-
vention took place in parallel with control
group receiving treatment in AAA ward so
high likelihood of contamination. It was
not clear whether the reviewing pharmacist
was the investigating pharmacist. It was not
clear whether the pharmacist delivering the
intervention was the same pharmacist who
provided a more limited service to the con-
trol participants
Selective reporting (reporting bias) Low risk All outcomes mentioned were reported;
however, no prior study protocol was avail-
able
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Other bias High risk Outcome assessment did not appear to
have been blinded, although the assessment
of the severity of the outcome was
Summary risk of bias Unclear risk Unclear
Kripalani 2012
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: 25-35 days post discharge
Duration: hospital admission to 1-4 days post discharge
Providers: clinical pharmacist (note: “pharmacist-led”, but importantly collaborative
with inpatient and outpatient physicians)
Participants Setting/participants: 862 participants (intervention: 430; control: 432). Adults hospi-
talised at Vanderbilt University Hospital or BWH, USA for acute coronary syndromes
or acute decompensated heart failure
Study period: May 2008 and September 2009
Exclusion criteria: people being discharged within 3 hours; were too ill to participate;
could not communicate in English or Spanish; had active psychosis, bipolar disorder,
delirium or severe dementia; had hearing or vision impairment; did not manage their
own medications; were unlikely to be discharged to home; lacked a telephone or were in
police custody
Transition of care: admission and discharge from hospital
Age (mean): intervention: 61 (SD 14) years; control: 59 (SD 14) years
Male (%): intervention: 59.1%; control: 58.2%
Ethnicity (%): intervention: white 75.4%; black 18.2%; other: 6.4%; control: white:
78.3%; black: 16.6%; other: 5.1%
Interventions Intervention: 4 components: pharmacist-assisted MR, tailored inpatient counselling by
a pharmacist, provision of low-literacy adherence aids and individualised telephone fol-
low-up after discharge. 11 study pharmacists performed MR at the time of enrolment,
discharge and inhospital transfers. They communicated with the treating physicians
to resolve any clinically relevant, unintentional medication discrepancies. Intervention
counselling was sensitive to the participant’s health literacy and cognition. It was typically
provided during 2 sessions, or during a single session when discharge occurred on the
day of enrolment. During the initial meeting, the pharmacist assessed the participant’s
baseline understanding of medications and prescription labels, barriers to adherence,
and social support. The second meeting generally occurred at discharge and included
tailored counselling on the discharge medication regimen and the participant’s needs, as
previously identified. The pharmacist focused on changes between the preadmission and
discharge regimen; strategies to promote adherence and minimise adverse effects and
high-risk medications, such as insulin or warfarin. Pharmacists confirmed understanding
by using “teach back” and provided low-literacy adherence aids, including a tablet box
and illustrated daily medication schedule.Within 1-4 days after discharge, an unblinded
research co-ordinator called intervention participants and used a structured interview to
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identify medication-related problems. As needed, pharmacists then called to address any
identified issues in collaboration with the treating inpatient and responsible outpatient
physicians
Control: participants’ treating physicians and nurses performed MR and provided dis-
charge counselling. At each hospital, MR was facilitated by electronic records from the
hospital and affiliated clinics, as well as internally developed interfaces to construct a
preadmission medication list. At BWH, the programme had additional features (such as
reminders to complete a preadmission medication list and integration with order entry)
and required providers to continue, stop or change each preadmission medication at
admission; this application, combined with process redesign, was previously shown to
reduce potential ADEs. Participants assigned to usual care were not routinely provided
with a tablet box, illustrated medication schedule or telephone follow-up
Outcomes Primary composite outcome: number of clinically important medication errors per par-
ticipant within 30 days after hospital discharge. This included preventable or ameliorable
ADEs and potential ADEs due to medication discrepancies or non-adherence
Clinical important medication errors per participant within 30 days post discharge:
adjudicators followed a standardised approach based on previously validated methods to
ascertain the presence of ADEs and to grade severity, preventability and ameliorability.
For each medication discrepancy or episode of non-adherence, adjudicators graded the
potential for harm if left uncorrected; if the likelihood of potential harm exceeded 50%,
it was counted as a potential ADE. A drug implicated in an ADE was not eligible to be
adjudicated as a potential ADE in the same participant. For each ADE and potential
ADE, adjudicators categorised the severity as significant, serious or life-threatening,
following rules and examples from an adjudication manual. Disagreements between the
independent adjudicators about whether or not a medication was implicated in a study
outcomewere uncommon (approximately 3% for ADEs and 5% for potential ADEs) and
occurred with similar frequency at each site. Disagreements were resolved by discussion
or, in about 5% of cases, with assistance from a third adjudicator
Preventable or ameliorable ADEs: potential ADEs due to discrepancies or non-adherence
Preventable or ameliorable ADEs judged to be serious, life-threatening or fatal
2 independent clinician adjudicators, blinded to treatment assignment. Each adjudicator
reviewed all available medical records during the 30 days after discharge and the results
of a participant follow-up telephone interview conducted by research staff 25-35 days
after discharge
Notes Data on all discrepancies retrieved through direct contact with author. Additional data
and analysis received through contact with the author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by site and
diagnosis, in permuted blocks of 2-6 par-
ticipants, by a computer program that
maintained allocation concealment (page
2, methods)
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Allocation concealment (selection bias) Low risk Randomisation was stratified by site and
diagnosis, in permuted blocks of 2-6 par-
ticipants, by a computer program that
maintained allocation concealment (page
2, methods)
Were baseline outcome measurements sim-
ilar?
Unclear risk Not possible to do, as the outcomes were
discrete events occurring after discharge
(page 3, Outcomes)
Were baseline characteristics similar? Low risk Similar for most characteristics, with the
exception of age (intervention: 61 years;
control: 59 years). Extensive reporting of
other characteristics, and little or no differ-
ences identified (page 4, last sentence and
table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very little attrition, balanced between the
2 groups (Figure 1 and table 2)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk Outcomes were determined by 2 inde-
pendent clinician adjudicators who were
blinded to treatment assignment (page 3,
outcomes, paragraph 2)
Was the study adequately protected against
contamination?
Unclear risk Participants were randomised. However,
HCPs delivered care commonly to both
groups, although the pharmacist interven-
tion was restricted to the intervention
group. Also, at each hospital, MR was fa-
cilitated electronically (page 2, methods)
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in the results section (page 3, out-
comes and follow-up; page 6, Tables 2 and
3)
Other bias High risk Not all participants received the full inter-
vention as intended, although the vast ma-
jority did (page 9, Figure 1, discussion)
Summary risk of bias Low risk Low
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Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: preadmission clinic assessment to postsurgical unit
Duration: surgical preadmission clinic appointment to surgical procedure
Providers: hospital-based pharmacists (no mention of specific training)
Participants Setting/participants: 464 participants (intervention: 227; control: 237). Tertiary care
university, affiliated teaching hospital in Toronto, Ontario, Canada. All consecutive par-
ticipants who had a surgical preadmission clinic visit before undergoing surgical proce-
dures from the urology; plastic surgery; general surgery; thoracic surgery; gynaecology
oncology; and ear, nose and throat services were eligible for inclusion
Exclusion criteria: people scheduled for discharge on the same day as their surgery
Transition of care: presurgical admission clinic (orders prepared for review at postoper-
ative surgical review also)
Age (median): intervention: 57 (range 18-89) years; control: 57 (range 16-86) years
Male: intervention: 52.5%; control: 54.7%
Ethnicity: not reported
Interventions Intervention: provider-orientated interventions using a combined intervention of the
pharmacist as part of the multidisciplinary team completing structured medication as-
sessments and a postoperative medication order form in the surgical preadmission clinic.
Pharmacists in the preadmission clinic conducted a standardised comprehensive medi-
cation history interview and assessment focusing on the participant’s current homemed-
ication regimen. This was documented in the health record, and the results were used
by the pharmacist to generate a preprinted postoperative medication order form for pre-
operative home medications. Through the use of check boxes, the surgeon indicated on
this medication order form after surgery which home medications were to be reordered.
Home medications that required further clarification before being ordered on hospital
admission (e.g. conflicting information between participant report vs medication vials)
or that required special management in the postoperative setting (e.g. anticoagulants,
antiplatelets, analgesics and hypoglycaemic agents) were listed in the bottom section of
the form. A detailed description of the issue was written in the medical record to be
considered by the surgeon at hospital admission. On reassessment, the continuation of
medications listed in this section required that the physician write a separate medication
order. Pharmacists conducted telephone interviews with participants they were unable
to see in the clinic. If needed, the pharmacist contacted the participant’s community
pharmacy or family physician to clarify the medication regimen. After postoperative ad-
mission, the pharmacist also attempted to verify with the participant if any medication
changes had been made since the clinic assessment. Before study implementation, nurses
and participating physicians were instructed on the proper use of the new medication
order form
Control: standard care consisted of nurses conducting medication histories with partici-
pants at the surgical preadmission clinic or occasionally over the telephone. Medication
history information was entered in the hospital eHR and printed. Surgeons could re-
fer to this printout to generate their postoperative medication orders. The participant’s
community pharmacy or family physician was contacted for additional medication clar-
ifications if needed. It was not standard practice to routinely follow-up after surgery to
clarify medication changes since the clinic assessment
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Outcomes Postoperative medication discrepancy: defined as any medication clarification related
to home medications that was made during the postoperative period. Medication dis-
crepancies could be associated with any of the following: drug, dosage, duration, fre-
quency, formulation, route of administration, appropriateness of restarting medications,
orders requesting the pharmacist to clarify medications, illegible orders and miscella-
neous items. On admission of participants to surgical inpatient units, the pharmacists
prospectively identified participants’ medication discrepancies. Medication discrepancies
were detected using a systematic approach whereby the participants’ home medications
were compared with the AMOs. If an in congruency was detected and the reason was
not documented in the medical record, this was clarified with the medical team and
participant. Medication discrepancies included unintentional and undocumented inten-
tional discrepancies. An undocumented intentional discrepancy was one in which the
physician had made an intentional choice to add, change or discontinue a medication
but was not clearly documented. These discrepancies were recorded because they can
lead to confusion for the healthcare team and to potential medication errors
Characteristics and clinical severity of postoperativemedicationdiscrepancies: the clinical
effect of the postoperative medication discrepancies was assessed independently by 3
pharmacy clinician evaluators. For each postoperative medication discrepancy, the degree
of effect was based on the potential that the discrepancy could result in “unlikely”,
“possible”, or “probable” participant discomfort or clinical deterioration (or both) if the
discrepancy was not identified and addressed. This ranking system was adapted from
the method used by Cornish 2005. Each evaluator independently reviewed blinded
participant data collection forms, pharmacy participant profiles if available, and medical
record orders if needed. The reviewers then rated themedication discrepancies and voted;
if disagreements occurred, discussion ensued until a consensus was reached
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients were centrally ran-
domised by an independent ward clerk to
the intervention or standard care arm us-
ing a random number computer genera-
tor in blocks of 24 (the daily maximum
number of patients seen at the clinic).
The treatment assignments were sealed in
sequentially numbered, identical, opaque
envelopes according to the allocation se-
quence” (page 1035)
Allocation concealment (selection bias) Low risk Treatment assignments sealed in sequen-
tially numbered, identical, opaque en-
velopes according to allocation sequence
(page 1035)
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Were baseline outcome measurements sim-
ilar?
Unclear risk Baseline outcome reporting not reported,
per protocol method used and sensitivity
analysis also undertaken (page 1037)
Were baseline characteristics similar? Low risk Table 1 gave baseline participant charac-
teristics in the intervention and standard
care groups. There was little or no differ-
ence between the 2 groups except for the
number of home medications. Participants
in the intervention group vs the standard
care group had a greater number of home
medications (intervention: 4; control: 3; P
= 0.001) (page 1037, Table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 47 participants had their plan of care
changed after randomisation and were not
admitted to a postsurgical unit partici-
pating in the study during the study pe-
riod; therefore, they were excluded from
the main study analysis. 1 same-day dis-
charge participant was incorrectly ran-
domised into the study and was also ex-
cluded from the main study analysis (page
1037)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk On admission of study participants to the
participating surgical inpatient units, the
pharmacists prospectively identified partic-
ipants’ medication discrepancies. Medica-
tiondiscrepancieswere detected using a sys-
tematic approach whereby the participants’
homemedications were compared with the
AMOs. If an in congruency was detected
and the reason was not documented in the
medical record, this was clarified with the
medical team and participant. Medication
discrepancies included unintentional and
undocumented intentional discrepancies.
An undocumented intentional discrepancy
was one in which the physician had made
an intentional choice to add, change or dis-
continue a medication but was not clearly
documented.
Although every effort was made to con-
ceal the treatment groups during the clin-
ical assessment, the assignment of the par-
ticipant was unblinded if the independent
assessors thought they needed to look into
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the medication discrepancy in more detail
(page 1035)
Was the study adequately protected against
contamination?
High risk All participants attended the preadmission
clinic. Both control and pharmacists inter-
ventions taking place within same clinic
(page 1035)
Selective reporting (reporting bias) Low risk Both a priori outcomes were identified; dis-
crepancies and clinical impact
Other bias High risk A per protocol analysis was performed in-
stead of an intention-to-treat analysis. Par-
ticipants admitted to inpatient units not
participating in this study were not for-
mally assessed formedication discrepancies
- a possible selection bias (page 1040)
Summary risk of bias Low risk Low
Lalonde 2008
Methods Study design: randomised trial
Unit of allocation: block randomisation of participants stratified by medical ward
Unit of analysis: participant
Follow-up: recruited prior to discharge and then contacted at home 1 week following
discharge
Duration: admission to discharge from hospital
Providers: clinical pharmacist
Participants Setting/participants: 83 participants (intervention: 42; control: 41). Cité de la Santé de
Laval hospital and in pharmacies in Laval, Quebec, Canada
Inclusion criteria: aged ≥ 18 years; discharged from a geriatric, family-medicine or
psychiatric ward; discharged with ≥ 2 pharmacotherapeutic changes and have had a
medication history taken by a clinical pharmacist during hospitalisation
Exclusion criteria: person spoke neither French nor English, were transferred to another
hospital or rehabilitation centre, were unreachable or unavailable for a telephone in-
terview following discharge, had no identified community pharmacy at discharge, had
already been recruited into this study during a previous hospitalisation or were unable
to provide informed consent
Transition of care: admission and discharge from hospital
Age (mean): intervention: 69.8 (SD 17.2) years; control: 72.8 (SD 13.4) years
Female: intervention: 73.8%; control: 73.2%
Ethnicity: not reported
Interventions Structural interventions - changes in the medical record system (MDP)
Intervention: after discussions with Laval hospital pharmacists, the MDP was adapted
fromMDPs in current use in other hospitals and at the Cité de la Santé de Laval hospital.
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The MDP included participant information (name, address, telephone numbers) and
contact information (names, telephone numbers) for the hospital physician and pharma-
cist. It also included the participant’s clinical information (weight, height, allergies, in-
tolerances) and pharmacotherapy information (drug name, dose, route, frequency, dura-
tion) and the pharmacist’s recommendations. Allmedications reported at admission were
listed along with their current status at discharge (represcribed without changes, repre-
scribed with changes, discontinued) and new medications added during hospitalisation.
At the time of hospital admission, ward pharmacists were responsible for documenting
medication history. If necessary, the participant’s community pharmacy was contacted
to complete or confirm the medication history. Medication changes during hospitali-
sation were documented from the hospital pharmacy MARs, physicians’ prescriptions
and pharmacists’ notes. All participants received the comprehensive pharmaceutical care
routinely provided by hospital pharmacists during their hospital stay and at discharge.
This included obtaining medication history, chart documentation, case discussion with
physicians and participant counselling at discharge. An MDP was completed for each
participant in the intervention group. If discrepancies were observed between the MDP
and the discharge prescription, pharmacists were responsible for reconciling the infor-
mation. However, on rare occasions, MDPs were completed before the discharge pre-
scriptions were finalised. MDP participants received a copy of the MDP, and a copy was
faxed to their treating physician and pharmacy or long-term care pharmacist
Control: participants received similar pharmaceutical care during their hospital stay and
at discharge. An MDP was completed for each control participant; however, a copy of
the MDP was not given to participants and was not sent to their treating physician and
community pharmacy. Participants received a conventional hospital discharge prescrip-
tion and, if relevant, a medication administration schedule with or without medication
information leaflets
Outcomes Intervention: medication discrepancies were evaluated between the MDP, considered as
the standard for purposes of the study, and 3 other sources of information: the discharge
prescription, the participant’s community pharmacy dispensing records, and the partic-
ipant’s MDP. Using MDP information, the status of each medication at discharge was
classified into 1 of 5 categories: represcribed without changes, represcribed with changes,
added during hospitalisation, discontinued during hospitalisation and not reported in
the MDP. In addition, for medications in the first 3 categories, the discrepancy was
further defined as a medication reported in the MDP only or a different medication
dosage reported (including discrepancies regarding the dosage, route of administration,
frequency of use and duration of use)
Clinical severity of discrepancies: severity was assessed as not clinically significant, clini-
cally significant but not life threatening, serious (i.e. life-threatening or may cause major
clinical problem or hospitalisation), not enough information to judge or not applicable
(discrepancy judged to be due to an MDP error)
Notes Clustering by discharge unit (geriatric, psychiatric, family medicine, other), and phar-
macies. No mention of this in the analysis
Contacted author for original data onparticipantswith “at least one discrepancy” between
MDP and discharge prescription
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation. “The randomisa-
tion, blocked in groups of 10, was strat-
ified by medical ward. Group allocation
was determined using a computer-gener-
ated, random-number table and placed in
numbered, sealed envelopes to be opened
in strict sequence” (page 1452)
Allocation concealment (selection bias) Low risk The randomisation, blocked in groups
of 10, was stratified by medical ward.
Group allocation was determined using a
computer-generated, random-number ta-
ble and placed in numbered, sealed en-
velopes to be opened in strict sequence
(page 1452)
Were baseline outcome measurements sim-
ilar?
Unclear risk No recording of outcomemeasures prior to
randomisation.
Were baseline characteristics similar? Low risk Presented as table. No obvious differences
between groups (page 1454, Table 3)
Incomplete outcome data (attrition bias)
All outcomes
High risk Copies of the discharge prescriptions were
obtained for 65 participants and copies
of the community pharmacy dispensing
records were obtained for all participants
but 1. 6 participants could not be con-
tacted for the telephone interview. Data
were missing for 18 participants because
they left the hospital with their discharge
prescription before the researchers could
record it (Table 2)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk A pharmacist systematically interviewed
participants by telephone approximately
1 week after discharge. Participants were
asked when and where they had their dis-
charge prescription filled and the name and
dosage taken of each of their medications
(medication, dosage, route of administra-
tion, duration of use). The participant’s
community pharmacy was then contacted
to obtain a listing of the participant’s active
medications available from the dispensing
records. Clinical severity was assessed by
blinded assessors
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Was the study adequately protected against
contamination?
Unclear risk Randomisation by individual participant
but allocated to medical wards. Also inter-
vention was a physical reminder of MDP
so unlikely to be contaminated
Selective reporting (reporting bias) Low risk Both outcomes reported on
Other bias High risk Numerous a priori exclusion criteria, in-
cluding not being available to take a tele-
phone call or being transferred to a nursing
home
Summary risk of bias High risk High
Marotti 2011
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: from presentation to the unit on day of surgery. Control participants were
contacted following discharge to construct preadmission medication list
Duration: participants admitted on day of surgery, medication history acquired
presurgery, prescribing perioperatively
Providers: group 1 and 2: pharmacist and RMO; control: RMO
Participants Setting/participants: 357 participants (intervention 1: 119; intervention 2: 118; control:
118). All adult elective surgery participants admitted to the John Hunter Hospital on
the day of surgery were candidates for inclusion in the study. John Hunter Hospital is a
750-bed regional tertiary referral hospital in Newcastle, New SouthWales, Australia. Ap-
proximately 92% of elective surgery participants staying≥ 1 night were admitted on the
day of surgery. Higher-risk participants (approximately 62% of all surgical participants
who stay ≥ 1 night) were seen by a nurse and a doctor in a preoperative assessment and
preparation clinic before admission. Surgery types included general; cardiothoracic; gy-
naecology; vascular; urology; ear, nose and throat; faciomaxillary and transplant surgery.
Orthopaedic surgery participants were excluded due to local process differences. Par-
ticipants were excluded from the trial if they took no regular medications, were unable
to provide consent, had medications charted during a preoperative clinic visit or were
admitted as a day-only participant
Transition of care: hospital admission
Age (median): intervention 1: 62 (IQR 52-71) years; intervention 2: 64 (IQR 47-75)
years; control: 65 (IQR 54-75) years
Male: intervention 1: 55%; intervention 2: 51%; control: 49%
Ethnicity: not reported
Interventions Intervention group 1 (preoperative pharmacist medication history only): pharmacist
interviewed participants at time of admission on day of surgery and documented a regular
medication list
Intervention group 2 (preoperative pharmacist medication history and supplementary
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prescribing on the day of surgery): pharmacist interviewed participants at the time of ad-
mission on the day of surgery and documented a regular medication list. The pharmacist
also prescribed their regular medicines on the medication chart. Pharmacist prescribing
was guided by protocols advising which medications should be withheld and for how
long, for each type of surgery. These were developed before the study in consultation
with surgeons and anaesthetists and approved by the hospital’s drug and therapeutics
committee
Control: usual care involved no clinical pharmacist consultation prior to surgery. These
participants had their medications charted immediately prior to surgery or postopera-
tively by the medical officer in the normal time frame. New medications required peri-
operatively were charted by a medical officer in the usual way, for all 3 groups
Outcomes Missed doses of regular medication (itemised tomissed dose or incorrect dose/frequency)
: participant’s regular medication list was compared with their inpatient medication
chart to determine number of missed doses during their inpatient stay. Comparisons
were based on hospital protocols for regular medication management. Decisions to
change medicines and cease medicines that were clearly documented were also taken into
consideration. In the control group, the participant’s regular medication list was obtained
from the participant post discharge by the trial pharmacist by telephone. A combination
of the preoperative questionnaire filled out by the participant, the admission and progress
notes, and lists faxed from the community pharmacy and community doctor were used
to prompt the participant on their regular medication prior to admission. The final list
was then used as the participant’s regular medication list for the purpose of comparison
with their inpatient orders
Incorrect dose, frequency or missed medication doses postoperatively of significant med-
ications such as beta-blockers, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors,
antiplatelets and anticoagulants
Notes Contacted author for original data to reanalyse for primary outcome. Reanalysed original
data with the reported outcomes “different dose or frequency per participant” to equal
“any discrepancy per participant.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised via a com-
puter-generated list, held by an indepen-
dent investigator to ensure allocation con-
cealment. Randomisation was done in per-
muted blocks of 60 to ensure balance of
numbers in each group (page 1065)
Allocation concealment (selection bias) Low risk Held by independent investigator to ensure
allocation concealment (page 1065)
Were baseline outcome measurements sim-
ilar?
Unclear risk Not recorded
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Were baseline characteristics similar? Low risk No major differences (page 1066, Table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal lost to follow-up (2 in 1 group)
(page 1067, Figure 1)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk Outcome measures were collected after
discharge by an independent technician
through retrospective chart review and
participant administration system records
(page 1066)
Was the study adequately protected against
contamination?
High risk intervention groups were unable to be
blinded from the participant, pharmacist
or the clinicians,
introducing the opportunity for bias. It was
also recognised thatmedicationhistory tak-
ing postdischarge over the telephone was
not an ideal method of taking an accurate
medication history and may have resulted
in medications being omitted from the
medication history. For this reason, other
secondary sources were utilised in prompt-
ing the participant to gain as accurate a
list as possible. It was also possible that the
presence of a pharmacist in the periopera-
tive service highlighted the importance of
prescribing regular medications for partic-
ipants. Each of these factors may have arti-
ficially improved the results for the control
group
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in the results section
Other bias Unclear risk Stated it was an intention to treat analysis
and meta-analysis now done with original
study numbers
Summary risk of bias Low risk Low
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Methods Study design: randomised trial
Unit of allocation: participant (but clustered by 2 inpatient units, not clear if adjusted
for this)
Unit of analysis: participant
Follow-up: from admission to discharge
Duration: hospital discharge
Providers: hospital pharmacist
Participants Setting/participants: 253 participants (intervention: 134; control: 119). Family practice
participants discharged from 2 family practice patient units. The study was conducted at
The Moncton Hospital, South-East Health Regional Health Authority, Moncton, New
Brunswick, Canada. The Moncton Hospital is a 381-bed regional hospital that provides
tertiary care services
Inclusion criteria: being discharged between 8 am and 2 pm, not discharged to another
hospital, prescribed ≥ 1 prescription medication at discharge, completion of informed
consent form, participant’s community pharmacy had signed study participation agree-
ment and no previous enrolment in the study from a prior admission
Exclusion criteria: not able to answer the questions needed to complete the study (i.e.
the surveys) or if they would not be available for follow-up after their discharge
Transition of care: hospital discharge
Age (mean): intervention: 67.3; control: 61.8
Female (%): intervention: 69%; control: 68%
Ethnicity: not reported
Interventions Intervention: “seamless care pharmacist” carried out the MR process by reviewing dis-
charge prescriptions (as written by a physician) and compared these with the MAR
and the participant’s medical chart to identify any discrepancies in the discharge orders.
This pharmacist also reviewed the intervention participant’s drug regimen at discharge
as part of a comprehensive pharmaceutical care workup. The pharmacist also identified
problems with drug therapy and communicated these to the participant’s community
pharmacy, hospital staff and family physician(s). Additionally, the seamless care phar-
macist performed the medication discharge counselling to all intervention participants
and provided them with a medication compliance chart
Control: hospital’s standard of care at discharge where a nurse on the unit performed the
discharge counselling and manually transcribe the discharge notes from the participant’s
medical chart
Outcomes Frequency and potential clinical impact of DTPsm as identified by a seamless care
pharmacist at time of discharge and frequency and potential clinical impact of DTIOs
in hospital discharge medication orders as identified by the seamless care pharmacist as
part of the MR process
Frequency and potential clinical impact of DTPsm: DTP defined as an event or cir-
cumstance involving drug treatment that actually or potentially interfered with the par-
ticipant experiencing an optimum outcome of medical care. The DTPs were classified
into 1 of the categories previously established by Strand 1990. To facilitate the CP in
monitoring the participant’s progress, each DTP was individually supplemented with
additional relevant information such as laboratory findings, diagnosis and general par-
ticipant notes. This provided the CP with a more complete picture of the participant’s
drug therapy and medical conditions. With this additional information provided to the
CP for follow-up, the DTP was termed DTPsm to better reflect its true composition.
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The complete list of DTPsm was generated for each participant and faxed to their CP
and copied to the family physician at the time of discharge
Frequency and potential clinical impact of DTIOs: the seamless care pharmacist also
carried out aMRprocess by reviewing the intervention participant’s dischargemedication
list as prepared by the physician or hard copies of discharge prescriptions (or both) and
comparing these with the hospital’s computerised MAR for the day of discharge, and
progress and consultation notes. Variations between the discharge medication list and
theMAR and participant’s medical chart were identified and recorded as either a DTIO.
An inconsistency was defined as an alteration in a drug order component occurring
between the MAR and discharge medication list. An omission was defined as a deletion
of a drug order component occurring between the MAR and the discharge medication
list. All variations were further classified into subgroupings according to the nature of
the variation. The subgroupings were: dose, drug, duration, frequency and legal. These
subgroupings were chosen based on a previous pilot project
Notes Very broad exclusion criteria of “they would not be available for follow-up after their
discharge.”
Possible unit of analysis error
The DTIO recorded at discharge in the intervention group was actually recording done
as part of the intervention. The recording done in the chart review post discharge only
looked at a small sample (28/134 participants). This was chosen as the intervention
group outcome because it post dated the intervention and was not recorded while the
intervention was being delivered
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patient was then randomised to the
intervention or control group using com-
puter generated random numbers pro-
duced by the hospital’s Information tech-
nology services” (page 66)
Allocation concealment (selection bias) Low risk “The patient was then randomised to the
intervention or control group using com-
puter generated random numbers pro-
duced by the hospital’s Information Tech-
nology services. The physician and nursing
staff were blinded to the participants’ study
group allocation to ensure that all partic-
ipants received the same standard of care
while hospitalised.”
Were baseline outcome measurements sim-
ilar?
Unclear risk Not recorded
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Were baseline characteristics similar? High risk Differences between intervention group
and control group, not allowed for in anal-
ysis (Table 1)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk Spot checking only and not done blindly by
second pharmacist. Study pharmacist was
the intervention and reported the primary
outcome (page 68)
Was the study adequately protected against
contamination?
High risk Possibility of contamination and no men-
tion made of risk.
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in the results section
Other bias High risk Study pharmacist conducted the interven-
tion and recorded the outcome at the same
time. Also participants only selected be-
tween house of 8 am to 2 pm. Broad exclu-
sion categories including those “whowould
not be able available for follow-up after
their discharge”
Summary risk of bias Low risk Low
Pevnick 2018
Methods Study design: parallel-group randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: ED attendance to hospital admission
Duration: hospital admission only
Providers: pharmacist, PSPTs
Randomisation: investigators reviewed the eHR to identify ED participants for whom
providers had already placed an admission order. Upon identifying trial candidates, in-
vestigators reviewed inclusion/exclusion criteria. After enrolling participants meeting cri-
teria, investigators used RANDI2 randomisation software to randomise each participant.
Each block of 6 consecutively enrolled participants was allocated in a 2:2:2 distribution
across the three study groups
Participants Setting/participants: Cedars-Sinai Medical Center is a large university-affiliated hospital.
3-arm randomised controlled trial of 306 inpatients. Eligible participants were medi-
cally complex participants admitted to Cedars-Sinai Medical Center through the ED.
Enrolment screening occurred Mondays through Thursdays from approximately 11 am
to 8 pm
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Study period: 7 January 2014 to 14 February 2014.
Transition of care: hospital admission
Baseline characteristics
Ethnicity (white): intervention 1: 73%; intervention 2: 64%; control: 65%
Control
• Female: 48 (48%)
• Age (mean): 71 (SD 18)
• Number of regular medicines (mean): 15 (SD 7)
• Weighted Charlson Comorbidity score (mean): 3.1 (SD 2.4)
Intervention 1
• Female: 54 (52%)
• Age (mean): 72 (SD 16)
• Number of regular medicines (mean): 15 (SD 7)
• Weighted Charlson Comorbidity score (mean): 3.5 (SD 2.8)
Intervention2
• Female: 55 (54%)
• Age (mean): 71 (SD 16)
• Number of regular medicines (mean): 15 (SD 6)
• Weighted Charlson Comorbidity score (mean): 3.6 (SD 2.6)
Overall
• Female: not recorded
• Age: not recorded
• Number of regular medicines: not recorded
• Weighted Charlson Comorbidity score: not recorded
Inclusion criteria: medically complex participants admitted to Cedars-Sinai Medical
Center through the ED, ≥ 10 active chronic prescription medications in the eHR,
history of acute myocardial infarction or congestive heart failure in the eHR problem list,
admission from a SNF, history of transplant, or active anticoagulant, insulin or narrow
therapeutic index medications (online supplementary appendix)
Exclusion criteria: previously enrolled in study, or if admitted to paediatric or trauma
services or transplant services with pharmacists
Pretreatment: no evident differences.
Participant characteristics, including age, sex, race, ethnicity, insurance, number of med-
ications, income and co morbidities, were similar across study groups (Table 1)
Interventions Intervention 1: pharmacist: usual care + a pharmacist had primary responsibility for
obtaining the AMH. Obtaining the initial AMH usually began with reviewing the med-
ication regimen present in the eHR if one was available from a prior encounter. Next,
participants, families and carers present in the ED were interviewed. Tablet bottles,
medication lists and SNF MARs were also reviewed. In cases where sources matched
convincingly, no further efforts were undertaken. However, in most cases, other sources
including family, pharmacies providers or a combination of these were contacted until
questions were resolved. This was consistent with a published protocol for obtaining
a BPMH. Pharmacists attempted to complete all intervention-arm AMHs soon after
the ED decision to admit was made and before any AMOs were placed, such that the
workflow of admitting physicians would not be affected, and that there would be no
need to contact and convince admitting physicians to fix AMHs or AMOs retroactively.
All pharmacists and pharmacy technicians underwent standardised training in obtaining
AMHs. Didactic training generally took 8-16 hours and included: review of background
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publications; review of locally created general and ED-specificMRmanuals with detailed
guides of AMHwork flows, the participant interview and eHR utilisation; and a didactic
training evaluation. Experiential training included observing > 5 AMHs obtained by an
expert pharmacist, followed by the trainee obtaining > 5 AMHs under the proctoring of
an expert pharmacist. Training continued until proctors deemed trainees competent
Intervention 2: PSPT: usual care + a PSPT had primary responsibility for obtaining the
AMH.Obtaining the initial AMHusually began with reviewing themedication regimen
present in the eHR if one was available from a prior encounter. Next, participants,
families and carers present in the ED were interviewed. Tablet bottles, medication lists
and SNF MARs were also reviewed. In cases where sources matched convincingly, no
further efforts were undertaken. However, in most cases, other sources including family,
pharmacies, providers or a combination of these were contacted until questions were
resolved. This was consistent with a published protocol for obtaining a BPMH. PSPTs
attempted to complete all intervention-group AMHs soon after the ED decision to
admit was made and before any AMOs were placed, such that the workflow of admitting
physicians would not be affected, and that there would be no need to contact and
convince admitting physicians to fix AMHs or AMOs retroactively. PSPTs presented
their AMHs to a supervising pharmacist to allow the pharmacist to decide whether data
sources needed further review, orwhether theAMHwas ready to be entered into the eHR.
Requiring pharmacists to enter PSPTs’ AMHs into the eHR ensured that pharmacists
reviewed all medications in the AMH, and constituted the pharmacist supervision of
PSPTs. All pharmacists and pharmacy technicians underwent standardised training in
obtaining AMHs. Didactic training generally took 8-16 hours and included: review of
background publications; review of locally created general and ED-specific MRmanuals
with detailed guides of AMHwork flows, the participant interview and eHR utilisation;
and a didactic training evaluation. Experiential training included observing > 5 AMHs
obtained by an expert pharmacist, followed by the trainee obtaining > 5 AMHs under the
proctoring of an expert pharmacist. Training continued until proctors deemed trainees
competent
Control: all arms received usual care for participants admitted from the ED, which com-
monly involved multiple process variations. eHR-derived medication regimen accuracy
was subject to variation in the knowledge and efforts of prior providers, which are often
driven by participant acuity and participant care priorities. Participants and carers’ recall
of medication regimens varies over time and across participants. Nurse and physician
contributions likely varied in accordance with their pharmacological training and with
competing obligations, including participants’ requests for home medications. Finally,
physicians may place AMOs before or after participants have had their AMH obtained
by an inpatient nurse (dotted lines and italicised text highlight common process varia-
tions in Figure 1). To minimise unnecessary overlap, inpatient pharmacists and nurses
were advised not to initiate new efforts to improve upon pharmacist-approved AMHs.
However, theywere able to address any concerning AMHor AMOdata that arose during
clinical care
Outcomes Length of stay, tertiary outcome, study not powered to detect
• Outcome type: continuous
• Notes: not actually reported, except that there was no difference
Hospital readmissions (any), tertiary outcome, study not powered to detect
• Outcome type: continuous
• Notes: not actually reported, except that there was no difference
AMH errors per participant
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• Outcome type: continuous
• Direction: lower was better
Mean severity-weighted AMO error score per participant
• Outcome type: continuous
• Direction: lower was better
Mean severity-weighted AMH error per participant
• Outcome type: continuous
• Direction: lower was better
AMO errors per participant
• Outcome type: continuous
• Direction: lower was better
• Data value: endpoint
Notes Sponsorship source: National Institute On Aging and the National Center for Advanc-
ing Translational Science of the NIH under awards K23AG049181 and UCLA CTSI
KL2TR000122
Country: USA
Setting: Cedars-Sinai Medical Center Emergency Department, a large university affili-
ated hospital
Authors name: Joshua M Pevnick
Institution: Department of Medicine, Division of General Internal Medicine, Cedars-
Sinai Health System
Email: Joshua.Pevnick@cshs.org
Address: Department of Medicine, Division of General Internal Medicine, Cedars-Sinai
Health System, 8700 Beverly Blvd, B113, Los Angeles, CA 90048, USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Investigators used RANDI2 ran-
domisation software to randomise each pa-
tient. 8 Each block of six consecutively en-
rolled patients was allocated in a 2:2:2 dis-
tribution across the three study arms (fig-
ure 1).“
Allocation concealment (selection bias) Low risk Quote: ”Patients meeting criteria, investi-
gators used RANDI2 randomisation soft-
ware to randomise each patient. 8 Each
block of six consecutively enrolled patients
was allocated in a 2:2:2 distribution across
the three study arms (figure 1)
Were baseline outcome measurements sim-
ilar?
Unclear risk Not recorded
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Were baseline characteristics similar? Unclear risk Table 1, no statistical analysis. However,
populations appear similar across most
variables, with the exception of having a
history of acute myocardial infarction and
anticoagulant, insulin or narrow therapeu-
tic index drug
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk Because the reference standard pharma-
cist obtained their AMH while the partici-
pants were still hospitalised and used con-
temporaneous information (e.g. conversa-
tions with participants and family mem-
bers), study group could not be masked.
Because of the vast amount of complex in-
formation that might be consulted in de-
termining error severity, we also chose not
to mask study group with case summaries
for other reviewers
Was the study adequately protected against
contamination?
High risk Participants were randomised. No clear
separation of groups, contamination was
possible
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
presented in the results section (page 4-5)
Other bias Unclear risk Potential for sampling bias
Summary risk of bias Low risk Low
Schnipper 2006
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: admission to outcome assessment at 30 days following discharge (± 3 days)
Duration: discharge from hospital to 3-5 days later
Providers: pharmacist
Participants Setting/participants: 176 participants (intervention: 92; control: 84). Participants ad-
mitted to 1 of 4 teams on the general medicine service, BWH, Boston, MA, USA
Inclusion criteria: people who were being discharged home and who could be contacted
30 days after discharge, spoke English and were cared for by a BWH primary care
physician or internal medicine resident
Exclusion criteria not listed.
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Transition of care: hospital discharge
Age (mean): intervention: 60.7 (SD 17.2) years; control: 57.7 (SD 15.9) years
Female: intervention: 67%; control: 65%
Ethnicity: not recorded
Interventions Intervention: pharmacist intervention on the day of discharge consisted of several parts.
First, discharge medication regimens were compared with preadmission regimens and all
discrepancies were reconciled with the medical team’s help. Participants were screened
for previous DRPs, including non-adherence, lack of efficacy and adverse effects. The
pharmacist reviewed the indications, directions for use and potential adverse effects of
each discharge medication with the participant and discussed significant findings with
the medical team. During the follow-up telephone call, the pharmacist compared the
participant’s self-reportedmedication list with the discharge list, exploring any discrepan-
cies. The pharmacist also asked about medication adherence, possible ADEs and adher-
ence with scheduled follow-up and laboratory appointments. Significant findings were
entered into the eMR used by all BWH outpatient practices and communicated to the
participant’s primary care physician via a standard e-mail template
Control: usual care received routine review of medication orders by a ward-based phar-
macist and medication counselling by a nurse at the time of discharge. Nursing discharge
counselling typically focused on medication directions and may have included a discus-
sion of indications or potential adverse effects, especially for new medications. These
sessions sometimes included informal MR, such as comparing discharge medications
with those currently prescribed in the hospital
Outcomes Primary outcome: presence of a preventable ADEs 30 days after hospital discharge
Secondary outcomes: all ADEs (preventable or not), participant satisfaction, healthcare
utilisation, medication adherence and medication discrepancies
Presence of a preventable ADE in participants 30 days after hospital discharge: pre-
ventable ADEs were assessed with a modified version of the method developed by Bates
1995 and their group. Participants were asked a screening question for new or worsen-
ing symptoms since hospital admission. In the case of an affirmative response, follow-
up questions elicited details about these symptoms and their relation to medications.
Case summaries were prepared from these responses, medication lists at admission and
discharge, the hospital discharge summary, any available outpatient visit notes, discharge
summaries from ED visits or hospital readmissions, and laboratory test results in the
month since discharge. For all hospital admissions or ED visits, blinded physician adju-
dicators assessed any relationship to medication use or preventability. Preventable med-
ication-related ED visits or readmissions were considered to be preventable ADEs. If
participants could not be contacted by telephone 30 days after discharge but had been
readmitted to the hospital or visited the ED, case summaries were prepared and ADEs
assessed as described in the preceding paragraph but without the participants’ responses.
This improved our ability to detect serious and preventable ADEs while minimising
bias due to loss to follow-up. Because ADE assessment without participant responses
was less well established than assessment using participant interview, all ED visits or
readmissions that were at least possibly medication related were automatically reviewed
by an independent, blinded expert in drug safety at BWH
All ADEs (preventable or not): 2 of 3 physician adjudicators blinded to treatment group
independently determined whether an ADE had occurred, using the Naranjo algorithm
Participant satisfaction: satisfaction with hospitalisation and discharge processes was
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assessed with a standard questionnaire
Health care utilisation: including scheduled and unscheduled clinic visits, urgent care
and ED visits, and hospital admissions, were assessed by survey questions and hospital
administrative data. Administrative data fromBWHwere subsequently chosen as the gold
standard for hospital admission and ED visits because we found evidence of participant
under-reporting andminimal evidence of readmissions to other hospitals (i.e. no hospital
readmissions and only 3 self-reported ED visits, all in the intervention group, that could
not be confirmed by BWH administrative data)
Medication adherence: assessed by asking participants whether they had taken each
medication exactly as prescribed during the previous day and on how many days during
the previous week. We collected pharmacy refill data for a subset of participants who
used the hospital outpatient pharmacy, to confirm the validity of this approach
Medication discrepancies: determined by comparing the discharge medication regimen
with themedications reported by each participant at 30 days.Differences not attributable
to a physician’s order or completion of a prescribed course of treatment were considered
discrepancies
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by computer-generated al-
gorithm, and treatment assignments, kept
in sealed opaque envelopes, were opened
only after participant consent was obtained
Allocation concealment (selection bias) Low risk Randomisation by computer-generated al-
gorithm, and treatment assignments, kept
in sealed opaque envelopes, were opened
only after participant consent was obtained
Were baseline outcome measurements sim-
ilar?
Unclear risk Not recorded
Were baseline characteristics similar? Low risk Increased hospitalisation in the control
group. the characteristics were measured
and reported. The cutoff for “statistical sig-
nificance was 10%”, however, this seems
reasonable for the sample size. Reviewing
the data provided in Table 1, the variables
that might cause concern at a 5% signif-
icance level were ’hospitalised in the past
year’ and ’someone to help when patient
returns home’ (Table 1)
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Incomplete outcome data (attrition bias)
All outcomes
Low risk The proportion of missing data was similar
in the intervention and control groups. The
losses seem balanced across the 2 groups,
and the effect size for primary outcome and
for discrepancy was non-significant. Addi-
tionally, it seems to be per-protocol analysis
in the paper (even though the stated statis-
tical analysis claims to follow the intention-
to-treat principal) (page 567, Flowchart)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Low risk All participants in the trial were contacted
30 days after discharge (SD 3 days) by a
research assistant blinded to treatment as-
signment (page 566)
Was the study adequately protected against
contamination?
High risk Allocation between medical teams, may
have been opportunity for contamination
between HCPs
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in the results section
Other bias Low risk None
Summary risk of bias Low risk Low
Schnipper 2011
Methods Study design: randomised trial (cluster)
Unit of allocation: primary care practice
Unit of analysis: per participant
Follow-up: admission and 30 days post discharge
Duration: preadmission to readmission to primary care (post discharge)
Providers: Information Communication Technology Tool
Participants Setting/participants: 759 participants, clustered by 19 primary care sites and 2 secondary
care facilities (380 participants in intervention practices, and 379 in usual care). Primary-
care practices affiliated with BWH and Massachusetts General Hospital, USA
Inclusion criteria: inpatients belonging to these practices, aged > 55 years and ≥ 5
medications
Exclusion criteria: not reported.
Transition of care: post hospital discharge, readmission to primary care
Age: not reported
Female: not reported
Ethnicity: not reported
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Interventions Intervention: novel tool built into an ambulatory EMR. The tool compares the pread-
mission medication list in the ambulatory EMR to the hospital discharge medication
list, highlights all changes and allows the EMR medication list to be updated
Control: usual care in primary care practice, no more information provided
Outcomes Proportionof concordantmedications (exactmatches inmedication, dose and frequency)
Accuracy of EMRmedication list: 30 days after discharge, participants were contacted by
telephone, and a research assistant obtained the “gold-standard” postdischarge medica-
tion regimen by including all discharge medications, removing any planned completions
in therapy and incorporating any reported changes made by participants’ physicians since
discharge. The documented ambulatory EMR medication list at the time of the call was
compared to this gold-standard regimen and the proportion of concordant medications
(exact matches in medication, dose, and frequency) was calculated
Notes Outcome of discrepancies seemed to be averaged across practices
Contacted author, but did not provide more information.
Unit of analysis error, allocation was by practice, analysis by individual. Therefore, ad-
justment made with intracluster correlation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “[Practices] matched and ran-
domised to receive the tool or usual care”
No further details provided
Allocation concealment (selection bias) Low risk Allocation by practice at start of study
Were baseline outcome measurements sim-
ilar?
Unclear risk Not reported
Were baseline characteristics similar? High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
Unclear risk Not specified
Was the study adequately protected against
contamination?
Low risk Allocation by practice
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods were
present in results section
Other bias High risk Abstract only, full paper never published
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Summary risk of bias Unclear risk Unclear
Tompson 2012
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: admission to discharge only
Duration: up to 24 hours post hospital admission
Providers: hospital pharmacist, communication with CP and RMO
Participants Setting/participants: 487 participants (intervention: 203; control: 284). “High risk”
patients of 5 Australian hospitals (2 Tasmania, 2 in Western Australia and 1 Victoria)
Inclusion criteria: aged ≥ 50 years, ≥ 2 chronic conditions (≥ 1 of which was cardio-
vascular, diabetes mellitus or chronic obstructive pulmonary disease; and were taking
≥ 3 chronic medications. Participants had to be able to nominate a regular GP and
community pharmacy, not live in a residential aged care facility and were able to provide
informed consent
Transition of care: hospital admission
Age (mean): intervention: 70.7 (SD 10.3) years; control: 73.8 (SD 9.5) years
Female (%): intervention: 46.8%; control: 52.5%
Ethnicity: not reported
Interventions Intervention: hospital-based trial pharmacist utilised the following to construct a rec-
onciled list of medication: community pharmacy’s 6 months dispensing history, com-
prehensive interview with participant, review of the participant’s own medication, in-
formation obtained from the GP, the hospital doctor’s initial medication history. CP
records were transferred by secure electronic website or fax. Reconciled and initial drug
charts were compared for discrepancies. Discrepancies for intervention participants were
discussed with the attending doctor
Control: usual care, which was building of the reconciled list as described in the inter-
vention but did not communicate discrepancies to their attending doctor
Outcomes Drug discrepancies: for intervention participants the reconciled admission medication
list and the initial drug chart were compared and discrepancies between the 2 identified
and documented. Discrepancies were classified as omissions of medications, wrong med-
ications and dosing errors, those discussed with doctor (in the intervention group) and if
deemed to be intentional were removed from the total. To decide if they were intentional
in the control group a chart review was done by the trial pharmacist. The hospital-based
trial pharmacist observed the management of each participant’s medication regimen for
the duration of their stay. Progress of the resolution of identified discrepancies was as-
sessed for all participants at number of time points: admission, within 48 hours, over
48 hours, before discharge. For intervention participants the discrepancies were actively
followed up by staff, whereas for control participants the process was purely observational
The outcome time point recorded in the forest plot of this review was the discrepancy
rate “not resolved during the hospital stay”
Readmission: defined as within 5 days of discharge
Length of stay: no definition provided
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Notes Figures of the primary outcome “one or more discrepancies per patient” were reported
as percentages in published paper. Author contacted and provided the original absolute
figures
Conducted in a number of sites ?clustering effect - although randomisation was at par-
ticipant level. “patients randomised centrally.”
Possible major bias with all discrepancies in the intervention group discussed with the
doctor and removed if deemed to be intentional. The same process was not undertaken
in the control and may have led to misclassification. Instead they relied on chart review
to decide if intentional or not
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation tables
(page 641)
Allocation concealment (selection bias) High risk “Trial not blinded to group allocation”
(page 645)
Were baseline outcome measurements sim-
ilar?
Unclear risk Not reported
Were baseline characteristics similar? High risk Difference in baseline details on age only
(Table 2)
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawn/death/discharge with no addi-
tional details (page 642)
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk No blinding of outcome assessors to group
allocation (page 641)
Was the study adequately protected against
contamination?
High risk Same physicians and pharmacists manag-
ing usual and intervention groups
Selective reporting (reporting bias) Low risk Discrepancies was selected outcome and it
was reported.
Other bias High risk Selection bias - no nursing home residents
or those without a GP or pharmacist were
not included
Summary risk of bias High risk High
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Vega 2016
Methods Study design: parallel-group randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: first cycle through to third cycle of chemotherapy (depending on group
allocation)
Duration: chemotherapy clinic appointments
Providers: pharmacists
Randomisation: randomisation (1:1) was carried out by random number assignment
Participants Setting/participants: oncology patients. Carried out in Puerta del Mar University Hos-
pital, Cádiz, Spain, a tertiary care centre with 620 beds. Randomisation of 172 partici-
pants, of which 147 were included (intervention: 76; control: 71)
Study period: February and September 2013
Transition of care: outpatient provided chemotherapy
Baseline characteristics
Ethnicity: not reported
Intervention
• Female: 39 (51%)
• Age (mean): 60.2 (SD 13.2)
• Number of regular medicines: not reported
• Charlson Comorbidity Index (mean): 5.1 (SD 2.2)
Control
• Female: 43 (61%)
• Age (mean): 60.7 (SD 12.4)
• Number of regular medicines: not reported
• Charlson Comorbidity Index: 5.4 (SD 2.3)
Inclusion criteria: aged > 18 years who started or changed chemotherapy in an outpa-
tient setting for some oncological disorder and who were also receiving ≥ 1 additional
outpatient medication on a chronic basis (prescription or non-prescription medication)
Exclusion criteria: medication history could not be obtained due to cognitive impairment
or the lack of a career capable of supplying the required information (or both)
Pretreatment: some baseline characteristics were different between groups (e.g. diagnosis,
gender distribution, major polymedication)
Interventions Intervention: pharmacist-led MR programme that was specifically developed for cancer
patients during the first cycle of chemotherapy. Standard practice for the intervention
group included validation of chemotherapy and supportive care medications in the treat-
ment protocol: indication, dose, route and administration sequence, dose adjustments
based on toxicity, and stability of intravenous preparations
Control: standard practice included validation of chemotherapy and supportive care
medications in the treatment protocol: indication, dose, route and administration se-
quence, dose adjustments based on toxicity and stability of intravenous preparations.
Standard practice did not include MR. The MR programme was applied to control
participants in the third cycle of chemotherapy
Outcomes Reconciliation error that reached the participant
• Outcome type: dichotomous
• Reporting: fully
• Direction: lower was better
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• Data value: endpoint
Notes Sponsorship source: “No outside funding supported this study.”
Country: Spain
Setting: oncology patients treated in the outpatient setting at Puerta del Mar University
Hospital, Cádiz, Spain
Authors name: Triana Gonzalez-Carrascosa Vega
Institution: Hospital Universitario Puerta del Mar, Cádiz, Spain
Email: trianaglez-carrascosavega@hotmail.com
Address: Hospital de Jerez, Ronda de Circunvalación s/n, 11407, Jerez de laFrontera,
Cádiz, Spain
Significant bias in that control group participants who were too unwell to have third
cycle of chemotherapy were not included in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization (1:1) was carried
out by random number assignment.”
Allocation concealment (selection bias) Unclear risk Not reported
Were baseline outcome measurements sim-
ilar?
Unclear risk Outcomes not reported at baseline
Were baseline characteristics similar? High risk Some baseline characteristics were differ-
ent. In particular, “the number of patients
with major poly-medication according to
the criteria of Bjerrum et al. was found
to be greater in the intervention group”.
There were also differing diagnoses be-
tween groups (e.g. lung, stomach and ovar-
ian cancer), as well as a different gender dis-
tribution, with more women than men in
the control group
Incomplete outcome data (attrition bias)
All outcomes
Low risk In general missing outcome data appeared
balanced in numbers but reasons for miss-
ing data differed slightly
Quote: “...randomisation of 172 patients,
of which 147 were included (76 patients in
the intervention group and 71 controls)”
(Flowchart, Figure 2)
Similar number of participants excluded in
each group (intervention: 11; control: 14)
; however, 10 (of 14) participants in con-
trol group were excluded as they did not
reach cycle 3, all in intervention appeared
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to reach cycle 3
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk Quote: “Since the intervention was a pro-
fessional act, blind patient assignment was
not possible.”
Was the study adequately protected against
contamination?
High risk No clarity on who administered interven-
tion to control group. Contamination was
possible and no mention of it
Selective reporting (reporting bias) Low risk All proposed outcomes were reported.
Other bias High risk Unbalanced gender distribution between
groups. Some baseline characteristics dif-
ferent between groups but no adjustment
in analysis
Summary risk of bias Unclear risk Unclear
Yau 2008
Methods Study design: randomised trial
Unit of allocation: participant
Unit of analysis: participant
Follow-up: admission to inpatient ward until follow-up 3 days following discharge
Duration: hospital discharge
Providers: resident pharmacist
Participants Setting/participants: 29 participants (intervention: 13; control: 16). Inpatient wards at
the Cross Cancer Institute hospital in Edmonton, AB, Canada which consisted of 59
beds that provided specific care for cancer patients
Inclusion criteria: aged≥ 18 years, had≥ 1 home medication or herbal medication, and
were under the care of 1 of the 3 clinical associate physicians that agreed to participate
in the study
Exclusion criteria: inpatients who were radioactive such as selectron patients, people who
were to remain in hospital < 72 hours, language barrier such as unable to speak English,
and people who were readmitted into the hospital but had already been enrolled on the
study
Transition of care: hospital discharge
Age (mean): intervention: 50.6 years; control: 54.9 years
Female (%): intervention: 53.8%; control: 25%
Ethnicity: no information provided, but English speakers only being a recruitment re-
quirement
Interventions Intervention: standard care + pharmacist discharge MR, which entailed a pharmacist-
conducted participant interview, telephone calls to community pharmacies, telephone
calls to a participant’s GP and a review of medication list from the Alberta Electronic
Health Record to obtain a BPMH of a participant’s home medications. In addition, the
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last 24-hour hospital MAR was reviewed and documented. A discharge MR tool was
created showing the participant’s home medications (including non-prescription drugs
and herbals), medications on last MAR and medication changes. The pharmacy resident
acted as the pharmacist in this study group. The discharge MR tool acted as a resource
for the physician and discharge nurse to help in the assessment of prescribing discharge
medications. Afterwards, a medication list for health professionals was created and sent
out to the participant’s community pharmacy and family physician for information
purposes. A participant discharge medication list was also provided for the participant
Control: standard of care involved the physician or nurse asking the participant if they
had medications on the last hospital MAR at home. The physician would then write a
prescription for medications that they believe the participant needs and does not have at
home. Standard care involved MR by the pharmacist at admission. At discharge, stan-
dard of care involved review of participant MAR and an interview with the participant
regarding home medications by the physician or nurse. The clinical associate physician
assessed which medications to prescribe to the participants at discharge. Discharge coun-
selling was done by either discharge nurse or physician. No discharge MR was done by
a pharmacist
Outcomes Unintentional discrepancies: for both control and study participants, baseline discharge
medication lists were created by the investigator after participant had been discharged
from the hospital. The baseline discharge medication list represented what the physician
believed the participant was taking when discharged to home. This list was then verified
by the physician. 3 days after discharge, participants received a telephone interview by
the pharmacist, at home or discharge facility, regarding what medications and herbal
medications theywere currently taking. Medications taken at home or transferred facility
was compared to the baseline discharge medication list to identify any medication dis-
crepancies. The investigator classified each discrepancy in accordance to the Safer Health
Care Now campaign guidelines as “Intentional Documented Discrepancy”, “Intentional
Undocumented Discrepancy” or “Unintentional Discrepancy”
Clinical importance of discrepancies: panel of investigators, which included 1 physician,
1 pharmacist and 1 pharmacy resident, analysed the discrepancies for harm. Severity of
discrepancies were also determined by the same panel of investigators as either “Unlikely
to cause harm”, “Potential to cause moderate harm” or “Potential to cause severe or
serious harm” based on adapted criteria set by Cornish 2005. Unlikely to cause harm
would result in little to no effect on the participant. Potential to cause moderate harm
would result in moderate discomfort to the participant such as an adverse effect. Potential
to cause severe or serious harm would cause significant morbidity to the participant
requiring immediate medical attention or hospitalisation
Notes Unpublished. Conference poster only, author supplied unpublished manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail described
Allocation concealment (selection bias) Unclear risk No detail described
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Were baseline outcome measurements sim-
ilar?
Unclear risk Not recorded
Were baseline characteristics similar? Low risk The characteristics of both groups did not
differ (Table 1).
Incomplete outcome data (attrition bias)
All outcomes
High risk ≥ 6 participants lost to follow-up with no
reason why.
Was knowledge of the allocated inter-
ventions adequately prevented during the
study?
High risk Study pharmacist recorded outcome and
applied intervention too
Was the study adequately protected against
contamination?
High risk Quote: “As the prescribers knew they were
part of the study, prescribers may have been
more attentive to the patient’s home med-
ications when discharging the patient.”
Selective reporting (reporting bias) Low risk All specified outcomes were reported.
Other bias High risk Unpublished study, small sample size
Summary risk of bias High risk High
AAA: Acute Assessment and Admission unit; ADE: adverse drug event; AMH: admission medication history; AMO: admission med-
ication order; BPMH: best possible medication history; BWH: Brigham and Women’s Hospital; CCDR: Central Clinical Data
Repository; CP: community pharmacist; CPSS2: Computerised Patient Support System 2; CRP: clinical research pharmacist; DMP:
designated medical practitioner; DRP: drug-related problem; DTIO: drug therapy inconsistencies and omissions; DTP: drug-
therapy (related) problem; DTPsm: drug-therapy problems for seamless monitoring; ED: emergency department; eHR: electronic
health record; EMR: electronic medical record; FMIS: family medicine inpatient service; GP: general practitioner; HCP: healthcare
provider; ICOC: Iowa Continuity of Care; PMR: patient medication record; MAI: Medication Appropriateness Index; MAR: med-
ication administration record; MDP: medication discharge plan; MMAS-8: Morisky Medication Adherence Scale; MR: medication
reconciliation; MRP: medication reconciliation pharmacist; NCCMERP: National Coordinating Council for Medication Error
Reporting and Prevention; NEHR: National Electronic Health Record; NHBPS: Nursing Home Behaviour Problem Scale; NHGP:
National Healthcare Group Polyclinic; NIH: National Institutes of Health; NIHR: National Institute for Health Research; OPD:
Out Patient Department; PAC: preadmission clinic; PCM: pharmacist case manager; PCP: primary care provider; PSPT: pharmacist
supervised pharmacy technician; QoL: quality of life; RMO: resident medical officer; SD: standard deviation; SNF: skilled nursing
facility; SOP: standard operating procedure; UD: unintentional discrepancy; VTE: venous thromboembolism.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Corbett 2011 Insufficient detail available to make judgement on inclusion. Unable to contact authors
Fernandes 2011 Control group included medication reconciliation
NCT01819974 Proceeded to ineligible study design, DOI 10.1007/s11096-016-0345-y
NCT02047448 Intervention not as per protocol
NCT02368548 Intervention not as per protocol
Quach 2015 Primary outcome not consistent with protocol
Romero 2015 Primary outcome not consistent with protocol
Characteristics of ongoing studies [ordered by study ID]
ISRCTN23949491
Trial name or title Medicines reconciliation at the interface: a pilot randomised controlled trial to determine the costs and effects
of a pharmacy provided service
Methods Pilot RCT
Participants • Men or women aged ≥ 18 years
• Admitted with prescribed medicines (≥ 1 regular/non-prescription medication) to 1 of 5 adult medical
wards with prescribed medicines
• Not received MR service from the pharmacy team as part of routine pharmaceutical input at the point
of recruitment
• Identified from hospital computer system as being admitted within the previous 24 hours
Interventions Medicines reconciliation vs medicines reconciliation within 24 hours of admission by the study pharmacist
Outcomes Primary outcomes
• Length of stay measured at discharge
Secondary outcomes
• Feasibility measured at end of study
• Morbidity and mortality measured at 3 months
• Participant satisfaction measured at 3 months
• Quality of life measured at 3 months
• Level of medication errors
Starting date July 2012
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Contact information Miss Amanda Bale
Email: amanda.bale@addenbrookes.nhs.uk
Cambridge, UK
Notes Conference presentation (Medication errors: do they persist in primary care and can they be identified?) and
thesis reporting pilot results of ongoing MedRec study (https://ueaeprints.uea.ac.uk/48020/)
doi.org/10.1186/ISRCTN23949491.
Linked to review’s included study Cadman 2017.
NCT00844025
Trial name or title Pharmaceutical care and clinical outcomes for the elderly taking potentially inappropriate medication
Methods RCT
Participants Inclusion criteria
• Hospitalised people aged ≥ 65 years
• Taking ≥ 6 prescribed medicines regularly, including ≥ 1 potential inappropriate medication
Exclusion criteria
• People who refused informed consent
• Discharged before consent could be obtained
• Cognitive impaired
Interventions Intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medi-
cation review, medication reconciliation, participant education and recommended actions
Control group:
“Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist
and nurse”
Outcomes • Number of unsolved drug-related problems
• Rate of ADE during hospitalisation
• Number of potentially inappropriate medication
Starting date February 2009
Contact information Liu Jen Wei, Shin Kong Wo Ho-Su Memorial Hospital, Department of Pharmacy, Taipei, Taiwan
Notes clinicaltrials.gov/show/NCT00844025
Listing not updated and no response from study co-ordinator.
NCT01082978
Trial name or title Portable health files improve quality of care and health outcomes: a randomized controlled trial (PHF-
Randomised Controlled Trial (RCT))
Methods RCT
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NCT01082978 (Continued)
Participants Inclusion criteria:
• Aged ≥ 60 years
• People living independently in the community. Hostel care acceptable, but participants who are not
independent requiring full nursing home care are excluded.
• 6 medical practitioner visits in previous 12 months
• ≥ 2 of the following confirmed chronic diseases that require prescription oral or parenteral drug
treatment or surgery and requiring at least annual specialist consultation: cardiovascular, respiratory,
endocrine, renal, neurological, gastrointestinal, hepatic, genitourinary, haematological, infective, rheumatic,
inflammatory, immunological or neoplastic disease.
• Participant’s GP must have access to a computer during the consultation visit.
• ≥ 2 medical specialists ≥ 1 of whom has access to a computer during the consultation visit.
• Able to understand the purpose of the trial and undergo full and valid informed consent.
Exclusion criteria:
• Life expectancy < 12 months.
• Inability to carry a paper PHF or ePHF and having no carer willing and able to accomplish same.
• Mentally unable to undertake valid informed consent.
• Participants who are not independent in the community, that cannot mobilise to see a specialist or
requiring full nursing home care
Interventions Intervention will be given a USB memory device that contains the PHF software. The PHFs contained core
medical data which functions as a subset of a comprehensive medical record. The PHF was updated by the
healthcare provider at each visit and could also be updated by participant between visits if necessary
Outcomes • Combined endpoint of deaths, hospitalisations
• Quality of life
• Health service utilisation and healthcare costs
• Medication errors, duplicative investigations
• Clinical workflow
• Participant and healthcare provider acceptability and satisfaction with PHF
• Guidelines uptake and documentation
• Health literacy
• Information technology and computer expertise
• Adverse events
Starting date March 2010
Contact information Marissa ND Lassere, St George Hospital, Kogarah, New South Wales, Australia
Notes clinicaltrials.gov/show/NCT01082978
Study is ongoing
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NCT01195051
Trial name or title Medication reconciliation technology to improve quality of transitional care (MedMatch)
Methods RCT
Participants Inclusion criteria
• Participants admitted to the Medicine Service during a 12-month period.
• Physicians who provide inpatient or ambulatory care for participants.
• Pharmacists who provide care for participants.
Exclusion criteria
• Participants admitted but not seen in a primary-care clinic within the preceding 12 months.
• If an enrolled person is determined to be a prisoner or pregnant woman, then the study will
discontinue the person for research purposes or will submit an amendment at that time.
Interventions Electronic medication reconciliation
A new, computer-based application will be used to document and prescribe outpatient medications in the
inpatient setting
Outcomes • Reconciliation of outpatient medications
• Measurement of potential for harm and potential severity of harm
• Measurement and analysis of providers’ perspectives
• Measurement and analysis of participants’ perspectives
• Reportable financial and organisational dimensions
• Utilisation of intervention
• Measurement and analysis of drug-related medical errors
• Measurement of ADEs and near misses
• Medication discrepancies between preadmission and ambulatory follow-up
Starting date November 2010
Contact information Michael Weiner, MD, MPH
Indiana University School of Medicine, Department of Medicine
Indianapolis, Indiana, United States.
Notes clinicaltrials.gov/show/NCT01195051
Completed, but not submitted for publication yet.
No further response from study co-ordinators.
NCT02006797
Trial name or title Communication between hospital and community pharmacists: impact on drug management at discharge
(REPHVIM)
Methods Cluster RCT
Participants Inclusion criteria:
• Aged > 18 years
• Attending to the same CP for ≥ 3 months
• French speakers
Exclusion criteria
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NCT02006797 (Continued)
• People with a length stay over 21 days (too many therapeutic modifications)
• People who do not return to home
• People having palliative care or expected end of life (or both)
• People who will not give their informed consent
Interventions Medication reconciliation at discharge and communication of this intervention to participant’s CP
Outcomes • Drug-related problems
• All compounds of the composite primary outcome measure
• Clinical impact of problems
• Number of non-planned hospitalisation
• Participant satisfaction
• CP satisfaction about exchanges with hospital pharmacists
• Time spend by hospital pharmacist on reconciliation and communication to CP
• Percentage of drugs prescription modified by the hospital pharmacist at discharge
Starting date January 2014
Contact information Xavier Pourrat, Centre Hospitalier Régional Universitaire de Tours
Tours, France.
Notes clinicaltrials.gov/show/NCT02006797
Recruitment ongoing
NCT02135731
Trial name or title Medication review software to improve the accuracy of outpatient medication histories
Methods RCT
Participants Inclusion criteria
• Veteran with primary care appointment at Portland VA
• ≥ 3 medications in medication profile
Exclusion criteria
• Visual impairment
• Upper extremity neuromuscular impairment
• Cognitive impairment
• Unable to speak and read English
• Never been seen at a VA
Interventions Medication review software with pictures
The intervention is a self-service software program that displays each prescription on screen along with an
image of the pharmaceutical product. Participants must use response buttons to describe adherence patterns
and to advance through the questionnaire items
Outcomes Number of medication discrepancies from the reference standard
Starting date May 2014
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NCT02135731 (Continued)
Contact information Blake Lesselroth, Director, Portland Patient Safety Center of Inquiry, Portland VA Medical Center
Portland, USA
Notes clinicaltrials.gov/show/NCT02135731
Completed, but not submitted for publication yet.
NCT02413957
Trial name or title Medication reconciliation in comparison to an extensive medication safety check
Methods RCT
Participants Inclusion criteria
• Aged ≥ 65 years
• Written informed consent participant or the legal representative
• Existing medication therapy at hospitalisation
• Admission to 1 of the project wards via ED (non-elective)
Exclusion criteria
• Participants included in the study previously
Interventions Pharmacist take the BPMH, comparison of the BPMH with the admission order (AMO), clarify and solve
all discrepancies between the BPMH and the AMO
Outcomes • Incidence of ADEs
• Assessment of the clinical relevance of medication-related problems as determined by the French
Society of Clinical Pharmacy
• Assessment of the clinical relevance of discrepancies as determined by the French Society of Clinical
Pharmacy
• Number of medication-related problems
• Number of discrepancies
• Duration of taking the BPMH
Starting date January 2015
Contact information Albrecht Eisert, University Hospital Aachen, Aachen, Germany & Katharina Schmitz
Aachen, Germany.
Notes clinicaltrials.gov/show/NCT02413957
Completed but not yet submitted for publication
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NCT02482025
Trial name or title The Secure Messaging for Medication Reconciliation Tool (SMMRT) trial
Methods RCT
Participants Inclusion criteria
• Veterans aged ≥ 18 years
• Having a VA PCP at any VA facility in VISN-1
• Planned discharge home (as opposed to another facility)
• Computer and Internet access
• Anticipated to be discharged with ≥ 5 medications. Having a VA PCP will be defined as having seen
the provider within the past 2 years. Planned discharge home will be ascertained from the Veteran’s nurse;
approximately 75% of VA Boston discharges are to home. The nurse will also provide number of
anticipated discharge medications
Exclusion criteria
• Cognitive impairment (as determined by the Callahan screener)
Interventions Secure Messaging for Medication Reconciliation Tool (SMMRT), with a pharmacist communicating with
Veterans to review medications and reconcile discrepancies after hospital discharge via SecureMessaging (SM)
, within My HealtheVet (MHV), VA’s participant portal
Outcomes • Medication discrepancies
• Hospital utilisation
Starting date September 2015
Contact information Steven R Simon, MD MPH BS VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts, United States.
Notes clinicaltrials.gov/show/NCT02482025
NCT02598115
Trial name or title Impact of the implementation of collaborative pharmaceutical care on hospital admission drug prescriptions
for patients 65 years of age and older
Methods RCT
Participants Inclusion criteria
• Aged ≥ 65 years
• Patient or legal representative informed about study
• Patient admitted as an inpatient to 1 of the participating hospitals
• Available for 3 months of follow-up
Exclusion criteria:
• Participating in another drug study
• Under judicial protection
• Impossible to correctly inform the participant or legal representative
• Patient or legal representative refused to participate in study
• Expected life span of participant < 3 months of follow-up
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NCT02598115 (Continued)
• Impossible to contact participant after hospitalisation
• Hospitalisation for > 21 days
Interventions Collaborative Pharmaceutical Care
The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments
and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical
interventions recorded on the standardised support provided by the French Society of Clinical Pharmacy. The
pharmaceutical interventions are discussed during a collaborative interview
Outcomes • Number of participants with ≥ 1 preventable medication error
• Preventable medication error rate
• Number of participants at high risk for ADEs
• Readmission rate for inpatient hospitalisation
• Mortality rate
• Length of hospital stay
• Acceptance rate of pharmaceutical interventions during collaborative interview
• Avoided costs related to the occurrence of medication errors
• Satisfaction questionnaire (for healthcare professionals)
Starting date September 2016
Contact information Jean-Marie Kinowski, Centre Hospitalier Universitaire de Nimes,
Nimes, France.
Notes Completed, but not published as yet. No response from study co-ordinators
NCT02689076
Trial name or title Regional data exchange to improve care for Veterans after non-VA hospitalization
Methods RCT
Participants Inclusion criteria:
• Established participant in a Bronx VA or Indianapolis VA geriatrics or primary care clinic
• Aged ≥ 65 years
• Be consented in the local HIE
• Utilised any non-VA services in the previous 2 years, including: nursing laboratory physician pharmacy
or hospital services (or both)
Exclusion criteria:
• Refusal to sign informed consent or consent to access local HIE
Interventions HIE Notification plus Care Coordination
VA provider notification of non-VA hospitalisation via electronic HIE + posthospital geriatric care transitions
intervention
Outcomes • Hospital readmission
• Scheduled follow-up
• High-risk medication discrepancies
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NCT02689076 (Continued)
• Care transitions measure
Starting date March 2016
Contact information Kenneth S Boockvar, VA Office of Research and Development
James J. Peters VA Medical Center, Bronx, NY, USA.
Notes
NCT02871115
Trial name or title Pilot study of a pharmacy intervention for older adults with cancer
Methods RCT
Participants Inclusion criteria:
• Aged ≥ 65 years
• Diagnosed with any stage breast, gastrointestinal or lung cancer
• Panning to receive first-line chemotherapy at Massachusetts General Hospital
• Verbal fluency in English
Exclusion criteria:
• Unwilling or unable to participate in the study
• Significant psychiatric, cognitive or other comorbid disease which the treating clinician believes
prohibits informed consent or participation in the study
Interventions Pharmacy intervention: participants randomised to the pharmacy intervention (PRIME) will undergo evalu-
ation with a clinical pharmacist at their second or third chemotherapy infusion who will: 1. perform detailed
medication reconciliation and obtain allergy and vaccination history; 2. evaluate and document polyphar-
macy, potentially inappropriate medications, lack of appropriate medications; and 3. document their findings
in the medical record and discuss their recommendations the oncology team
Outcomes • Rates of study enrolment
• Rates of study completion
• Rates of study satisfaction
• Rates of medication list accuracy
• Change in the number of medications
• Number of medications
• Rates of polypharmacy
• Change in the number of potentially inappropriate medications
• Number of potentially inappropriate medications
• Rates of appropriate pneumococcal vaccinations
• Rates of appropriate influenza vaccinations
Starting date January 2017
Contact information Ryan Nipp, Massachusetts General Hospital,
Boston, Massachusetts, United States.
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NCT02871115 (Continued)
Notes Recruitment ongoing
NCT02905474
Trial name or title Harnessing mobile health technology to personalize the care of chronic kidney disease patients: medication
domain randomized controlled trial
Methods RCT
Participants Inclusion criteria
• Incident or prevalent participants aged ≥ 18 years
• English-speaking
• Able and willing to provide informed consent
Exclusion criteria:
• Chronic kidney disease stages 1 to 3a (estimated glomerular filtration rate of ≥ 45 mL/minute)
• Likely to receive a kidney transplant within 3 months of enrolment into trial
• Living in a long-term care or rehabilitation institution, likely to have their care transferred to another
facility outside participating clinic areas during course of study
• Taking < 2 prescription medications
• Planning to travel or live consecutively out of the province of Ontario for > 1 month
• Participating in another intervention trial
• Cognitive impairment
Interventions eKidneyCare
The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for
updated medication profiles to be sent directly to the participant’s smart phone for the renal clinic pharmacy
information system
Outcomes • Medication discrepancy
• Clinic blood pressure
• Ambulatory blood pressure
• Chronic kidney disease-specific laboratory values
• Medication discrepancy proportion of participants
• Satisfaction
• Quality of life
Starting date May 2016
Contact information Alexander G Logan, Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Toronto, Ontario, Canada.
Notes
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NCT03029052
Trial name or title A comparative pilot study in an infectious disease department assessing the impact ofmedication reconciliation
at discharge associated with a participant’s counseling session, both provided by a pharmacist, on participant’s
care after discharge
Methods RCT
Participants Inclusion criteria
• Aged ≥ 18 years
• Hospitalised in infectious disease department
• Chronic disease and a current medical prescription including ≥ 3 drugs
• Discharged home or nursing home
• Not opposed to the study
Exclusion criteria
• Foreigners, people under legal guardianship
• Advanced dementia (Mini Mental State Examination score < 20) or telephone tracking impossible
• Primary care physician opposed to answer questionnaire
Interventions Behavioural: reconciliation In addition to standardhealthcare procedures, the pharmacistwill analyse discharge
prescriptions and proceed tomedication reconciliation. A participant’s counselling sessionwill also be provided
by the pharmacist. A reconciliation mail will be addressed to the PCP
Outcomes • Proportion of inhospital prescription changes not maintained by the PCP 1 month after discharge
The number of inhospital prescription changes will be evaluated only on discharge prescription transmitted
to the participant (after prescription analysis by a clinical pharmacist in the “reconciliation” group)
Compared to the list of all current medications at admission, inhospital prescription changes include the
following:
• adding a new drug
• discontinuing a drug
• drug switch
• modifying a dose
Among these hospital prescription changes, some will not be maintained by the PCP 1 month after discharge
Inhospital prescription changes not maintained by the PCP will be evaluated on the first prescription of the
PCP following discharge
Starting date February 2017
Contact information Frederique Bouchand. Centre d’Investigation Clinique et Technologique 805
Garches, France.
Notes
NCT03173690
Trial name or title Medicines reconciliation at an intensive care unit
Methods RCT
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Participants Inclusion criteria
• Aged ≥ 18 years belonging to the hospitals intake area written informed consent by the participant or
his/her next to kin.
Exclusion criteria
• People without next to kin
• Not Norwegian speaking, in need of a translator medication reconciliation performed earlier
• People with Guillain-Barre or myasthenia gravis, due to long expectancy of stay
• Short life expectancy, decided in cooperation with the physician
Interventions Receive medication reconciliation at the intensive care unit + medication reconciliation at the ward
Outcomes • Number of participants with ≥ 1 discrepancy between medications listed on hospital chart and
medications used at home before hospital admittance.
• Clinical relevance of the observed medical discrepancies
Starting date February 2017
Contact information Silje Engdal Ørnes. Akershus University Hospital Lørenskog, Akershus, Norway
Notes
Westbrook 2016
Trial name or title Stepped-wedge cluster randomised controlled trial to assess the effectiveness of an electronic medication
management system to reduce medication errors, adverse drug events and average length of stay at two
paediatric hospitals: a study protocol
Methods Cluster RCT
Participants Inclusion criteria
• eMM implementation is occurring at 2 paediatric hospitals. All participants receiving medications on
the study wards will be included in the study and all nurses who provide medication administration to
patients on these wards will be eligible to participate in the direct observational study.
• No age limit.
Exclusion criteria:
• “eMM will not be available in the intensive care units (ICUs), theatres or outpatients”
Interventions eMM allows electronic prescribing, recording of drug dispensing, drug administration, and medication rec-
onciliation and monitoring processes. The system allows for the ordering and administration of all oral, and
intravenous medications and fluids, but excludes anaesthesia medications. The eMM contains both passive
and active decision support in the form of links to guidelines, policies, protocols, order sets, order sentences,
safety alerts (e.g. drug-drug interactions, dose range checks) and dosage calculators. During the course of the
study, the eMM system will be accessible via any computer in the hospital allocated for inpatient clinical care,
but will not be available for patients in the intensive care units, theatres or outpatients. The system will be
predominantly accessed in hospital wards and in the hospital pharmacy. Both fixed and mobile computing
devices are available to staff using the system. Medication reconciliation on admission and at discharge will
be performed using the eMM system when implemented. On admission, medication histories are taken and
converted to inpatient orders. While the participant is in hospital any new medication orders will be created
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Westbrook 2016 (Continued)
within the eMM system. On discharge, a discharge medication reconciliation occurs and orders are converted
to paper prescriptions for the participant. Participants then have their prescriptions filled at community phar-
macies
Outcomes • Medication errors
• ADEs
• PADES
Starting date April 2016
Contact information Professor JI Westbrook. Centre for Health Systems and Safety Research, Australian Institute of Health Inno-
vation, Macquarie University, Sydney, New South Wales, Australia
Notes ACTRN12616001452482
Williams 2013
Trial name or title Project impact: improving participant adherence through communication at transition
Methods RCT
Participants People with HIV/AIDS being discharged from the university hospital
Interventions An accurate list of discharge medications is identified by a pharmacy team. This pharmacy team will 1.
compare the discharge medication list to participants’ prehospitalisation list of medications; 2. identify any
medication errors and communicate these with the appropriate healthcare provider; 3. conduct a face-to-
face consultation with intervention participants, counselling them on the discharge medications; and 4. call
participants 3-5 days post discharge to review discussion and identify problems. The discharge medication
list is communicated to participants’ healthcare providers and community pharmacies
Outcomes • Rate of perfect discharge
• Participant and provider satisfaction
• Readmission rates
Starting date March 2013
Contact information M Williams, University of Cincinnati, USA and Teresa Cavanaugh
Notes “Completing data analysis” in 2015; no further response since
ADE: adverse drug event; AMO: admission medication order; BPMH: best possible medication history; CI: confidence interval; CP:
community pharmacist; ED: emergency department; eMM: electronic medication management; ePHF: electronic portable health
file; GP: general practitioner; HIE: health information exchange; IQR: interquartile range; MR: medication reconciliation; PADE:
preventable adverse drug event; PCP: primary care provider; PHF: portable health file; RCT: randomised controlled trial; SD:
standard deviation; VA: Veteran’s Affairs.
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D A T A A N D A N A L Y S E S
Comparison 1. Medication reconciliation versus standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 At least 1 medication discrepancy
per participant (dichotomous)
20 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 Reconciliation at any time
point
20 4629 Risk Ratio (IV, Random, 95% CI) 0.53 [0.42, 0.67]
1.2 Reconciliation at
admission
4 1167 Risk Ratio (IV, Random, 95% CI) 0.43 [0.27, 0.68]
1.3 Reconciliation at discharge 5 649 Risk Ratio (IV, Random, 95% CI) 0.71 [0.50, 1.02]
1.4 Reconciliation throughout
hospital stay
2 933 Risk Ratio (IV, Random, 95% CI) 0.92 [0.80, 1.07]
1.5 Reconciliation at
preadmission clinic
3 1082 Risk Ratio (IV, Random, 95% CI) 0.38 [0.13, 1.11]
2 Number of medication
discrepancies per participant
(continuous)
4 1963 Mean Difference (IV, Random, 95% CI) -1.18 [-2.58, 0.23]
3 Discrepancies per participant
medication (dichotomous)
2 3595 Risk Ratio (IV, Random, 95% CI) 0.13 [0.01, 1.29]
4 Discrepancies per participant
medication (continuous, per
medication)
1 82 Mean Difference (IV, Fixed, 95% CI) -2.10 [-9.64, 5.44]
5 Preventable adverse drug events 3 1253 Risk Ratio (IV, Random, 95% CI) 0.37 [0.09, 1.57]
6 Adverse drug events 4 1363 Risk Ratio (IV, Random, 95% CI) 1.09 [0.91, 1.30]
7 Mortality 1 190 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.27, 2.08]
8 Medication adherence
(non-adherent with at least 1
medication)
2 379 Risk Ratio (IV, Random, 95% CI) 0.76 [0.41, 1.42]
9 Emergency department (ED)
visits
1 61 Risk Ratio (IV, Random, 95% CI) 0.07 [0.00, 1.07]
10 Unplanned rehospitalisation 5 1206 Risk Ratio (IV, Random, 95% CI) 0.72 [0.44, 1.18]
11 Hospital usage (composite
measure of ED,
rehospitalisation)
4 597 Risk Ratio (IV, Random, 95% CI) 0.78 [0.50, 1.22]
12 Length of stay 2 475 Mean Difference (IV, Random, 95% CI) 0.48 [-1.04, 1.99]
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Analysis 1.1. Comparison 1 Medication reconciliation versus standard care, Outcome 1 At least 1
medication discrepancy per participant (dichotomous).
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 1 At least 1 medication discrepancy per participant (dichotomous)
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Reconciliation at any time point
Becerra-Camargo 2013 71/117 117/125 6.4 % 0.65 [ 0.56, 0.76 ]
Beckett 2012 12/41 21/40 4.9 % 0.56 [ 0.32, 0.98 ]
Char 2017 15/95 54/94 5.1 % 0.27 [ 0.17, 0.45 ]
Crotty 2004 35/56 26/54 5.8 % 1.30 [ 0.92, 1.83 ]
Eggink 2010 16/41 30/44 5.4 % 0.57 [ 0.37, 0.88 ]
George 2011 15/162 17/172 4.4 % 0.94 [ 0.48, 1.81 ]
Hale 2013 13/194 136/190 5.0 % 0.09 [ 0.05, 0.16 ]
Hawes 2014 6/12 19/21 4.8 % 0.55 [ 0.31, 0.99 ]
Heng 2013 3/20 12/20 2.8 % 0.25 [ 0.08, 0.75 ]
Ibrahim 2012 81/125 84/125 6.4 % 0.96 [ 0.81, 1.15 ]
Kripalani 2012 165/423 183/428 6.4 % 0.91 [ 0.78, 1.07 ]
Kwan 2007 41/202 86/214 5.9 % 0.51 [ 0.37, 0.69 ]
Lalonde 2008 27/41 28/41 6.0 % 0.96 [ 0.71, 1.31 ]
Marotti 2011 22/239 41/118 5.3 % 0.26 [ 0.17, 0.42 ]
Nickerson 2005 1/28 67/119 1.3 % 0.06 [ 0.01, 0.44 ]
Schnipper 2006 44/72 43/66 6.1 % 0.94 [ 0.73, 1.21 ]
Schnipper 2011 88/114 88/113 6.4 % 0.99 [ 0.86, 1.14 ]
Tompson 2012 56/203 234/284 6.2 % 0.33 [ 0.27, 0.42 ]
Vega 2016 3/76 21/71 2.6 % 0.13 [ 0.04, 0.43 ]
Yau 2008 3/13 10/16 2.9 % 0.37 [ 0.13, 1.07 ]
Subtotal (95% CI) 2274 2355 100.0 % 0.53 [ 0.42, 0.67 ]
Total events: 717 (Reconciliation), 1317 (Control)
Heterogeneity: Tau2 = 0.23; Chi2 = 217.63, df = 19 (P<0.00001); I2 =91%
Test for overall effect: Z = 5.16 (P < 0.00001)
2 Reconciliation at admission
Becerra-Camargo 2013 71/117 117/125 28.8 % 0.65 [ 0.56, 0.76 ]
0.005 0.1 1 10 200
Favours reconciliation Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Beckett 2012 12/41 21/40 20.7 % 0.56 [ 0.32, 0.98 ]
Marotti 2011 22/239 41/118 22.8 % 0.26 [ 0.17, 0.42 ]
Tompson 2012 56/203 234/284 27.7 % 0.33 [ 0.27, 0.42 ]
Subtotal (95% CI) 600 567 100.0 % 0.43 [ 0.27, 0.68 ]
Total events: 161 (Reconciliation), 413 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 30.00, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.61 (P = 0.00030)
3 Reconciliation at discharge
Eggink 2010 16/41 30/44 23.9 % 0.57 [ 0.37, 0.88 ]
Ibrahim 2012 81/125 84/125 33.4 % 0.96 [ 0.81, 1.15 ]
Nickerson 2005 1/28 67/119 3.2 % 0.06 [ 0.01, 0.44 ]
Schnipper 2006 44/72 43/66 30.8 % 0.94 [ 0.73, 1.21 ]
Yau 2008 3/13 10/16 8.8 % 0.37 [ 0.13, 1.07 ]
Subtotal (95% CI) 279 370 100.0 % 0.71 [ 0.50, 1.02 ]
Total events: 145 (Reconciliation), 234 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 14.74, df = 4 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.85 (P = 0.065)
4 Reconciliation throughout hospital stay
Kripalani 2012 165/423 183/428 77.8 % 0.91 [ 0.78, 1.07 ]
Lalonde 2008 27/41 28/41 22.2 % 0.96 [ 0.71, 1.31 ]
Subtotal (95% CI) 464 469 100.0 % 0.92 [ 0.80, 1.07 ]
Total events: 192 (Reconciliation), 211 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
5 Reconciliation at preadmission clinic
George 2011 15/162 17/172 31.8 % 0.94 [ 0.48, 1.81 ]
Hale 2013 13/149 136/183 33.2 % 0.12 [ 0.07, 0.20 ]
Kwan 2007 41/202 86/214 35.0 % 0.51 [ 0.37, 0.69 ]
Subtotal (95% CI) 513 569 100.0 % 0.38 [ 0.13, 1.11 ]
Total events: 69 (Reconciliation), 239 (Control)
Heterogeneity: Tau2 = 0.84; Chi2 = 29.28, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Chi2 = 23.42, df = 4 (P = 0.00), I2 =83%
0.005 0.1 1 10 200
Favours reconciliation Favours control
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Analysis 1.2. Comparison 1 Medication reconciliation versus standard care, Outcome 2 Number of
medication discrepancies per participant (continuous).
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 2 Number of medication discrepancies per participant (continuous)
Study or subgroup Reconciliation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Becerra-Camargo 2013 117 2.43 (3.14) 125 4.23 (3.26) 24.8 % -1.80 [ -2.61, -0.99 ]
Farley 2014 394 11.32 (6.7546) 198 11.37 (7.24) 22.5 % -0.05 [ -1.26, 1.16 ]
Kripalani 2012 423 0.76 (1.245) 428 0.94 (1.652) 26.9 % -0.18 [ -0.38, 0.02 ]
Pevnick 2018 183 0.6 (1.1) 95 3.2 (2.9) 25.8 % -2.60 [ -3.20, -2.00 ]
Total (95% CI) 1117 846 100.0 % -1.18 [ -2.58, 0.23 ]
Heterogeneity: Tau2 = 1.90; Chi2 = 66.98, df = 3 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Medication reconciliation versus standard care, Outcome 3 Discrepancies per
participant medication (dichotomous).
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 3 Discrepancies per participant medication (dichotomous)
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Eggink 2010 25/407 62/425 50.2 % 0.42 [ 0.27, 0.66 ]
Hale 2013 14/1194 449/1569 49.8 % 0.04 [ 0.02, 0.07 ]
Total (95% CI) 1601 1994 100.0 % 0.13 [ 0.01, 1.29 ]
Total events: 39 (Reconciliation), 511 (Control)
Heterogeneity: Tau2 = 2.65; Chi2 = 43.95, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Medication reconciliation versus standard care, Outcome 4 Discrepancies per
participant medication (continuous, per medication).
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 4 Discrepancies per participant medication (continuous, per medication)
Study or subgroup Reconciliation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lalonde 2008 41 13.2 (16.6) 41 15.3 (18.2) 100.0 % -2.10 [ -9.64, 5.44 ]
Total (95% CI) 41 41 100.0 % -2.10 [ -9.64, 5.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Medication reconciliation versus standard care, Outcome 5 Preventable
adverse drug events.
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 5 Preventable adverse drug events
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ibrahim 2012 4/125 18/125 34.8 % 0.22 [ 0.08, 0.64 ]
Kripalani 2012 133/423 125/428 42.4 % 1.08 [ 0.88, 1.32 ]
Schnipper 2006 1/79 8/73 22.8 % 0.12 [ 0.01, 0.90 ]
Total (95% CI) 627 626 100.0 % 0.37 [ 0.09, 1.57 ]
Total events: 138 (Reconciliation), 151 (Control)
Heterogeneity: Tau2 = 1.26; Chi2 = 12.56, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Medication reconciliation versus standard care, Outcome 6 Adverse drug
events.
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 6 Adverse drug events
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Crotty 2004 9/56 6/54 3.5 % 1.45 [ 0.55, 3.79 ]
Ibrahim 2012 25/125 23/125 12.4 % 1.09 [ 0.65, 1.81 ]
Kripalani 2012 133/423 125/428 77.6 % 1.08 [ 0.88, 1.32 ]
Schnipper 2006 14/79 12/73 6.5 % 1.08 [ 0.53, 2.18 ]
Total (95% CI) 683 680 100.0 % 1.09 [ 0.91, 1.30 ]
Total events: 181 (Reconciliation), 166 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Medication reconciliation versus standard care, Outcome 7 Mortality.
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 7 Mortality
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cadman 2017 6/95 8/95 100.0 % 0.75 [ 0.27, 2.08 ]
Total (95% CI) 95 95 100.0 % 0.75 [ 0.27, 2.08 ]
Total events: 6 (Reconciliation), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Medication reconciliation versus standard care, Outcome 8 Medication
adherence (non-adherent with at least 1 medication).
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 8 Medication adherence (non-adherent with at least 1 medication)
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ibrahim 2012 16/125 30/125 43.5 % 0.53 [ 0.31, 0.93 ]
Schnipper 2006 36/67 33/62 56.5 % 1.01 [ 0.73, 1.39 ]
Total (95% CI) 192 187 100.0 % 0.76 [ 0.41, 1.42 ]
Total events: 52 (Reconciliation), 63 (Control)
Heterogeneity: Tau2 = 0.15; Chi2 = 3.81, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Medication reconciliation versus standard care, Outcome 9 Emergency
department (ED) visits.
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 9 Emergency department (ED) visits
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Hawes 2014 0/24 11/37 100.0 % 0.07 [ 0.00, 1.07 ]
Total (95% CI) 24 37 100.0 % 0.07 [ 0.00, 1.07 ]
Total events: 0 (Reconciliation), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Medication reconciliation versus standard care, Outcome 10 Unplanned
rehospitalisation.
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 10 Unplanned rehospitalisation
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Cadman 2017 30/95 37/101 40.8 % 0.86 [ 0.58, 1.28 ]
Char 2017 6/91 4/93 12.5 % 1.53 [ 0.45, 5.25 ]
Hawes 2014 0/24 12/37 3.0 % 0.06 [ 0.00, 0.98 ]
Pevnick 2018 36/183 27/95 38.6 % 0.69 [ 0.45, 1.07 ]
Tompson 2012 1/203 9/284 5.2 % 0.16 [ 0.02, 1.22 ]
Total (95% CI) 596 610 100.0 % 0.72 [ 0.44, 1.18 ]
Total events: 73 (Reconciliation), 89 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 7.27, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Medication reconciliation versus standard care, Outcome 11 Hospital usage
(composite measure of ED, rehospitalisation).
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 11 Hospital usage (composite measure of ED, rehospitalisation)
Study or subgroup Reconciliation Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Hawes 2014 0/24 15/37 2.5 % 0.05 [ 0.00, 0.78 ]
Crotty 2004 9/56 15/54 22.7 % 0.58 [ 0.28, 1.21 ]
Ibrahim 2012 30/125 35/125 38.3 % 0.86 [ 0.56, 1.30 ]
Schnipper 2006 28/92 25/84 36.5 % 1.02 [ 0.65, 1.61 ]
Total (95% CI) 297 300 100.0 % 0.78 [ 0.50, 1.22 ]
Total events: 67 (Reconciliation), 90 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 5.76, df = 3 (P = 0.12); I2 =48%
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Medication reconciliation versus standard care, Outcome 12 Length of stay.
Review: Impact of medication reconciliation for improving transitions of care
Comparison: 1 Medication reconciliation versus standard care
Outcome: 12 Length of stay
Study or subgroup Reconciliation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cadman 2017 95 4.15 (6.1423) 102 4.55 (5.9397) 43.5 % -0.40 [ -2.09, 1.29 ]
Pevnick 2018 183 6.3541 (6.2723) 95 5.2 (4.4756) 56.5 % 1.15 [ -0.12, 2.43 ]
Total (95% CI) 278 197 100.0 % 0.48 [ -1.04, 1.99 ]
Heterogeneity: Tau2 = 0.63; Chi2 = 2.08, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (Ovid)
Date of search: 18 January 2018
No. Search terms Results
1 medication reconciliation/ 577
2 ((medication? or medicine? or drug or drugs or pharmacist? or
pharmacy or pharmacies or formulary or formularies or pre-
scription? or prescrib*) adj3 (reconcil* or review or reviewing)
).ti,ab
11733
3 ((medication? or medicine? or drug or drugs or pharmacist?
or pharmacy or pharmacies or formulary or formularies or
prescription? or prescrib*) adj3 (assess* or audit?)).ti,ab
17391
4 (stopp or beer’s criteria).ti,ab. 556
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(Continued)
5 (medication? adj2 discrepanc*).ti,ab. 248
6 ((medication? or prescribing) adj2 error?).ti,ab. 4927
7 stewardship.ti,ab. 3087
8 or/1-7 36728
9 medication systems, hospital/ 3303
10 pharmacy service, hospital/ 10470
11 ((pharmaceutical care or pharmacy or pharmacies or pharma-
cist? or prescribing) and (inpatient? or hospital* or ward? or
unit or units)).ti
3712
12 ((pharmaceutical care or pharmacy or pharmacies or pharma-
cist? or prescribing) adj2 (inpatient? or hospital* or ward? or
unit or units)).ab
3441
13 ((medication? or prescribing or prescription? or dispensing)
adj2 system?).ti,ab. and (hospital* or ward or wards or (care
adj2 unit?) or inpatient?).ti,hw
660
14 or/9-13 16361
15 pharmacists/ or pharmacists’ aides/ 13100
16 pharmaceutical services/ or drug information services/ or clin-
ical pharmacy information systems/
11972
17 drugmonitoring/ ormedication therapymanagement/ or drug
therapy/ or drug therapy, computer-assisted/
48333
18 prescriptions/ or drug prescriptions/ or pharmaceutical prepa-
rations/ or drug therapy/ or drug dosage calculations/ or elec-
tronic prescribing/ or medication systems/
102601
19 medication errors/ or polypharmacy/ or inappropriate pre-
scribing/
15666
20 drug utilization review/ 3349
21 (pharmacy or pharmacies or pharmacist? or prescription? or
prescribing).ti
51608
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(Continued)
22 (pharmacist-led or pharma* initiated or ((driven or lead or led)
adj2 pharmacist?)).ab
510
23 (prescribing adj2 pattern?).ab. 1949
24 (“physician-pharmacist?” or “doctor-pharmacist?”).ti,ab. 203
25 ((improv* or optimi?ing or optimi?e? or optimal*) and (dos-
ing or dosage or pharmac* or prescrib* or prescript*)).ti. or (
(improv* or optimi?ing or optimi?e? or optimal*) adj2 (phar-
maceutical care or pharmacy or prescrib* or prescript*)).ab
6723
26 ((pharmaceutical adj (care or consult*)) or (pharmacist? adj2
(care or consult* or intervention? or managed))).ab
3304
27 ((drug therapy or drug regime? or medication? or medicines
or pharmacy or pharmacist? or pharmaceutical or prescrib* or
prescription?) adj2 (audit* or monitor* or reconcil* or review?
)).ti,ab
7205
28 ((medication? or prescrib* or pharmac*) adj2 (manage? or
management or service? or system?)).ti,ab
18412
29 ((“drug therapy” or dosage? or dose? or medication? or pre-
scription? or prescrib* or pharmacist? or pharmaceutical care)
adj2 (managing or management or monitor*)).ti,ab
9567
30 (“drug utili?ation” adj2 (review? or reconcil* or audit?)).ab. or
(“drug utili?ation” and (review? or reconcil* or audit?)).ti
323
31 (inappropriate* adj2 (medicine? or medication? or prescrib* or
drug?)).ti,ab
2461
32 drug utilization/ 18323
33 or/15-32 211178
34 ((care or patient?) adj3 transition*).ti,ab. 7308
35 (hospital adj3 releas*).ti,ab. 543
36 “hospital to home”.ti,ab. 2169
37 patient admission/ or patient discharge/ or patient readmis-
sion/ or patient transfer/
56153
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(Continued)
38 (patient? or hospital* or medical centre or medical centres or
medical center?).ti,hw. and (discharg* or admission? or admit-
ting or readmission? or readmit* or transfer? or transferred or
transferring).ti
32990
39 ((patient? or care facility ormedical facility or hospital? ormed-
ical centre or medical centres or medical center? or emergency
or ward or wards or unit or units or (intensive adj2 care) or
icu or acute care or (hospital? adj2 department?)) adj2 (dis-
charg* or admission? or admitting or readmission? or transfer?
or transferring or transferred)).ab
113634
40 (exp academic medical centers/ or exp hospital units/ or exp
hospitals/ or exp ambulatory care facilities/) and (transfer or
transferred or discharge or admission? or readmission? or re-
admission?).ti
7886
41 ((earlie* or early) adj2 discharg*).ab. 3828
42 ((icu or (intensive adj2 care) or acute care or unit or units or
ward or wards or department) adj3 transition*).ti,ab
540
43 (transfer* adj3 emergency).ti,ab. 732
44 (hospital adj8 (transfer? or transferred)).ti,ab. 5637
45 discharge.ti. 18232
46 (discharge adj3 (medication? or prescription? or communica-
tion? or (information adj2 exchang*))).ab
1675
47 or/34-46 183427
48 8 and 47 1747
49 (and/14,47) not 48 627
50 (and/33,47) not (or/48-49) 3074
51 (randomized controlled trial or controlled clinical trial).pt. or
randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti
1067990
52 exp animals/ not humans.sh. 4316367
53 51 not 52 984770
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(Continued)
54 intervention?.ti. or (intervention? adj6 (clinician? or collabo-
rat* or community or complex or design* or doctor? or edu-
cational or family doctor? or family physician? or family prac-
titioner? or financial or gp or general practice? or hospital? or
impact? or improv* or individuali?e? or individuali?ing or in-
terdisciplin* or multicomponent or multi-component or mul-
tidisciplin* or multi-disciplin* or multifacet* or multi-facet*
or multimodal* or multi-modal* or personali?e? or personali?
ing or pharmacies or pharmacist? or pharmacy or physician?
or practitioner? or prescrib* or prescription? or primary care or
professional* or provider? or regulatory or regulatory or tailor*
or target* or team* or usual care)).ab
220003
55 (pre-intervention? or preintervention? or “pre intervention?”
or post-intervention? or postintervention? or “post interven-
tion?”).ti,ab
15424
56 (hospital* or patient?).hw. and (study or studies or care or
health* or practitioner? or provider? or physician? or nurse? or
nursing or doctor?).ti,hw
813565
57 demonstration project?.ti,ab. 2224
58 (pre-post or “pre test*” or pretest* or posttest* or “post test*”
or (pre adj5 post)).ti,ab
87300
59 (pre-workshop or post-workshop or (before adj3 workshop)
or (after adj3 workshop)).ti,ab
824
60 trial.ti. or ((study adj3 aim?) or “our study”).ab. 847155
61 (before adj10 (after or during)).ti,ab. 417535
62 (“quasi-experiment*” or quasiexperiment* or “quasi random*”
or quasirandom* or “quasi control*” or quasicontrol* or (
(quasi* or experimental) adj3 (method* or study or trial or
design*))).ti,ab,hw
124582
63 (“time series” adj2 interrupt*).ti,ab,hw. 1745
64 (time points adj3 (over ormultiple or three or four or five or six
or seven or eight or nine or ten or eleven or twelve or month*
or hour? or day? or “more than”)).ab
12815
65 pilot.ti. 51962
66 pilot projects/ 97108
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(Continued)
67 (clinical trial or controlled clinical trial or multicenter study).
pt
684276
68 (multicentre or multicenter or multi-centre or multi-center).
ti
37800
69 random*.ti,ab. or controlled.ti. 939029
70 (control adj3 (area or cohort? or compare? or condition or
design or group? or intervention? or participant? or study)).ab.
not (controlled clinical trial or randomized controlled trial).pt
509609
71 “comment on”.cm. or review.ti,pt. or randomized controlled
trial.pt
3417201
72 (rat or rats or cow or cows or chicken? or horse or horses or
mice or mouse or bovine or animal?).ti
1479919
73 exp animals/ not humans.sh. 4316367
74 (or/54-70) not (or/71-73) 2607618
75 ((or/48-50) and 53) not placebo*.ti,ab,hw. 570
Embase (Ovid)
Date of search: 18 January 2018
No. Search terms Results
1 medication therapy management/ 5857
2 ((medication? or medicine? or drug or drugs or pharmacist? or
pharmacy or pharmacies or formulary or formularies or pre-
scription? or prescrib*) adj3 (reconcil* or review or reviewing)
).ti,ab
17895
3 ((medication? or medicine? or drug or drugs or pharmacist?
or pharmacy or pharmacies or formulary or formularies or
prescription? or prescrib*) adj3 (assess* or audit?)).ti,ab
26682
4 (stopp or beer’s criteria).ti,ab. 1068
5 (medication? adj2 discrepanc*).ti,ab. 520
6 ((medication? or prescribing) adj2 error?).ti,ab. 7616
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(Continued)
7 stewardship.ti,ab. 4001
8 or/1-7 58665
9 ((pharmaceutical care or pharmacy or pharmacies or pharma-
cist? or prescribing) and (inpatient? or hospital* or ward? or
unit or units)).ti
6980
10 ((pharmaceutical care or pharmacy or pharmacies or pharma-
cist? or prescribing) adj2 (inpatient? or hospital* or ward? or
unit or units)).ab
7158
11 ((medication? or prescribing or prescription? or dispensing)
adj2 system?).ti,ab. and (hospital* or ward or wards or (care
adj2 unit?) or inpatient?).ti,hw
1334
12 or/9-11 13581
13 (pharmacist-led or pharma* initiated or ((driven or lead or led)
adj2 pharmacist?)).ab
1122
14 (prescribing adj2 pattern?).ab. 3190
15 (“physician-pharmacist?” or “doctor-pharmacist?”).ti,ab. 374
16 ((improv* or optimi?ing or optimi?e? or optimal*) and (dos-
ing or dosage or pharmac* or prescrib* or prescript*)).ti. or (
(improv* or optimi?ing or optimi?e? or optimal*) adj2 (phar-
maceutical care or pharmacy or prescrib* or prescript*)).ab
10259
17 ((pharmaceutical adj (care or consult*)) or (pharmacist? adj2
(care or consult* or intervention? or managed))).ab
7272
18 ((drug therapy or drug regime? or medication? or medicines
or pharmacy or pharmacist? or pharmaceutical or prescrib* or
prescription?) adj2 (audit* or monitor* or reconcil* or review?
)).ti,ab
12580
19 inappropriate prescribing/ 2397
20 (“drug utili?ation” adj2 (review? or reconcil* or audit?)).ab. or
(“drug utili?ation” and (review? or reconcil* or audit?)).ti
492
21 (inappropriate* adj2 (medicine? or medication? or prescrib* or
drug?)).ti,ab
3888
22 or/13-21 36120
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(Continued)
23 *pharmacist/ 20055
24 *drug monitoring/ or medication therapy management/ or
*drug therapy/ or computer-assisted drug therapy/
261987
25 *prescription/ or *drug therapy/ or *dose calculation/ or elec-
tronic prescribing/
270752
26 *medication error/ or polypharmacy/ 16802
27 (pharmacy or pharmacies or pharmacist? or prescription? or
prescribing).ti
85551
28 ((medication? or prescrib* or pharmac*) adj2 (manage? or
management or service? or system?)).ti,ab
30503
29 ((“drug therapy” or dosage? or dose? or medication? or pre-
scription? or prescrib* or pharmacist? or pharmaceutical care)
adj2 (managing or management or monitor*)).ti,ab
14674
30 “drug use”/ 91682
31 (or/23-30) and (reconcil* or audit or audits or auditing).ti,ab 5371
32 or/22,31 38459
33 ((care or patient?) adj3 transition*).ti,ab. 11039
34 (hospital adj3 releas*).ti,ab. 746
35 “hospital to home”.ti,ab. 2909
36 (patient? or hospital* or medical centre or medical centres or
medical center?).ti,hw. and (discharg* or admission? or admit-
ting or readmission? or readmit* or transfer? or transferred or
transferring).ti
50556
37 ((patient? or care facility ormedical facility or hospital? ormed-
ical centre or medical centres or medical center? or emergency
or ward or wards or unit or units or (intensive adj2 care) or
icu or acute care or (hospital? adj2 department?)) adj2 (dis-
charg* or admission? or admitting or readmission? or transfer?
or transferring or transferred)).ab
179998
38 (hospital/ or (academic medical centers or hospital units or
ambulatory care facilities).ti,ab.) and (transfer or transferred
or discharge or admission? or readmission? or re-admission?).
7897
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(Continued)
ti
39 ((earlie* or early) adj2 discharg*).ab. 5740
40 ((icu or (intensive adj2 care) or acute care or unit or units or
ward or wards or department) adj3 transition*).ti,ab
673
41 (transfer* adj3 emergency).ti,ab. 1097
42 (hospital adj8 (transfer? or transferred)).ti,ab. 9489
43 discharge.ti. 22467
44 (discharge adj3 (medication? or prescription? or communica-
tion? or (information adj2 exchang*))).ab
3388
45 or/33-44 238270
46 8 and 45 3696
47 (and/12,45) not 46 796
48 (and/32,45) not (or/46-47) 959
49 controlled clinical trial/ or controlled study/ or randomized
controlled trial/
5126441
50 randomi?ed.ti. or ((random* or control) adj3 (group? or co-
hort? or patient? or hospital* or department?)).ab. or (con-
trolled adj2 (study or trial)).ti
884146
51 (random sampl* or randomdigit* or randomeffect* or random
survey or random regression).ti,ab. not randomized controlled
trial/
75111
52 (exp animals/ or exp invertebrate/ or animal experiment/ or
animal model/ or animal tissue/ or animal cell/ or nonhuman/
) and (human/ or normal human/ or human cell/)
17622202
53 (exp animals/ or exp invertebrate/ or animal experiment/ or
animal model/ or animal tissue/ or animal cell/ or nonhuman/
) not 52
6002861
54 (or/49-50) not (or/51,53) 3543579
55 intervention?.ti. or (intervention? adj6 (clinician? or collabo-
rat* or community or complex or design* or doctor? or edu-
cational or family doctor? or family physician? or family prac-
titioner? or financial or gp or general practice? or hospital? or
281936
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(Continued)
impact? or improv* or individuali?e? or individuali?ing or in-
terdisciplin* or multicomponent or multi-component or mul-
tidisciplin* or multi-disciplin* or multifacet* or multi-facet*
or multimodal* or multi-modal* or personali?e? or personali?
ing or pharmacies or pharmacist? or pharmacy or physician?
or practitioner? or prescrib* or prescription? or primary care or
professional* or provider? or regulatory or regulatory or tailor*
or target* or team* or usual care)).ab
56 (pre-intervention? or preintervention? or “pre intervention?”
or post-intervention? or postintervention? or “post interven-
tion?”).ti,ab
20724
57 (hospital* or patient?).hw. and (study or studies or care or
health* or practitioner? or provider? or physician? or nurse? or
nursing or doctor?).ti,hw
2144042
58 demonstration project?.ti,ab. 2615
59 (pre-post or “pre test*” or pretest* or posttest* or “post test*”
or (pre adj5 post)).ti,ab
135195
60 (pre-workshop or post-workshop or (before adj3 workshop)
or (after adj3 workshop)).ti,ab
1221
61 trial.ti. or ((study adj3 aim?) or “our study”).ab. 1207481
62 (before adj10 (after or during)).ti,ab. 542862
63 (time points adj3 (over ormultiple or three or four or five or six
or seven or eight or nine or ten or eleven or twelve or month*
or hour? or day? or “more than”)).ab
17836
64 pilot.ti. or (pilot adj (project? or study or trial)).ab. 117052
65 (multicentre or multicenter or multi-centre or multi-center).
ti
55018
66 random*.ti,ab. or controlled.ti. 1185707
67 (control adj3 (area or cohort? or compare? or condition or
design or group? or intervention? or participant? or study)).ab
777592
68 *experimental design/ or *pilot study/ or quasi experimental
study/
13212
69 (“quasi-experiment*” or quasiexperiment* or “quasi random*”
or quasirandom* or “quasi control*” or quasicontrol* or (
141696
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(Continued)
(quasi* or experimental) adj3 (method* or study or trial or
design*))).ti,ab
70 (“time series” adj2 interrupt*).ti,ab. 1830
71 or/55-70 5150452
72 (rat or rats or cow or cows or chicken? or horse or horses or
mice or mouse or bovine or animal?).ti
1680464
73 (exp animals/ or exp invertebrate/ or animal experiment/ or
animal model/ or animal tissue/ or animal cell/ or nonhuman/
) and (human/ or normal human/ or human cell/)
17622202
74 (exp animals/ or exp invertebrate/ or animal experiment/ or
animal model/ or animal tissue/ or animal cell/ or nonhuman/
) not 73
6002861
75 71 not (or/72,74) 4515431
76 ((or/46-48) and 54) not placebo*.ti,ab,hw. 1089
Cochrane Library: CENTRAL, CDSR, DARE, NHS EED, HTA (WILEY)
Search date: 18 January 2018
No. Search terms
#1 [mh “medication reconciliation”]
#2 ((medication ormedicine or drug or drugs or pharmacist or pharmacy or pharmacies or formulary or formularies or prescription
or prescrib*) near/3 (reconcil* or review or reviewing)):ti,ab
#3 ((medication ormedicine or drug or drugs or pharmacist or pharmacy or pharmacies or formulary or formularies or prescription
or prescrib*) near/3 (assess* or audit)):ti,ab
#4 (stopp or beer’s criteria):ti,ab
#5 (medication near/2 discrepanc*):ti,ab
#6 ((medication or prescribing) near/2 error):ti,ab
#7 stewardship:ti,ab
#8 {or #1-#7}
#9 [mh “medication systems, hospital”]
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#10 [mh “pharmacy service, hospital”]
#11 ((pharmaceutical care or pharmacy or pharmacies or pharmacist or prescribing) and (inpatient or hospital* or ward? or unit or
units)):ti
#12 ((pharmaceutical care or pharmacy or pharmacies or pharmacist or prescribing) near/2 (inpatient or hospital* or ward or unit
or units)):ab
#13 ((medication or prescribing or prescription or dispensing) near/2 system):ti,ab and (hospital* or ward or wards or (care near/
2 unit) or inpatient):ti,kw
#14 {or #9-#13}
#15 [mh pharmacists] or [mh “pharmacists’ aides”] or [mh “pharmaceutical services”] or [mh “drug information services”] or [mh
“clinical pharmacy information systems”] or [mh “drugmonitoring”] or [mh “medication therapymanagement”] or [mh “drug
therapy”] or [mh “drug therapy, computer-assisted”] or [mh prescriptions] or [mh “drug prescriptions”] or [mh “pharmaceutical
preparations”] or [mh “drug dosage calculations”] or [mh “electronic prescribing”] or [mh “medication systems”] or [mh
“medication errors”] or [mh polypharmacy] or [mh “inappropriate prescribing”] or [mh “drug utilization review”]
#16 (pharmacy or pharmacies or pharmacist or prescription or prescribing):ti
#17 (pharmacist-led or (pharma* initiated) or ((driven or lead or led) near/2 pharmacist)):ab
#18 (prescribing near/2 pattern):ab
#19 (“physician-pharmacist” or “doctor-pharmacist”):ti,ab
#20 ((improv* or optimi?ing or optimi?e or optimal*) and (dosing or dosage or pharmac* or prescrib* or prescript*)):ti or ((improv*
or optimi?ing or optimi?e or optimal*) near/2 (pharmaceutical care or pharmacy or prescrib* or prescript*)):ab
#21 ((pharmaceutical near/1 (care or consult*)) or (pharmacist near/2 (care or consult* or intervention or managed))):ab
#22 (((drug therapy) or (drug regime) or medication or medicine or pharmacy or pharmacist or pharmaceutical or prescrib* or
prescription) near/2 (audit* or monitor* or reconcil* or review)):ti,ab
#23 ((medication or prescrib* or pharmac*) near/2 (manage or management or service or system)):ti,ab
#24 ((“drug therapy” or dosage or dose or medication or prescription or prescrib* or pharmacist or pharmaceutical care) near/2
(managing or management or monitor*)):ti,ab
#25 (“drug utili?ation” near/2 (review or reconcil* or audit)):ab or (“drug utili?ation” and (review or reconcil* or audit)):ti
#26 (inappropriate* near/2 (medicine or medication or prescrib* or drug?)):ti,ab
#27 [mh “drug utilization”]
#28 {or #15-#27}
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#29 ((care or patient) near/3 transition*):ti,ab
#30 (hospital near/3 releas*):ti,ab
#31 hospital to home:ti,ab
#32 [mh “patient admission”]
#33 [mh “patient discharge”]
#34 [mh “patient readmission”]
#35 [mh “patient transfer”]
#36 (patient or hospital* or medical centre or medical centres or medical center):ti,kw and (discharg* or admission or admitting
or readmission or readmit* or transfer or transferred or transferring):ti
#37 ((patient or (care facility) or (medical facility) or hospital or (medical centre) or (medical centres) or (medical center) or
emergency or ward or wards or unit or units or (intensive near/2 care) or icu or (acute care) or (hospital near/2 department))
near/2 (discharg* or admission or admitting or readmission or transfer or transferring or transferred)):ab
#38 [mh “academic medical centers”]
#39 [mh “hospital units”]
#40 [mh hospitals]
#41 [mh “ambulatory care facilities”]
#42 {or #38-#41} and (transfer or transferred or discharge or admission or readmission or re-admission):ti
#43 (earl* near/2 discharg*):ab
#44 ((icu or (intensive near/2 care) or acute care or unit or units or ward or wards or department) near/3 transition*):ti,ab
#45 (transfer* near/3 emergency):ti,ab
#46 (“hospital” near/8 (transfer or transferred)):ti,ab
#47 discharge:ti
#48 (“discharge” near/3 (medication or prescription or communication or (information near/2 exchang*))):ab
#49 {or #29-#37, #42-#48}
#50 #8 or #14 or #28
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#51 #49 and #50
CINAHL (EBSCO)
Date of search: 18 January 2018
No. Search terms Results
S1 MH medication reconciliation 623
S2 TI (((medication# or medicine# or drug or drugs or pharma-
cist# or pharmacy or pharmacies or formulary or formularies
or prescription# or prescrib*) N3 (reconcil* or review or re-
viewing))) OR AB (((medication# or medicine# or drug or
drugs or pharmacist# or pharmacy or pharmacies or formulary
or formularies or prescription# or prescrib*) N3 (reconcil* or
review or reviewing)))
3,776
S3 TI (((medication# or medicine# or drug or drugs or pharma-
cist# or pharmacy or pharmacies or formulary or formularies
or prescription# or prescrib*) N3 (assess* or audit#))) OR AB
(((medication# or medicine# or drug or drugs or pharmacist#
or pharmacy or pharmacies or formulary or formularies or pre-
scription# or prescrib*) N3 (assess* or audit#)))
3,733
S4 TI ((stopp or beer’s criteria)) OR AB ((stopp or beer’s criteria)
)
142
S5 TI (medication# N2 discrepanc*) OR AB (medication# N2
discrepanc*)
94
S6 TI (((medication# or prescribing) N2 error#)) ORAB (((med-
ication# or prescribing) N2 error#))
3,228
S7 TI stewardship OR AB stewardship 851
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 11,595
S9 MH Medication Systems AND hospital 395
S10 MH pharmacy service AND hospital 866
S11 TI ((PHARMACEUTICAL CARE or PHARMACY or
PHARMACIES or PHARMACIST#or PRESCRIBING) and
(inpatient# or hospital* or WARD# or UNIT or UNITS))
704
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S12 AB ((PHARMACEUTICAL CARE or PHARMACY or
PHARMACIES or PHARMACIST# or PRESCRIBING)N2
(inpatient# or hospital* or WARD# or UNIT or UNITS))
694
S13 (TI (((medication# or prescribing or prescription# or dispens-
ing) N2 system#)) OR AB (((medication# or prescribing or
prescription# or dispensing) N2 system#))) AND (TI ((hos-
pital* or WARD or WARDS or (CARE N2 UNIT#) or IN-
PATIENT#)) OR MW ((hospital* or WARD or WARDS or
(CARE N2 UNIT#) or INPATIENT#)))
233
S14 S9 OR S10 OR S11 OR S12 OR S13 2,177
S15 MH Pharmacists OR MH Pharmacy technician 5,119
S16 MH drug information services OR MH clinical pharmacy
information systems OR pharmaceutical services
2,188
S17 MHDrugMonitoring ORMHDrug TherapyORMHDrug
Therapy, Computer-Assisted OR Medication Therapy Man-
agement OR MH dosage calculations OR MH Medication
Systems OR Electronic Prescribing
12,243
S18 MH prescription, drugs OR prescriptions OR pharmaceutical
preparations OR MH medication errors OR MH polyphar-
macy OR MH drug utilization OR inappropriate prescribing
42,050
S19 TI (pharmacy or pharmacies or pharmacist# or prescription#
or prescribing)
16,927
S20 AB (pharmacist-led or pharma* initiated or ((driven or lead or
led) N2 pharmacist#))
204
S21 AB (PRESCRIBING N2 PATTERN#) 354
S22 TI ((“physician-pharmacist#” or “doctor-pharmacist#”)) OR
AB ((“physician-pharmacist#” or “doctor-pharmacist#”))
37
S23 TI (((IMPROV* orOPTIMI#INGorOPTIMI#E# orOPTI-
MAL*) and (DOSINGorDOSAGEor PHARMAC* or PRE-
SCRIB* or PRESCRIPT*))) OR AB (((IMPROV* or OP-
TIMI#INGorOPTIMI#E# orOPTIMAL*)N2 (PHARMA-
CEUTICAL CARE or PHARMACY or PRESCRIB* or PRE-
SCRIPT*)))
1,571
S24 AB ((pharmaceutical N1 (care or consult*)) or (pharmacist#
N2 (care or consult* or intervention# or managed)))
711
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S25 TI (((drug therapy or drug regime# or medication# or
medicineS or pharmacy or pharmacist# or pharmaceutical
or PRESCRIB* or prescription#) N2 (audit* or monitor* or
RECONCIL* or review#))) OR AB (((drug therapy or drug
regime# or medication# or medicineS or pharmacy or phar-
macist# or pharmaceutical or PRESCRIB* or prescription#)
N2 (audit* or monitor* or RECONCIL* or review#)))
3,177
S26 TI (((medication# or prescrib* or pharmac*) N2 (manage# or
management or service# or system#))) OR AB (((medication#
or prescrib* or pharmac*) N2 (manage# or management or
service# or system#)))
6,355
S27 TI (((“drug therapy” or dosage# or dose# or medication# or
PRESCRIPTION# or PRESCRIB* or PHARMACIST# or
PHARMACEUTICAL CARE) N2 (managing or manage-
ment or monitor*))) OR AB (((“drug therapy” or dosage# or
dose# or medication# or PRESCRIPTION# or PRESCRIB*
or PHARMACIST# or PHARMACEUTICAL CARE) N2
(managing or management or monitor*)))
3,695
S28 AB ((“drug utili#ation” N2 (review# or reconcil* or audit#)))
ORTI ((“drug utili#ation” and (review# or reconcil* or audit#
)))
58
S29 AB ((inappropriate* N2 (medicine# or medication# or pre-
scrib* or drug#))) OR TI ((inappropriate* N2 (medicine# or
medication# or prescrib* or drug#)))
828
S30 MH drug utilization 4,058
S31 S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR
S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR
S29 OR S30
68,421
S32 TI (((care or patient#) N3 transition*)) OR AB (((care or pa-
tient#) N3 transition*))
3,039
S33 TI (hospital N3 releas*) OR AB (hospital N3 releas*) 146
S34 TI “hospital to home” OR AB “hospital to home” 1,040
S35 MH Patient admission OR MH Patient discharge OR MH
readmission OR MH transfer, discharge
23,786
S36 (TI ((patient# or hospital* or medical centre or medical cen-
tres or medical center#)) OR MW ((patient# or hospital* or
medical centre or medical centres or medical center#))) AND
12,379
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TI ((discharg* or admission# or admitting or readmission# or
readmit* or transfer# or transferred or transferring))
S37 AB ((patient# or care facility or medical facility or hospital#
or medical centre or medical centres or medical center# or
emergency or ward or wards or unit or units or (intensive N2
care) or ICU or acute care or (hospital# N2 department#))
N2 (discharg* or admission# or admitting or readmission# or
transfer# or transferring or transferred))
25,943
S38 (MH “Academic medical centers+” or MH “Hospital Units+”
or MH “Hospitals+” or MH “Ambulatory Care Facilities+”)
AND TI ((transfer or transferred or discharge or admission#
or readmission# or re- admission#))
3,084
S39 AB ((earlie* or early) N2 discharg*) 1,028
S40 TI (((icu or (intensive N2 care) or acute care or unit or units
or ward or wards or department) N3 transition*)) OR AB (
((icu or (intensive N2 care) or acute care or unit or units or
ward or wards or department) N3 transition*))
394
S41 TI (transfer*N3 emergency)ORAB (transfer*N3 emergency) 217
S42 TI ((hospital N8 (transfer# or transferred))) OR AB ((hospital
N8 (transfer# or transferred)))
1,441
S43 TI (discharge N3 (medication# or prescription# or commu-
nication# or (information N2 exchang*)))
142
S44 S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR
S39 OR S40 OR S41 OR S42 OR S43
51,391
S45 S8 AND S44 680
S46 (S14 AND S44) NOT S45 130
S47 (S31 AND S44) NOT (S45 OR S46) 1,513
S48 (MM “Clinical Trials+”) 9,428
S49 TI (“clinical study” or “clinical studies”) or AB (“clinical study”
or “clinical studies”)
8,077
S50 TI random* or AB random* 129,817
S51 TI (control group or control groups OR control* experiment*
or control* design or controlled study) OR AB (control group
OR control groups or control* cohort* or controlled experi-
58,585
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ment* controlled design or controlled study)
S52 TI (cluster N2 trial* or cluster N2 study or cluster N2 group
or cluster N2 groups or cluster N2 cohort or cluster N2 design
or cluster N2 experiment*) ORAB (cluster N2 trial* or cluster
N2 study or cluster N2 group or cluster N2 groups or cluster
N2 cohort or cluster N2 design or cluster N2 experiment*)
2,274
S53 TI multicentre or multicenter or multi-centre or multi-center 25,616
S54 AB ((multicent* n2 design*) or (multicent* n2 study) or (mul-
ticent* n2 studies) or (multicent* n2 trial*)) or AB ((multi-
cent* n2 design*) or (multi-cent* n2 study) or (multi-cent* n2
studies) or (multi-cent* n2 trial*))
8,351
S55 TI controlled AND TI (trial or trials or study or experiment*
or intervention)
23,370
S56 S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55
191,654
S57 ((S45 or S46 or S47) AND S56) 364
Science Citation Index Expanded (SCI-EXPANDED) - 1945-present
Conference Proceedings Citation Index- Science (CPCI-S) - 1990-present
Date of search: 18 January 2018
No. Search terms Results
#01 (TS=(Medication Reconciliation) or TI=((medication? or
medicine? or drug or drugs or pharmacist? or pharmacy or
pharmacies or formulary or formularies or prescription? or pre-
scrib*) NEAR/3 (reconcil* or review or reviewing)) or TI=(
(medication? or medicine? or drug or drugs or pharmacist? or
pharmacy or pharmacies or formulary or formularies or pre-
scription? or prescrib*) NEAR/3 (assess* or audit?)) or TI=
(stopp or beer’s criteria) or TI=(medication? NEAR/2 discrep-
anc*) or TI=((medication? or prescribing) NEAR/2 error?) or
TI=stewardship)
2,715
#02 (TS=“hospital medication system” OR TS= “hospital Medica-
tion systems”)
15
#03 (TI=(physician-pharmacist or doctor-pharmacist) or TI=(
(IMPROV* or OPTIMI?ING or OPTIMI?E? or OPTI-
MAL*) and (DOSINGorDOSAGEor PHARMAC* or PRE-
SCRIB* or PRESCRIPT*)) or TS=((IMPROV* or OPTIMI?
ING or OPTIMI?E? or OPTIMAL*) AND (PHARMACEU-
56,744
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TICAL CARE or PHARMACY or PRESCRIB* or PRE-
SCRIPT*)) or TS=((pharmaceutical NEAR (care or consult*)
) or (pharmacist? NEAR/2 (care or consult* or intervention?
or managed))) or TI=((drug therapy or drug regime? or med-
ication? or medicineS or pharmacy or pharmacist? or phar-
maceutical or PRESCRIB* or prescription?) AND (audit* or
monitor* or RECONCIL* or review?)) or TI=((medication?
or prescrib* or pharmac*) NEAR/2 (manage? or management
or service? or system?)) or TI=((“drug therapy” or dosage? or
dose? or medication? or PRESCRIPTION? or PRESCRIB*
or PHARMACIST? or PHARMACEUTICAL CARE) AND
(managing or management or monitor*)) or TS=(“drug utili?
ation”NEAR/2 (review? or reconcil* or audit?))ORTI=(“drug
utili?ation” and (review? or reconcil* or audit?)) or TI=(inap-
propriate* NEAR/2 (medicine? or medication? or prescrib* or
drug?)) or TS=“Drug utilization”)
#04 TI=((care or patient?) NEAR/3 transition*) or TI=(hospital
NEAR/3 releas*) or TI=“hospital to home” or TS=(“Patient
admission” or “Patient discharge” or “Patient readmission” or
“Patient transfer”)
2,730
#05 TS=(“Academic Medical Centers” or “Hospital Units” or
“Hospitals” or “Ambulatory Care Facilities”) and TI=(transfer
or transferred or discharge or admission? or readmission? or
re-admission?)
2,379
#06 TS=(earl* NEAR/2 discharg*) 4,468
#07 TI=((icu or (intensive NEAR/2 care) or acute care or unit
or units or ward or wards or department) AND (transfer or
transition*))
2,074
#08 TI=(transfer* NEAR/3 emergency) 157
#09 TI=(hospital NEAR/8 transfer*) 487
#10 TI=(discharge near/4 patient) or TI=(discharge near/4 pa-
tients) or TI=(discharge near/4 hospital*) or TI=(discharge
near/4 early) or TI=(discharge near/4 pharmacist*) or TI=(dis-
charge near/4 physician*) or TI=(discharge near/4 nurse) or
TI=(discharge near/4 nurses)
5,243
#11 TS=(discharge NEAR/3 (medication? or prescription? or com-
munication? or (information NEAR/2 exchang*)))
1,280
#12 #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 16,074
#13 #12 AND #1 180
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#14 (#2 and #12) NOT #13 0
#15 (#3 and #12) NOT (#13 or #14) 387
#16 TI=(random* or trial or study or pilot or comparative or tool
or tools or innovat* or organisation* or organization* or im-
pact or influence or change or changing or reduce or improv*
or quality or implement*) or TS=(random* or trial or study
or pilot or comparative or tool or tools or innovat* or organ-
isation* or organization* or impact or influence or change or
changing or reduce or improv* or quality or implement*)
19,657,830
#17 ((#13 or #14 or #15) and #16) not (TS=placebo* or TI=
placebo* or TI=animal or TS=animal or TS=animals)
533
#18 TS=“medication reconciliation” 768
#19 TI=((medication? or prescription?) and reconcil*) 15
#20 TS=((medication? NEAR/3 reconcil*) OR (prescription?
NEAR/3 reconcil*))
62
#21 (#18 or #19 or #20) not (#17 or TI=placebo* or TS=placebo*
or TI=animal or TS=animal)
653
#22 #21 OR #17 1,186
PsycINFO (Ovid)
Date of search: 18 January 2018
No. Search terms Results
1 ((medication? or medicine? or drug or drugs or pharmacist? or
pharmacy or pharmacies or formulary or formularies or pre-
scription? or prescrib*) adj3 (reconcil* or review or reviewing)
).ti,ab
1540
2 ((medication? or medicine? or drug or drugs or pharmacist?
or pharmacy or pharmacies or formulary or formularies or
prescription? or prescrib*) adj3 (assess* or audit?)).ti,ab
2759
3 (stopp or beer’s criteria).ti,ab. 108
4 (medication? adj2 discrepanc*).ti,ab. 28
5 ((medication? or prescribing) adj2 error?).ti,ab. 486
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6 stewardship.ti,ab. 570
7 or/1-6 5323
8 ((pharmaceutical care or pharmacy or pharmacies or pharma-
cist? or prescribing) and (inpatient? or hospital* or ward? or
unit or units)).ti
141
9 ((pharmaceutical care or pharmacy or pharmacies or pharma-
cist? or prescribing) adj2 (inpatient? or hospital* or ward? or
unit or units)).ab
183
10 ((medication? or prescribing or prescription? or dispensing)
adj2 system?).ti,ab. and (hospital* or ward or wards or (care
adj2 unit?) or inpatient?).ti,hw
33
11 or/8-10 318
12 (pharmacy or pharmacies or pharmacist? or prescription? or
prescribing).ti
4842
13 (pharmacist-led or pharma* initiated or ((driven or lead or led)
adj2 pharmacist?)).ab
67
14 (prescribing adj2 pattern?).ab. 276
15 (“physician-pharmacist?” or “doctor-pharmacist?”).ti,ab. 15
16 ((improv* or optimi?ing or optimi?e? or optimal*) and (dos-
ing or dosage or pharmac* or prescrib* or prescript*)).ti. or (
(improv* or optimi?ing or optimi?e? or optimal*) adj2 (phar-
maceutical care or pharmacy or prescrib* or prescript*)).ab
539
17 ((pharmaceutical adj (care or consult*)) or (pharmacist? adj2
(care or consult* or intervention? or managed))).ab
247
18 ((drug therapy or drug regime? or medication? or medicines
or pharmacy or pharmacist? or pharmaceutical or prescrib* or
prescription?) adj2 (audit* or monitor* or reconcil* or review?
)).ti,ab
1222
19 ((medication? or prescrib* or pharmac*) adj2 (manage? or
management or service? or system?)).ti,ab
2962
20 ((“drug therapy” or dosage? or dose? or medication? or pre-
scription? or prescrib* or pharmacist? or pharmaceutical care)
adj2 (managing or management or monitor*)).ti,ab
1984
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21 (“drug utili?ation” adj2 (review? or reconcil* or audit?)).ab. or
(“drug utili?ation” and (review? or reconcil* or audit?)).ti
42
22 (inappropriate* adj2 (medicine? or medication? or prescrib* or
drug?)).ti,ab
376
23 or/12-22 9143
24 ((care or patient?) adj3 transition*).ti,ab. 1497
25 (hospital adj3 releas*).ti,ab. 65
26 “hospital to home”.ti,ab. 302
27 (patient? or hospital* or medical centre or medical centres or
medical center?).ti,hw. and (discharg* or admission? or admit-
ting or readmission? or readmit* or transfer? or transferred or
transferring).ti
2548
28 ((patient? or care facility ormedical facility or hospital? ormed-
ical centre or medical centres or medical center? or emergency
or ward or wards or unit or units or (intensive adj2 care) or
icu or acute care or (hospital? adj2 department?)) adj2 (dis-
charg* or admission? or admitting or readmission? or transfer?
or transferring or transferred)).ab
8673
29 (academic medical centers or hospital units or hospitals or
ambulatory care facilities).ti,ab. and (transfer or transferred or
discharge or admission? or readmission? or re-admission?).ti
428
30 ((earlie* or early) adj2 discharg*).ab. 231
31 ((icu or (intensive adj2 care) or acute care or unit or units or
ward or wards or department) adj3 transition*).ti,ab
105
32 (transfer* adj3 emergency).ti,ab. 54
33 (hospital adj8 (transfer? or transferred)).ti,ab. 402
34 discharge.ti. 1317
35 (discharge adj3 (medication? or prescription? or communica-
tion? or (information adj2 exchang*))).ab
218
36 or/24-35 12324
37 7 and 36 139
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38 (11 and 36) not 37 39
39 (23 and 36) not (37 or 38) 159
40 double-blind.tw. 12286
41 random* assigned.tw. 18670
42 control.tw. 223726
43 or/40-42 243995
44 intervention?.ti. or (intervention? adj6 (clinician? or collabo-
rat* or community or complex or design* or doctor? or edu-
cational or family doctor? or family physician? or family prac-
titioner? or financial or gp or general practice? or hospital? or
impact? or improv* or individuali?e? or individuali?ing or in-
terdisciplin* or multicomponent or multi-component or mul-
tidisciplin* or multi-disciplin* or multifacet* or multi-facet*
or multimodal* or multi-modal* or personali?e? or personali?
ing or pharmacies or pharmacist? or pharmacy or physician?
or practitioner? or prescrib* or prescription? or primary care or
professional* or provider? or regulatory or regulatory or tailor*
or target* or team* or usual care)).ab
86090
45 (pre-intervention? or preintervention? or “pre intervention?”
or post-intervention? or postintervention? or “post interven-
tion?”).ti,ab
6072
46 (hospital* or patient?).hw. and (study or studies or care or
health* or practitioner? or provider? or physician? or nurse? or
nursing or doctor?).ti,hw
29550
47 demonstration project?.ti,ab. 594
48 (pre-post or “pre test*” or pretest* or posttest* or “post test*”
or (pre adj5 post)).ti,ab
30129
49 (pre-workshop or post-workshop or (before adj3 workshop)
or (after adj3 workshop)).ti,ab
343
50 trial.ti. or ((study adj3 aim?) or “our study”).ab. 95648
51 (before adj10 (after or during)).ti,ab. 36705
52 (“quasi-experiment*” or quasiexperiment* or “quasi random*”
or quasirandom* or “quasi control*” or quasicontrol* or (
(quasi* or experimental) adj3 (method* or study or trial or
28131
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design*))).ti,ab,hw
53 (“time series” adj2 interrupt*).ti,ab,hw. 420
54 (time points adj3 (over ormultiple or three or four or five or six
or seven or eight or nine or ten or eleven or twelve or month*
or hour? or day? or “more than”)).ab
3165
55 pilot.ti. 9575
56 (multicentre or multicenter or multi-centre or multi-center).
ti
1643
57 random*.ti,ab. or controlled.ti. 115275
58 (control adj3 (area or cohort? or compare? or condition or
design or group? or intervention? or participant? or study)).ab.
not (controlled clinical trial or randomized controlled trial).pt
69642
59 “comment on”.cm. or review.ti,pt. or randomized controlled
trial.pt
89807
60 review.ti. 89807
61 (rat or rats or cow or cows or chicken? or horse or horses or
mice or mouse or bovine or animal?).ti
61497
62 (or/44-58) or experimental design/ or between groups design/
or quantitative methods/ or quasi experimental methods/
389594
63 exp animals/ or animal?.ti,id,hw. 169482
64 62 not (or/60-61,63) 355108
65 ((or/37-39) and 43) not placebo*.ti,ab,hw. 41
COS Conference Papers Index (ProQuest)
ProQuest Dissertations & Theses: UK & Ireland (ProQuest)
ProQuest Dissertations & Theses Global Search (ProQuest)
Date of search: 18 January 2018
(subject(“Prescription drugs”) AND subject(“Reconciliation”)) OR (((ti,ab(((medication* OR medicine* OR drug OR drugs OR
pharmacist* OR pharmacy OR pharmacies OR formulary OR formularies OR prescription* OR prescrib*) NEAR/3 (reconcil* OR
review OR reviewing)) OR ((medication* OR medicine* OR drug OR drugs OR pharmacist* OR pharmacy OR pharmacies OR
formularyOR formulariesORprescription*ORprescrib*)NEAR/3 (assess*ORaudit*))OR (stoppORbeer’s criteria)OR (medication*
NEAR/2 discrepanc*) OR ((medication* ORprescribing) NEAR/2 error*)OR (stewardship)) OR su(medication reconciliation)) AND
ti,ab((patient* OR “care facility” OR “medical facility” OR hospital* OR “medical centre” OR “medical centres” OR “medical center*”
OR emergency OR ward OR wards OR unit OR units OR (intensive NEAR/2 care) OR ICU OR “acute care” OR (hospital* NEAR/
2 department*)) NEAR/2 (discharg* OR admission* OR admitting OR readmission* OR transfer* OR transferring OR transferred)))
OR (ti(medication OR medicine OR drug OR drugs OR prescription*) AND ti(reconcil*)))
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Joanna Briggs Institute Library
Date of Search: January 22, 2018
1 “medication management“
2 ”medication reconciliation“
3 ”medication systems“
4 ”medicines reconciliation“
5 “medicines discrepancies”
6 “medication discrepancies”
NHS Evidence Search
Date of Search January 22, 2018
filter AHRQ/Care Quality Commission/Centre for Reviews and Dissemination Health Technology Assessment/ National Institute for
Health and Care Excellence (includes National electronic Library for Medicines)/National Patient Safety Agency - National Reporting
and Learning Service/ National Prescribing Centre/ UKMi (includes Pharmline)/
1 “Medicines Management”
2 “Medication Reconciliation”
3 “Medicines Reconciliation”
4 “Medication systems”
Agency for Healthcare Research and Quality
Date of Search January 22, 2018
1 “Medication Reconciliation”
2 “Medicines Reconciliation”
3 “Medication Systems”
4 “Medicines Management”
or/1-4
National Research Register Archive (2000-2007)
Date of search 28 August 2013
1 “medication management”
2 “medication reconciliation”
3 “medication systems”
4 “medicines reconciliation”
5 “medicines discrepancies”
6 “medication discrepancies”
7 or/1-6
International Pharmaceuticals Abstract
Date of search 22 January 2018
1 “medication reconciliation”
2 “medicines reconciliation”
3 “medication management”
4 “medication discrepanc*”
5 “medicines discrepanc*”
6 “medication systems”
Open Grey
Date of search 22 January 2018
1 “medication reconciliation”
2 “medication management”
3 “medicines reconciliation”
4 “medication systems”
5 “medicines discrepancies”
6 “medication discrepancies”
National Institute for Health and Care Excellence (NICE)
Date of search 22 January 2018
1 “Medication Reconciliation”
2 “Medicines Reconciliation”
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3 “Medication Systems”
4 “Medicines Management”
Grey Literature Report
Date of search 22 January 2018
1 “medication reconciliation”
2 “medicines reconciliation”
3 “medication systems”
4“medicines management”
5 “medication discrepancies”
6 “medicines discrepancies”
World Health Organisation (WHO) -International Clinical Trials Registry Platform (ICTRP)
Date of search 22 January 2018
1. “medication reconciliation”
2. “medication management”
3. “Medication Systems”
4. “Medication Therapy Management”
5. “medication errors”
6. “Pharmacy service”
7. “Pharmacist”
8. “Pharmacy”
9. “Pharmacies”
10. “Medication discrepanc*”
11. “Prescrib*”
12. “Pharmaceutical Services”
13. “inappropriate prescribing”
14. “polypharmacy”
15. “Patient admission”
16. “Patient discharge”
17. “Patient readmission”
18. “Patient transfer”
Clinical Trials.gov, US National Institutes of Health (NIH)
Date of search 22 January 2018
1 “medication reconciliation”
2 “medicines reconciliation”
3 “medication errors”
4 “medication discrepancy”
Google Alerts (https://www.google.ie/alerts)
Final search: 23 April 2018
“medication reconciliation”
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Appendix 3. GRADE evidence profile
Certainty assessment of evidence for each outcome
No of studies Design Risk of bias Inconsis-
tency
Indirectness Imprecision Other Certainty
(overall
score)
Outcome: ≥ 1 medication discrepancy per participant (dichotomous)
20 Randomised
trials
Very serious
risk of bias
Very serious
inconsistency
Very serious
indirectness
No serious im-
precision
Large
effect size, no
Very low
(1)
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(Continued)
(20) (-2) (-2) (-2) confound-
ing, publica-
tion bias un-
detected
(+2)
Outcome: number of medication discrepancies per participant (continuous)
4 Randomised
trials
(4)
No serious risk
of bias
Very serious
inconsistency
(-2)
Serious indi-
rectness
(-1)
No serious im-
precision
No large effect
size
Very low
(1)
Outcome: Discrepancies per participant medication (dichotomous)
2 Randomised
trials
(2)
Very serious
risk of bias
(-2)
Very serious
inconsistency
(-2)
No serious in-
directness
Serious impre-
cision
(-1)
Very large ef-
fect size
(+2)
Very low
(1)
Outcome: preventable adverse drug events (PADEs)
3 Randomised
trials
(3)
Serious risk of
bias
(-1)
Very serious
inconsistency
(-2)
Very serious
indirectness
(-2)
Serious impre-
cision
(-1)
Large effect
size, publica-
tion bias un-
detected
(+2)
Very low
(1)
Outcome: adverse drug events (ADEs)
4 Randomised
trials
(4)
Serious risk of
bias
(-1)
No serious in-
consistency
Serious indi-
rectness
(-1)
No serious im-
precision
- Low
(2)
Outcome: unplanned rehospitalisation
5 Randomised
trials
(5)
Very serious
risk of bias
(-2)
No serious in-
consistency
No serious in-
directness
Serious impre-
cision
(-1)
Very large ef-
fect
size, no publi-
cation bias de-
tected
(+2)
Moderate
(3)
Outcome: hospital usage (composite measure of emergency department, rehospitalisation)
4 Randomised
trials
(4)
Very serious
risk of bias
(-2)
Serious incon-
sistency
(-1)
Serious indi-
rectness
(-1)
Serious impre-
cision
(-1)
No publi-
cation bias de-
tected
(+1)
Very low
(1)
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Appendix 4. EPOC Taxonomy of Interventions
Available from: epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/datacollectionchecklist.pdf
Type of intervention
2.1.1 Professional interventions
a. Distribution of educational materials (distribution of published or printed recommendations for clinical care, including clinical
practice guidelines, audio-visual materials and electronic publications. The materials may have been delivered personally or through
mass mailings.)
b. Educational meetings (healthcare providers who have participated in conferences, lectures, workshops or traineeships.)
c. Local consensus processes (inclusion of participating providers in discussion to ensure that they agreed that the chosen clinical
problem was important and the approach to managing the problem was appropriate.)
d. Educational outreach visits (use of a trained person who met with providers in their practice settings to give information with the
intent of changing the provider’s practice. The information given may have included feedback on the performance of the provider(s).
e. Local opinion leaders (use of providers nominated by their colleagues as ’educationally influential’. The investigators must have
explicitly stated that their colleagues identified the opinion leaders)
f. Participant-mediated interventions (new clinical information (not previously available) collected directly from participants and given
to the provider e.g. depression scores from an instrument)
g. Audit and feedback (any summary of clinical performance of health care over a specified period of time. The summary may also
have included recommendations for clinical action. The information may have been obtained from medical records, computerised
databases, or observations from participants)
The following interventions are excluded:
• Provision of new clinical information not directly reflecting provider performance which was collected from participants e.g. scores
on a depression instrument, abnormal test results. These interventions should be described as patient mediated.
• Feedback of individual participants’ health record information in an alternate format (e.g. computerised). These interventions should
be described as organisational.
h. Reminders (patient or encounter specific information, provided verbally, on paper or on a computer screen, which is designed or
intended to prompt a health professional to recall information. This would usually be encountered through their general education; in
the medical records or through interactions with peers, and so remind them to perform or avoid Page 10 checklist some action to aid
individual patient care. Computer aided decision support and drugs dosage are included.)
i. Marketing (use of personal interviewing, group discussion (’focus groups’), or a survey of targeted providers to identify barriers to
change and subsequent design of an intervention that addresses identified barriers.)
j. Mass media ((i) varied use of communication that reached great numbers of people including television, radio, newspapers, posters,
leaflets, and booklets, alone or in conjunction with other interventions; (ii) targeted at the population level.)
k. Other (Other categories to be agreed in consultation with the EPOC editorial team.)
2.1.2 Financial interventions
2.1.2.1 Provider interventions
a. Fee-for-service (provider has been paid for number and type of service delivered)
b. Prepaid (no other description)
c. Capitation (provider was paid a set amount per participant for providing specific care)
d. Provider salaried service (provider received basic salary for providing specific care)
e. Prospective payment (provider was paid a fixed amount for health care in advance)
f. Provider incentives (provider received direct or indirect financial reward or benefit for doing specific action)
g). Institution incentives (institution or group of providers received direct or indirect financial rewards or benefits for doing specific
action)
h. Provider grant/allowance (provider received direct or indirect financial reward or benefit not tied to specific action)
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i. Institution grant/allowance (institution or group of providers received direct or indirect financial reward or benefit not tied to specific
action)
j. Provider penalty (provider received direct or indirect financial penalty for inappropriate behaviour)
k. Institution penalty (institution or group of providers received direct or indirect financial penalty for inappropriate behaviour)
l. Formulary (added or removed from reimbursable available products)
m. Other (other categories to be agreed in consultation with the EPOC editorial team)
2.1.2.2 Patient interventions
a. Premium (patient payment for health insurance. It is important to determine if the patient paid the entire premium, or if the patient’s
employer paid some of it. This includes different types of insurance plans.)
b. Copayment (patient payment at the time of health care delivery in addition to health insurance e.g. in many insurance plans that
cover prescription medications the patient may pay 5 dollars per prescription, with the rest covered by insurance.)
c. User-fee (patient payment at the time of health care delivery.)
d. Patient incentives (patient received direct or indirect financial reward or benefit for doing or encouraging them to do specific action.)
e. Patient grant/allowance (patient received direct or indirect financial reward or benefit not tied to specific action.)
f. Patient penalty (patient received direct or indirect financial penalty for specified behaviour e.g. reimbursement limits on prescriptions.)
g. Other (other categories to be agreed in consultation with the EPOC editorial team)
2.1.3 Organisational interventions
2.1.3.1 Provider-orientated interventions
a. Revision of professional roles (Also known as ’professional substitution’, ’boundary encroachment’ and includes the shifting of
roles among health professionals. For example, nurse midwives providing obstetrical care; pharmacists providing drug counselling that
was formerly provided by nurses and physicians; nutritionists providing nursing care; physical therapists providing nursing care. Also
includes expansion of role to include new tasks.)
b. Clinical multidisciplinary teams (creation of a new team of health professionals of different disciplines or additions of new members
to the team who work together to care for participants)
c. Formal integration of services (bringing together of services across sectors or teams or the organisation of services to bring all services
together at one time also sometimes called ’seamless care’)
d. Skill mix changes (changes in numbers, types or qualifications of staff )
e. Continuity of care (including one or many episodes of care for inpatients or outpatients) • Arrangements for follow-up. • Case
management (including co-ordination of assessment, treatment and arrangement for referrals)
f. Satisfaction of providers with the conditions of work and the material and psychic rewards (e.g. interventions to ’boost morale’)
g. Communication and case discussion between distant health professionals (e.g. telephone links; telemedicine; there is a television/
video link between specialist and remote nurse practitioners)
h. Other (other categories to be agreed in consultation with the EPOC editorial team)
2.1.3.2 Patient-orientated interventions
a. Mail order pharmacies (e.g. compared to traditional pharmacies)
b. Presence and functioning of adequate mechanisms for dealing with participants’ suggestions and complaints
c. Consumer participation in governance of health care organisation d) Other (other categories to be agreed in consultation with the
EPOC editorial team)
2.1.3.3 Structural interventions
a. Changes to the setting/site of service delivery (e.g. moving a family planning service from a hospital to a school)
b. Changes in physical structure, facilities and equipment (e.g. change of location of nursing stations, inclusion of equipment where
technology in question is used in a wide range of problems and is not disease specific, for example an MRI scanner.)
c. Changes in medical records systems (e.g. changing from paper to computerised records, patient tracking systems)
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d. Changes in scope and nature of benefits and services
e. Presence and organisation of quality monitoring mechanisms
f. Ownership, accreditation, and affiliation status of hospitals and other facilities
g. Staff organisation
h. Other (other categories to be agreed in consultation with the EPOC editorial team)
2.1.4 Regulatory interventions
Any intervention that aims to change health services delivery or costs by regulation or law.
(These interventions may overlap with organisational and financial interventions.)
a. Changes in medical liability
b. Management of patient complaints
c. Peer review
d. Licensure
e. Other (other categories to be agreed in consultation with the EPOC editorial team)
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review.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Following completion of the search process a large number of randomised trials (amongst non-randomised trials) were identified for
inclusion. Following discussion with EPOC editors (Julia Worswick/Alain Mayhew), it was decided to limit the review to randomised
trials only. Randomised trials represent the best opportunity of limiting the bias of unrecognised effects in healthcare settings and
improving the external validity of effect estimates in disseminating the findings of this review. Presenting the results of randomised
trials only will provide greater confidence in the findings.
The title of the review differs from the protocol. The title was reworded to clarify medication reconciliation as the intervention of
interest.
The primary outcome described in the protocol was “discrepancies per patient or medication”. Upon completion of the search, we
refined this based on the included studies to “Discrepancies in prescription per patient or medication”.
We added the following outcomes from the protocol to this review:
• patient-related and outcome processes: medication adherence (non-adherent with at least one medication);
• healthcare utilisation: hospital usage (composite measure of emergency department, rehospitalisation).
The protocol listed potential subgroups for analysis. It was not possible to undertake this analysis for all of those subgroups listed (i.e.
people with chronic disease), due to insufficient data.
The risk of bias criteria were reworded to provide more clarity on their interpretation.
The protocol for this review listed Pharmline (National Electronic Library for Medicines) as a resource to search. This database was
subsequently subsumed (in its entirety, including archived material) into the NHS Evidence resource. Therefore, it was not searched
separately.
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